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Abstract 
Background and Aims 
Despite advances in surgery, radiation and chemotherapy, grade 4 astrocytoma, the 
commonest primary brain tumour, remains incurable with a dire prognosis related to its 
diffusely infiltrative nature. With photodynamic therapy, pre-treatment with a 
photosensitising drug and subsequent exposure to light of a specific wavelength can 
mediate selective tumour destruction. However, it is limited by light penetration. 
Bioluminescence results from conversion of chemical energy into light. This thesis 
explores whether bioluminescence generated inside astrocytoma cells in vitro and in in 
vivo can mediate PDT: light generation by target cells requires no knowledge of the 
exact location of every cell, thereby potentially overcoming the diffuse, infiltrative 
nature of astrocytomas. 
 
Methods 
in vitro: genetically modified U87 glioma cells expressing firefly luciferase (U87-luc) 
were generated, pre-treated with the photosensitisers hypericin or mTHPC, then 
incubated with d-luciferin to induce bioluminescence. Cell viability was assessed by 
MTT assay, haemocytometry, and a growth assay. Inhibition by lycopene, an 
antioxidant that suppresses PDT, was assessed. Control studies used untransfected U87 
cells.  
 
in vivo: U87-luc cells were xenografted subcutaneously and intracranially into CD1 
nu/nu mice. Mice were pre-treated with intraperitoneal mTHPC then given a 7 day 
infusion of d-luciferin (subcutaneously implanted pump). Tumour response was 
followed by bioluminescence imaging, volume measurements, and survival. Tumours 
were harvested for pathological examination and BrdU immunohistochemistry. 
 
Results 
in vitro: bioluminescence-mediated PDT produced significant cell death with both 
photosensitisers in U87-luc cells, which was suppressed by lycopene. There was no 
effect in untransfected cells that could not generate bioluminescence.  
 
 4 
in vivo: in 3 out of 4 trials, including one in an intracranial model, a treatment effect was 
demonstrated by a significant reduction of proliferation, as assessed by the proportion 
of BrdU positive cells in the ‘treatment’ group compared to controls. 
 
Conclusion 
Bioluminescence-mediated PDT kills tumour cells in vitro. Preliminary evidence of an 
effect in vivo supports the concept being explored further. 
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Part 1 Background and Aims 
This section will provide a background on the most common primary brain tumour, 
grade 4 astrocytoma, and will discuss reasons for its resistance to treatment, even to 
this day. Photodynamic therapy (PDT) will be introduced as an attractive adjunct to 
conventional treatments, yet it will be seen that the limitations specific to overcoming 
grade 4 astrocytoma remain. Bioluminescence, as a novel, endogenous, intrinsic light 
source to mediate photodynamic therapy will be explored: bioluminescence-mediated 
photodynamic therapy (bPDT). Its ability to overcome the treatment resistant 
characteristics of grade 4 astrocytoma will be proposed, and the rationale behind the 
study conducted will be outlined.  
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Chapter 1 Grade 4 Astrocytoma 
High-grade astrocytoma, specifically grade 4 astrocytoma, is an aggressive and highly 
debilitating primary brain tumour with an exceptionally poor prognosis. Despite 
advances in medicine over the last century, there has been little improvement in 
survival. In this chapter, astrocytomas will be defined and classified. Focusing on grade 
4 astrocytoma, the most common and deadly of primary brain tumours, its 
epidemiology will be discussed, illustrating the need for ongoing research into its 
treatment. The basis underlying the current standard of care of grade 4 astrocytoma will 
be reviewed, and the failings of this standard highlighted. The fundamental reason for 
treatment failure will be discussed, and the limitations of each aspect of standard care 
will be considered. Finally, the need of a novel approach will be appreciated.  
1.1 Classification and Epidemiology of Astrocytomas 
Gliomas are a type of primary tumour of the brain and spinal cord that are considered 
to arise from cells of glial origin. Such cells include astrocytes, oligodendrocytes, and 
ependymal cells. One third of all primary tumours of the brain and spinal cord are 
malignant, and gliomas account for 80% of these1. The most common of the gliomas 
are astrocytomas, which comprise of 75% of all gliomas1. In short, astrocytomas 
underlie the majority of malignant primary brain and spinal cord tumours.   
 
Based on their pathological appearance, and in order of increasing malignancy, the 
World Health Organisation has classified astrocytomas from grades 1-42, with grades 3 
and 4 being considered malignant (see Table 1). Specifically, grade 4 astrocytoma (see 
Figure 1), also termed glioblastoma multiforme, accounts for almost half (45.6%) of all 
malignant primary brain and spinal cord tumours, making it the most common 
malignant tumour of the brain and spinal cord1.  
 
Grade Anaplastic Features 
1 No anaplastic features 
2 Nuclear atypia 
3 Nuclear atypia and mitosis 
4 Nuclear atypia, mitosis, vascular endothelial proliferation, and necrosis 
 
Table 1 WHO Classification of Astrocytomas2 
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The incidence of grade 4 astrocytoma is 3.19 per 100 000, and the median age of 
diagnosis is 65 yrs1. Importantly, as the Western population ages and the number of 
adults aged 65 and older is expected to double by 2030, the incidence of cancer is 
projected to increase significantly: demographic trends for grade 4 astrocytoma project 
that its incidence rate will increase 66% between 2010 and 2050. Although this does 
not seem particularly impressive compared to more common cancers such as breast3, 
with an incidence of 124.8 per 100 0003, and lung, with an incidence of 58.7 per 100 
0004, malignant astrocytomas, and particularly grade 4 astrocytoma, have much more 
devastating prognoses. The 5-year survival for grade 4 astrocytoma is only 5.5%1 
compared to 89.4%3 and 17.4%4 for breast and lung cancer, respectively.  
1.2 Early Understanding and Treatment 
Early data provided an insight into the natural history of grade 4 astrocytoma. A 
retrospective study of 219 cases of grade 4 astrocytoma presenting to one institution 
from 1924-1952 found the survival rate of this disease to be 50% at 7 months, 33% at 1 
year, and near 0 % at 5 years5. Median survival was approximately 9 months. 84% had 
undergone some degree of tumour resection and 21% had undergone whole brain 
radiation. Separating those who had treatment from those who had not, the 1 year 
survival was 35% and 20%, respectively, yet the 2 year survival for both groups was 
approximately 5%. This indicated that those surviving beyond a year were more a 
reflection of the intrinsic biology of the tumour than representing the effectiveness of 
treatment.  
 
A prospective trial conducted by the Brain Tumour Study Group between 1969-1972 
reported the median survival of grade 4 astrocytoma to be only 14 weeks with surgical 
resection alone6 with the addition of adjuvant radiation doubling survival. The survival 
benefit of adjuvant radiation was subsequently confirmed in randomised controlled 
trials7,8, and the standard of care of those with grade 4 astrocytoma became 
cytoreductive surgery followed by whole brain radiation for the next several decades.  
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Figure 1 Slides Depicting the Characteristic Pathological Features of Grade 4 Astrocytoma 
Slides are courtesy of Dr S Salamat, University of Wisconsin Neuropathology. Slides a, b, and c are 
haematoxylin and eosin stained slides. The hypercellularity on a fibrillary (F) background, which is 
highlighted by immunohistochemical staining of glial fibrillary acidic protein (slide d), is characteristic of 
astrocytoma. There is also nuclear atypia, mitoses (M), vascular endothelial proliferation (V) and widespread 
necrosis (N) with nuclear palisading, all associated specifically with grade 4 astrocytoma.   
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1.3 Advances in Chemotherapy  
In an effort to improve the poor prognosis of grade 4 astrocytoma, extensive research 
into various chemotherapeutics was conducted. A meta-analysis of 12 randomised trials 
investigating the effect of chemotherapy on malignant astrocytoma was published in 
the Lancet in 20029. Data from a total of 3004 patients was analysed: the majority were 
diagnosed with grade 4 astrocytoma (63%). All patients had undergone some degree of 
surgical resection followed by radiation, either to the whole brain or the tumour and its 
margins. Chemotherapeutic agents included carmustine, lomustine, dacarbazine, and 
mitolactol. Overall, the results favoured the addition of chemotherapy to the standard of 
care, increasing median survival by 2 months, and increasing 1 year survival by 6% and 
2 year survival by 5%. However, findings of this meta-analysis could not be 
corroborated in subsequent trials. The Medical Research Council Brain Tumour 
Working Party initiated the largest randomised trial of adjuvant chemotherapy for high-
grade astrocytoma in an attempt to provide a definitive answer10. Between 1988 and 
1997, 674 patients were randomised to receive radiotherapy alone or radiotherapy and 
procarbazine, lomustine, and vincristine (PCV) chemotherapy. There was no significant 
difference in the median survival between the groups (9.5 months and 10 months, 
respectively). 
 
It was not until 2005 did a true advance in the management and understanding of high-
grade astrocytoma come to light. Stupp et al., conducted a randomised controlled trial 
investigating the effect of temozolomide, an oral alkylating agent11. 573 patients with 
grade 4 astrocytoma, the majority of whom had undergone debulking surgery, were 
randomly assigned to receive radiotherapy alone or radiotherapy and temozolamide. At 
the median follow up of 28 months, the median survival with radiotherapy alone was 
12.1 months, whereas that with radiotherapy and temozolomide was 14.6 months; a 
significant increase. 2 year survival with radiotherapy alone was 10.4%, whereas that 
with radiotherapy and temozolomide was 26.5%; again, another significant increase. 
Furthermore, progression free survival with radiotherapy alone was 5.0 months, 
compared to 6.9 months with radiotherapy and temozolomide, p < 0.001. This survival 
advantage was associated with a low rate of side effects: radiation and temozolomide in 
combination led to grade 3 and 4 haemotological toxic effects in only 7%. Based upon 
these results, the inclusion of temozolomide into the treatment protocol for those with 
grade 4 astrocytoma became standard of care. 
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Recognising that patients with grade 4 astrocytoma inevitably face disease progression 
despite maximum therapy including cytoreductive surgery, radiation, and 
temozolomide, rescue treatments have been investigated. Grade 4 astrocytoma is a 
highly vascularised tumour12 and is associated with over-expression of vascular 
endothelial growth factor (VEGF), a key regular of tumour-associated angiogenesis13-15. 
A recombinant, humanized, monoclonal IgG1 antibody has been raised against VEGF, 
bevacizumab (Avastin®). Its action is to inhibit angiogenesis and tumour growth. In 
2009, the FDA approved its use for recurrent grade 4 astrocytoma based upon only two, 
prospective, phase 2 trials, AVF3708g16 and NCI 06-C-0064E17. These studies included 
adult patients (aged ≥ 18) with histologically confirmed grade 4 astrocytoma that had 
recurred after prior standard radiotherapy and temozolomide, and both studies had an 
average follow up of only 4 months. The AVF3708g trial also included a treatment arm 
comprising of bevacizumab in combination with irinotecan. However, the study was 
not designed to compare outcomes between the two treatment groups. All efficacy 
evaluations were based on comparisons with historical control data.  The 6 month 
progression free survival in AVF3708g was 42.6%, and in NCI 06-C-0064E was 29%, 
both significantly better than historical controls. Subsequently, a phase 3, randomised, 
double-blind, placebo-controlled trial, was undertaken to evaluate the addition of 
bevacizumab to the standard protocol of radiation and temozolomide in those with 
newly diagnosed grade 4 astrocytoma18. Adults with confirmed grade 4 astrocytoma 
were treated with radiotherapy (60Gy) and daily temozolomide. Treatment with 
bevacizumab or placebo began during week 4 of radiotherapy and was continued for up 
to 12 cycles of maintenance temozolomide. At the time of disease progression, the 
assigned treatment was revealed, and bevacizumab therapy could be initiated or 
continued. A total of 637 patients were studied. There was no significant difference in 
the duration of overall survival between the bevacizumab and placebo groups (15.7 and 
16.1 months, respectively, p = 0.21). Progression-free survival was significantly longer 
in the becavizumab group compared to placebo (10.7 months vs 7.3 months, 
respectively, p = 0.007). Over time, an increased symptom burden, a worse quality of 
life, and a decline in neurocognitive function were more frequent in the bevacizumab 
group. Bevacizumab has not become part of standard treatment for newly diagnosed 
grade 4 astrocytoma, but remains an option for recurrent disease.  
 
The data supporting the use of bevacizumab is not strong. Furthermore, it is important 
to acknowledge an important confounding factor. VEGF inhibitors have been shown to 
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cause a rapid and impressive reduction in vascular permeability, resulting in restoration 
of the blood-brain-barrier (BBB), and decrease in cerebral oedema. Patients 
consequently feel much better quickly. Moreover, reflecting this dramatic effect, the 
area of contrast enhancing tumour on T1 weighted MRI is seen to significantly 
decrease, even within 24 hours19: as the BBB is restored, contrast extravasation 
reduces, so labelled a pseudoresponse. This makes tumour progression difficult to 
follow: patients on bevacizumab may be seen to clinically decline, but their imaging as 
judged by contrast enhancing tumour on T1 weighted MRI is seen to be stable. In such 
cases, the fluid-attenuated inversion recovery (FLAIR) sequence on MRI, which 
removes the effects of fluid, is better used to follow tumour progression20, and better 
correlates with the patients’ clinical state. However, tumour progression has been 
typically judged by the appearance of the contrast enhancing tumour on T1 weighted 
MRI, and for this reason, it may be that progression free survival has been inaccurately 
interpreted to be longer than it actually is. Consistent with this is the observation that 
once a patient has been recognised to have progressed on bevacizumab, their prognosis 
is extremely poor, with a median survival of only 3.8 ± 1 months21. Without using a 
reliable indicator of progression, the effect of bevacizumab cannot be accurately 
known. The most robust data is that for newly diagnosed disease, where no overall 
survival benefit has been associated with adding bevacizumab to the standard treatment 
protocol18.  
1.4 Advances in Understanding Pathogensis 
Interrogating their results further, Stupp et al., analysed the relationship between  
O6-methylguanine-DNA methyltransferase (MGMT) silencing and survival. MGMT is 
a DNA repair enzyme that removes alkyl groups from the O6 position of guanine, 
acting as an acceptor itself22. It is silenced by epigenetic methylation of the CpG 
dinucleotides in the promoter region of the MGMT gene (MGMT)23. Consequent loss of 
MGMT expression results in an inability to remove alkyl groups from methylated 
guanine and compromises the capacity for DNA repair.  
 
As an alkylating agent, temozolomide alkylates/methylates DNA, most commonly at 
the O6 and N7 positions of guanine residues. This damages the DNA, triggering tumour 
cell death. Taking into account the MGMT promoter methylation status of the patients, 
only those with tumours containing a methylated MGMT promoter i.e. those in whom 
DNA repair capacity was compromised, benefited from temozolomide: among patients 
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whose tumour contained a methylated MGMT promoter their median survival with 
radiotherapy alone was 15.3 months compared to 21.7 months with radiotherapy and 
temozolomide, a significant difference24. However, in those with tumours that did not 
have a methylated MGMT promoter, the difference in survival between the two 
treatment protocols was small and insignificant (11.8 months with radiation alone vs 
12.7 months with radiation and temozolomide). Interestingly, irrespective of treatment 
group, the presence of MGMT promoter methylation in the tumour was also an 
independent favourable prognostic factor.  
 
This study not only added temozolomide to the standard of care for those with grade 4 
astrocytoma, but heralded a whole research movement into the molecular classification 
of brain tumours (see Chapter 10).   
1.5 The Challenges of Grade 4 Astrocytoma 
Now, a decade on from Stupp et al.’s publication11, the standard of care for those with 
newly diagnosed grade 4 astrocytoma remains some degree of surgical resection or 
biopsy followed by radiation and temozolomide. The combination of radiation and 
temozolomide is that as described by Stupp et al. and comprises concurrent 
radiotherapy and temozolomide followed by adjuvant temozolomide. In those with a 
good Karnofsky performance score, the median survival is quoted as being between 12 
and 18 months. Although this is almost double that in the beginning of the 20th 
century, the gain in survival remains only in the order of months, and is modest (see 
Table 2). 
 
 Median Survival, months 
 Surgery Alone Surgery +Radiation Surgery+Radiation+Chemotherapy 
19585  9  
19786 3.5 7  
200511  12.1 14.6 
 
Table 2 Summary of Median Survival Over Time For Grade 4 Astrocytoma 
Information is derived from the studies described in sections 1.2 and 1.3. The data from 1978 has been 
adjusted from ‘weeks’ to ‘months.’ Over half a century the improvement in survival for grade 4 astrocytoma 
has only been in the order of months, and is modest.  
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Fundamental to the evasiveness of grade 4 astrocytoma is its infiltrative nature, and this 
was recognised very early on. Historically, patients were subjected to extensive 
resections that included lobectomies and even hemispherectomies in the hope that 
complete excision of the gross tumour and adjacent microscopically invaded tissue 
would result in cure. Such operations were almost always failures. Disregarding the 
immediate surgical mortality of such extensive surgeries, in a high percentage of 
patients, the disease had extended to involve the opposite hemisphere via the corpus 
callosum, and it was this disease that continued to grow leading to death of the patient: 
pathological study of 28 consecutive autopsy cases of grade 4 astrocytoma 
demonstrated that in 21 cases there was gross interhemispheric extension of the disease 
through the corpus callosum25.  
 
Developed in 1971, magnetic resonance imaging (MRI) became a standard part of the 
work up of a patient with a brain tumour by the late 1980s. Typically, high-grade 
astrocytomas were found to demonstrate prominent heterogeneity in signal intensity: on 
T2 weighted images, high-grade astrocytomas typically displayed a hyperintense core, 
a less hyperintense or normal intensity rim, and a surrounding area of high intensity26 
(see Figure 2b). Marked and irregular contrast enhancement was also characteristic (see 
Figure 2a and c). Traditionally, removal of the enhancing portion of the tumour would 
be considered a gross total resection. However, histological examination has shown 
that tumour cells extend at least 2 cm from the radiographical contrast enhancing mass. 
Specifically, tumour cells have been demonstrated to extend into the outer surrounding 
area of T2 hyperintensity, and in some cases, even beyond this. In one histologic 
study27, at the time of surgical resection or biopsy, biopsy specimens were also taken 
from areas of the brain considered to be normal on T1 and T2 weighted images. 
Numbers were limited for ethical reasons. 16 of the 23 and 4 of the 10 biopsies taken 
from areas considered normal on T1 and T2 weighted images, respectively, 
demonstrated tumour cells.  
 
It is this diffuse, microscopic infiltration that is fundamental to the recurrence of high-
grade astrocytoma following initial treatment. The most common site of recurrence is 
that of the original tumour location, with more than 90% of patients with high-grade 
astrocytoma recurring here28. Consistent with the diffuse nature of the disease, although 
less common, grade 4 astrocytoma will also recur through the development of new 
parenchymal lesions (see Figure 2f) or intraventricular spread remote to the site of the  
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Figure 2 A patient with grade 4 astrocytoma 
Images are courtesy of Dr M Baskaya, University of Wisconsin Neurosurgery. These are axial MR images from 
a 67 year old female diagnosed with grade 4 astroctyoma. The patient has two main, enhancing foci of disease 
seen on the T1 acquisitions with contrast: one in the right temporal lobe (a), and one in the right occipital lobe 
(c). The T2 acquisition (b) illustrates some typical characteristics of grade 4 astrocytoma; the hyperintense 
core (H1), a rim of normal intensity surrounded by an area of hyperintensity (H2). The patient underwent 
gross total resection of the enhancing disease (d and e). However, despite this and adjuvant radiotherapy and 
temozolomide, within 3 months, she had progression of disease in the corpus callosum crossing to the left side 
(f). This was a more aggressive course than expected as the MGMT promoter was methylated.  
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original tumour. It may be argued whether grade 4 astrocytoma is ever cured, and 
whether ‘recurrence’ is in fact progression of disease. Nevertheless, the mean time to 
tumour recurrence/progression varies between 4.9 months to 12 months. Of the 
conventional treatment modalities currently available, each have limitations to tackling 
the invasive nature of grade 4 astrocytoma.  
1.5.1 Limitations of Surgical Resection 
Understanding the invasive nature of grade 4 astrocytoma, which eludes the most 
sensitive of imaging techniques and the most powerful of operating microscopes, it can 
be seen that a complete resection of the tumour is unattainable. Some surgeons would 
advocate not only resecting the contrast enhancing part of the tumour, but also the rim 
of T2 hyperintensity surrounding it, eloquence of the brain permitting. However, 
tumour cells still extend beyond this. Certainly some degree of resection rather than 
biopsy alone has been shown to be beneficial29. However, whether the extent of 
surgical resection confers a survival advantage has been contentious. Several authors 
have attempted to draw conclusions from a number of small retrospective series30,31. 
However, analyses were limited by several factors: extent of resection was often 
subjective and dependent upon surgeon report as opposed to objective review of post 
operative imaging; patients were not stratified according to age and performance status, 
both strong prognostic indicators in themselves. Subsequently, one group from a large 
US cancer centre published more objective findings of their experience32. They 
analysed 416 consecutive patients with histologically proven grade 4 astrocytoma, who 
underwent tumour resection between 1993 and 1999. Although the analysis was 
retrospective, patient demographics, volumetric data and other tumour characteristics 
identified on MRI were collected prospectively. Five independent predictors of survival 
were found, one of them being the extent of resection. Defining tumour volume by the 
area of increased signal intensity on contrast-enhancing T1 weighted MR images, a 
significant survival advantage was associated with resection of 98% or more of the 
tumour volume: this resulted in a median survival of 13 months compared to 8.8 
months when a lesser resection was achieved. A more recent, similarly designed study, 
not only corroborated this findings, but suggested that even resections as low as 78% of 
the total conferred a survival advantage33. 
 
The closest examination of this issue in a randomised controlled manner was with the 
use of fluorescence to guide resection. 5-aminolevulinic acid (5-ALA) is a non-
fluorescent prodrug that, when given to patients orally, leads to the selective 
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intracellular accumulation of fluorescent porphyrins in malignant astrocytomas. At the 
time of surgical resection, using a modified operating microscope, the tumour can be 
viewed using conventional white light as well as using a violet-blue light, which causes 
the tumour cells that now contain the porphyrins to fluoresce. With the aid of this 
fluorescence, the surgeon can resect islands of infiltrative cells that may have escaped 
notice under conventional white light. In one European centre, 322 patients were 
randomised to undergo either standard microsurgical resection or fluorescence-guided 
resection34, followed by standard protocols for radiation and chemotherapy. Complete 
resection of the enhancing tumour was achieved in a significantly higher proportion of 
patients undergoing fluorescence-guided resection (65%) compared to those 
undergoing standard surgery (36%). Moreover, a higher proportion of those who had 
undergone fluorescence-guided resection reached 6 month progression free survival 
(41%) compared to those who had undergone standard surgery (21.1%). However, 
there was no difference in overall survival between the two groups. These results 
reflect the diffusely infiltrative nature of the disease: with optimum resection of local 
disease, the best that was achieved was prolonged time to disease progression, and thus 
improved symptom-free survival and quality of life. However, as distant malignant 
cells remained present, overall survival remained unchanged. Fluorescence guided 
resection will be discussed in more detail in Chapter 2.  
 
Another important limitation of surgery is that in many cases the tumour is intimately 
associated with an area of eloquence such as the motor cortex or thalamus. In 
attempting a gross total resection, there is significant risk of leaving the patient with a 
profound and permanent neurological deficit. Not only is this undesirable, but many 
oncologists will not commence adjuvant therapy in those with a Karnofsky 
performance score of less than 60 (a score of 60 is where a person requires occasional 
assistance but is able to care for most of their personal needs)35 or if the patient has 
significant disability: therefore a heroic attempt at a gross total resection leaving a 
patient with significant deficit would not effectively change the natural history of the 
disease. In such cases, obtaining a biopsy for a tissue diagnosis then proceeding with 
adjuvant therapy is more prudent. 
1.5.2 Limitations of Radiotherapy 
Radiation has been clearly shown to improve survival in high-grade astrocytoma: a 
meta-analysis of 6 randomised controlled trials demonstrated a significant survival 
benefit from post-operative radiotherapy36. Typically, radiation is given such that the 
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high-dose volume should incorporate the enhancing tumour plus a limited margin, e.g. 
2 cm. The total dose delivered is in the range of 50-60 Gy in fraction sizes of 1.8-2.0 
Gy. 
 
However, the response of the disease to radiotherapy clearly reinforces the 
pathogenicity of the distant islands of tumour cells that extend beyond the main tumour 
mass. 571 patients with high-grade glioma were randomised to three different 
chemotherapy regimes37. Those accrued in 1980 and 1981 received whole brain 
radiation, whereas those accrued in 1982 and 1983 were randomly assigned to receive 
whole brain radiation or whole brain radiation plus a boost to the enhancing tumour 
plus a 2 cm margin. There was no significant difference in survival between the three 
chemotherapy arms, and no differences in survival among the three different cohorts of 
radiation protocols: delivering additional radiation to the main tumour mass provided 
no survival benefit. More recently, radiosurgery has been used to deliver a high- and 
well-circumscribed dose of ionising radiation to a target, using a very steep gradient 
index and stereotactic targeting to minimise the adverse effect of radiation to 
surrounding structures. In a randomised trial, 200 patients with grade 4 astrocytoma 
were assigned to receive stereotaxic radiosurgery to the main tumour mass followed by 
conventional radiation and bis-chloroethylnitrosourea or treatment with conventional 
radiation and bis-chloroethylnitrosourea alone38. The addition of stereotaxic 
radiosurgery did not confer a survival advantage. Overall, focusing radiation on the 
main tumour mass is not enough to improve upon survival: it seems that it is the 
continuing survival of the distant islands of infiltrative cells that subsequently influence 
prognosis.  
 
The dose of radiation that can be delivered is limited by the risk of a delayed, but well 
documented, decline in cognitive function39. Furthermore, the efficacy of radiation is 
limited by the development of radiation resistant populations of cells. To overcome 
these problems, dose intensification strategies have been studied. Hyperfractionation 
involves the use of a larger number of smaller sized fractions to achieve a total dose of 
radiation that is higher than conventionally administered radiation in the same overall 
treatment time. Accelerated fractionation delivers 2 or 3 usual sized fractions each day 
with the goal of reducing overall treatment time, thereby decreasing the possibility of 
tumour repopulation during treatment. Hypofractionation uses fewer, but larger, 
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radiation fractions, again in an effort to reduce the overall treatment time. None of 
these strategies have been associated with a survival benefit36.  
 
Use of radiation sensitisers, chemicals that increase the lethal effects of radiation, have 
also been used to overcome the limitations of radiation. Two classes of radiation 
sensitisers have been studied in high-grade astrocytoma: hypoxic cell sensitisers and 
halogenated pyrimidines. Intraoperative in vivo measurements and PET studies have 
demonstrated the presence of hypoxic regions in high-grade astrocytoma, and in vitro 
studies have established that hypoxic cells are 2.5 to 3 times more resistant to radiation 
than well-oxygenated cells. Hypoxic cell sensitiers, typically nitroimidazoles, work to 
increase the effect of radiation on hypoxic tumour cells without increasing the radiation 
effect on the already well-oxygenated normal tissue. There have been 13 randomised 
studies comparing sensitised radiotherapy with nitroimidazoles to radiotherapy alone, 
with only one, the earliest and smallest of the studies, showing any benefit36. The 
second class of radiation sensitisers, the halogenated pyrimidines 5-bromodeoxyuridine 
and 5-iododeoxyuridine, are similar to the normal DNA precursor thymidine, except 
for having a halogen substituted in place of a methyl group. These compounds are 
competitively incorporated into DNA in place of thymidine, leading to increased 
radiation sensitivity: mitotically active tumour cells are more likely to incorporate these 
compounds than the more slowly replicating surrounding non-tumour cells, thereby 
making tumour cells more sensitive to the lethal effects of radiation. Compared to 
historical controls, patients with grade 3 astrocytoma treated with 5-bromodeoxyuridine 
during radiotherapy followed by adjuvant chemotherapy seemed to have a survival 
advantage40, although patients with grade 4 astrocytoma did not41. However, the 
subsequent RTOG randomised controlled trial comparing the effect of radiation with or 
without 5-bromodeoxyuridine followed by adjuvant chemotherapy on patients with 
grade 3 astrocytoma did not demonstrate a survival advantage42. 
 
Although radiotherapy confers a clear survival advantage over surgical resection alone 
in the management of grade 4 astrocytoma, its effect on the diffuse nature of the 
disease remains limited. Several strategies to overcome its limitations have been 
attempted without success.  
1.5.3 Limitations of Chemotherapy 
Chemotherapy faces many challenges in the treatment of intrinsic tumours of the brain. 
Among these include overcoming the BBB, unique to treating intrinsic brain tumours; 
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and overcoming the development of drug resistance, a challenge common to treating all 
cancers. 
1.5.3.1 The Blood Brain Barrier  
The endothelium of the cerebral capillary circulation, the anatomic basis of the BBB, is 
composed of tightly fused junctions, in contrast to the open endothelium of the 
peripheral circulation. This results in a continuous lipid layer that effectively restricts 
the movement of molecules into and out of the brain. Only small, electrically neutral, 
lipid-soluble molecules, with molecular weights up to 500 Da, can penetrate the BBB 
by passive diffusion. Temozolomide, the only chemotherapeutic agent currently used as 
standard of care of high-grade astrocytoma11, is able to cross the BBB due its small size 
of 194 Da and its lipophilic nature43. However, most chemotherapeutic agents do not 
have these traits.  
 
The limitations of the BBB may not seem so relevant to astrocytomas, as the areas of 
contrast enhancement that are so characteristic of high grade disease, reflect regions 
where the BBB has broken down, allowing intravenous contrast to extravasate into the 
surrounding tissues. However, those distant islands of invasive tumour cells, which do 
not contrast enhance and are radiographically invisible, can still evade chemotherapy 
agents because of the BBB.  
 
One strategy to overcome the BBB is to bypass it by directly infusing drug into the 
brain. In the search for chemotherapeutic agents, research at the National Cancer 
Institute led to the development of nitrosurea compounds over 40 years ago44. 
Subsequent, generation of more active analogues led to the discovery of one of the first 
agents effective against malignant glioma: 1,3-bis(2-chloroethyl)-1-nitrosurea (BCNU, 
carmustine) was shown to be highly effective in the treatment of intracerebral L1210, a 
murine leukaemia cell line, and in ensuing clinical trials, BCNU was found to confer 
some survival advantage over radiotherapy alone in patients with malignant glioma45-47. 
However, the systemic toxicities of BCNU, which include haematologic toxicity48, 
pulmonary fibrosis49,50, and secondary acute leukaemia51,52, proved limiting. Although 
the activity of systemically administered BCNU on intracranial tumours implied an 
ability to cross the BBB53, its toxicity limited its use. In an attempt to reduce these 
systemic toxicities but to continue benefiting from its efficacy led to research on local 
delivery methods. 
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Direct administration of BCNU through a catheter inserted in the surgical cavity was 
attempted in 1975 with no clear success, most likely due to the short half-life of BCNU 
in solution and to the limited delivery to the tumour tissue54. In the late 1980s, 
biodegradable polymer wafers that could be loaded with BCNU (Gliadel®, MGI 
Pharma, Inc.) were developed55. Following surgical resection, the wafers could be 
implanted in the surgical bed, and in the aqueous environment of the brain, hydrolysis 
of anhydride bonds of the polymer allows release of the BCNU, which diffuses into the 
surrounding brain tissue. This delivery system was proven superior to systemic 
administration in animal models and demonstrated limited systemic toxicity56. The 
wafers have been shown to release BCNU in vivo over a period of 21 days, the majority 
of the drug release taking place in the first 5-7 days57,58 and to degrade completely over 
a period of 6-8 weeks, with the polymer degradation products being eliminated through 
the urine57,59,60. 
 
Efficacy of BCNU-loaded wafers in high-grade glioma has been tested in three 
randomised, phase III trials. The first was performed in 222 patients with recurrent, 
malignant brain tumours requiring reoperation, the majority (approximately 62 % of 
each treatment group) being diagnosed with grade 4 astrocytoma61. Patients were 
randomly assigned to receive biodegradable polymer discs that were either loaded with 
3.85% BCNU or not. The median survival of those receiving carmustine-loaded 
polymer was significantly better than in those receiving the placebo polymer alone (31 
weeks vs 23 weeks respectively, p = 0.006). Analysing only those with grade 4 
astrocytoma, mortality at 6 months was significantly reduced in those receiving BCNU-
loaded polymer compared to those receiving the placebo polymer alone (44% vs 64% 
respectively, p = 0.02). Based upon this the Food and Drug Administration of the US 
approved the use of this treatment in those with recurrent grade 4 astrocytoma, 
although closer analysis revealed that the survival benefit at 6 months with treatment is 
lost at 1 year, when no difference in survival between the groups was seen.  
 
Two trials then examined the effect of the drug-loaded wafers on newly diagnosed 
high-grade gliomas.  The first trial was a randomised, double-blind study in only 32 
patients62. Again, patients were randomised to receive BCNU-loaded polymer discs at 
the time of surgery or placebo discs. Those in the treatment group had a significantly 
longer median survival compared to the placebo group (58.1 weeks vs 39.9 weeks 
respectively, p = 0.012). A larger randomised, placebo-controlled trial of 240 patients 
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followed63. The patients again underwent gross total resection and were randomised to 
receive BCNU-loaded polymer wafers or placebo. Again, the majority of patients had 
grade 4 astrocytoma. The median survival of those in the treatment group was again 
significantly greater than those in the placebo group (13.9 months vs 11.6 months 
respectively, p = 0.03). However, the progression free survival in each group was not 
significantly different and found to be 5.9 months. And, when those with grade 4 
astrocytoma were analysed as group, the difference in median survival in the treatment 
and placebo groups were not significantly different (13.5 months vs 11.4 months 
respectively, p = 0.10).  
 
Overall, there is no robust data supporting a survival benefit to delivering BCNU 
locally via degradable polymer wafers following resection in grade 4 astrocytoma. 
However, this is not surprising. The wafers allow delivery of BCNU at high 
concentrations of up to only 12 mm from the site of the polymer, as demonstrated in 
animal models57, while distant regions of the brain are exposed only to very low 
concentrations64. Again, the distant islands of infiltrative cells would be left relatively 
untouched.  
 
Furthermore, these studies with BCNU-loaded wafers revealed complications of local 
delivery. During the phase III clinical trials, the complication rate of the treatment 
group was similar to that of the placebo group62,63. However, in clinical practice more 
treatment-related complications were identified. The rate of post-craniotomy surgical 
infection after BCNU wafer placement was reported to be as high as 28%65. Extensive 
cerebral oedema that led to severe neurologic complication and death was also 
associated with BCNU wafer placement66. A case report also described obstructive 
hydrocephalus, severe toxicity and death following BCNU wafer placement when 
resection had led to a large opening in the ventricle67.  
 
Drug delivery via polymer wafers relies upon diffusion to distribute the drug through 
the brain. In an attempt to increase that distance a method of utilising convection to 
supplement diffusion has been developed, and is known as convection-enhanced 
delivery (CED)68. Convection results from a simple pressure gradient generated by a 
pump that pushes solute through a catheter targeted within the brain. Resulting bulk 
flow of interstitial fluid mediates the distribution of the solute, enhancing interstitial 
drug distribution. To perform CED, one or more catheters are stereotactically 
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implanted into the desired location via a burr hole or craniotomy. Many phase I and II 
clinical trials have established the safety of a variety of agents delivered by CED in 
those with malignant glioma, and include conventional chemotherapeutics69, cytotoxin-
ligand conjugates targeting cell surface receptors66, monoclonal antibodies with70 or 
without71 radioactive isotope conjugates, antisense oligonucleotides72, and liposomal 
vectors engineered to deliver gene therapies73. As CED is supposedly more efficient 
than diffusion-only-mediated delivery, CED infused doses do not need to be as high, 
thereby limiting local toxicity. 
 
There has only been one completed phase III trial using CED74. 296 patients presenting 
with first recurrence of grade 4 astrocytoma were randomised to receive either 
carmustine-impregnated polymer wafers or cintredekin besudotox delivered by CED 
following tumour resection. Cintredekin besudotox is a recombinant chimeric cytotoxin 
composed of human interleukin-13 (IL13) fused to a truncated, mutated form of 
Pseudomonas aeruginosa exotoxin A. This agent targets and kills tumour cells that 
express the IL13 receptor, which has been found to have a higher expression in 
malignant glioma than in low-grade disease of non-neoplastic glia75. No significant 
survival difference was found between the two treatment arms. In spite of several 
design flaws, including a statistical design that required a greater than 50% survival 
benefit over the active control arm; no other agents, even those FDA approved, having 
come close to this mark for recurrent grade 4 astrocytoma, CED overall has been 
limited by many technological factors. The first is that of catheter design. Early 
catheters were complicated by significant backflow around the catheter and along the 
insertion tract: real-time MRI has documented that reflux can be seen along the 
insertion tract in up to 20% of catheter placements76. Furthermore, considerable 
variability exists between neurosurgeons in surgical technique and placement accuracy: 
only 68% of catheter placements were performed per protocol specifications in the 
above phase III trial. Not only is research being conducted in improving catheter 
design, but also in producing software algorithms that define optimal trajectories that 
can be incorporated into the intraoperative navigation system typically used by 
neurosurgeons. 
 
Overall, there has been lack of study into the actual volume of distribution of these 
drugs in those with disease. The volume of drug distribution achievable has been 
reported as approximately 570 mm3 in normal brains of non-human primates77. 
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Although the distribution of drug via CED in normal brain is altered by the presence of 
tumour76, it has been shown that a drug delivered by CED can penetrate the infiltrative 
cells at the margin of grade 4 astrocytoma78. However, whether CED can deliver drug 
to distant sites of infiltrative cells to an extent that can impact upon survival 
significantly has yet to be determined. 
1.5.3.2 Drug Resistance 
It has been clearly demonstrated that those in whom the MGMT promoter is 
unmethylated i.e. those in whom DNA repair should be intact, temozolomide does not 
confer a survival benefit24. Furthermore, even those in whom the MGMT promoter is 
methylated will eventually succumb to their disease79, indicating that there must be 
mechanisms that underlie chemotherapy resistance.  
 
Several of these mechanisms involve DNA repair pathways. For example, the base 
excision repair pathway. Interestingly, temozolomide causes alkylation of guanine at 
the O6 position only 7% of the time. More commonly, alkylation occurs at the N-7 
position of guanine and the N-3 position of adenine, and can also occur at abasic sites. 
The base excision repair pathway mediates repair at these sites and several enzymes are 
implicated. Activity of poly (ADP-ribose) polymerase (PARP), another family of 
proteins involved in DNA repair, has been shown to be directly related to 
temozolomide resistance80-82, where inhibition of PARP increases susceptibility to 
temozolomide81. Based upon this, a phase I/II trial of temozolomide and the PARP 
inhibitor ABT-888 was conduced in patients with recurrent, temozolomide-resistant, 
grade 4 astrocytoma83 to establish drug dosing, scheduling, and a safety profile. A 
phase III trial to analyse efficacy awaits. Additionally, in vitro and in vivo evidence has 
demonstrated that alkyladenine-DNA glycosylase, the sole enzyme that excises the 
methyl group from the N-3 position of adenine, and Ape1, the major human abasic site 
endonuclease, mediate temozolomide resistance84. 
 
Another DNA repair pathway implicated in drug resistance is the mismatch repair 
(MMR) pathway. This pathway addresses insertion/deletion loops, and base-base 
mismatches. The system degrades the error-containing section of the newly synthesized 
DNA strand and thereby provides DNA polymerase with another chance to generate an 
error free copy of the template sequence85. Aberrant expression of the MMR pathway86 
and upregulation of certain components have been associated with temozolomide 
resistance85. 
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Recently, a novel pathway involving microRNA has been implicated in temozolomide 
resistance. cMyc is a transcription factor involved in cell cycle progression and 
apoptosis that is often constitutively expressed in cancer cells. in vitro and in vivo 
studies have shown it to be an important positive upstream regulator of the newly 
described microRNA miR-29c/REV3L axis: cMyc upregulation drives the 
downregulation of miR-29c, releasing its inhibition on REV3L, a DNA repair 
polymerase, resulting in increased REV3L expression, and consequent enhanced DNA 
repair capacity87. And hence, another mechanism of temozolomide resistance may be 
REV3L over expression and consequent sustained DNA repair. 
 
Several other modes of resistance have also been elucidated. One is that of 
intratumoural heterogeneity. When multiple, spatially distinct biopsies were taken from 
several grade 4 astrocytomas, significant intratumoural heterogeneity at the 
transcriptional, methylation, and mutational level was demonstrated86. For example, 
14% of the cases demonstrated intratumoural heterogeneity in MGMT promoter 
methylation levels with the percentage of methylation varying up to 4-fold within each 
case. Such intratumoural heterogeneity likely underlies not only resistance to treatment, 
but explains partial and variable responses to treatment. Interestingly, temozolomide 
itself has been implicated in promoting drug resistance. Recently, it has been suggested 
that in MGMT promoter methylated patients, treatment with temozolomide induces a 
hypermutated phenotype, resulting in DNA repair deficiency and enhanced chemo-
resistance. 
 
Overall, drug resistance is multi-modal and a significant limitation to chemotherapy. 
1.6 Summary 
Grade 4 astrocytoma is the commonest primary brain tumour. Despite advances in 
surgical technique, radiation, and chemotherapy, its prognosis remains poor.  
Overcoming its diffuse and infiltrative character is a challenge. Surgery and radiation 
focus on the main enhancing bulk of the disease. Chemotherapeutics are limited by the 
BBB and resistance mechanisms. It is clear a new approach to treating grade 4 
astrocytoma is needed.  
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Chapter 2 Photodynamic Therapy 
PDT is a method of achieving tumour cell kill where a photosensitising agent that 
localises relatively specifically in the tumour is administered and then activated by light 
of a specific wavelength. This leads to a sequence of photochemical and photobiologic 
processes that cause irreversible photodamage to tumour tissue88.  
2.1 Background 
Light has been used as therapy for more than 3000 years89,90. Ancient Egyptian, Indian 
and Chinese civilisations used light to treat various diseases including rickets, psoriasis, 
vitiligo, and skin cancer91. At the beginning of the 20th century in Denmark, Niels 
Finsen discovered the use of red light to treat small pox and UV light from the sun to 
treat cutaneous tuberculosis, discoveries for which he was subsequently awarded the 
Nobel Prize92. Around the same time, researchers found that certain chemicals in the 
presence of light would cause cell death. Certain wavelengths of light were found to be 
lethal to infusoria in the presence of acridine93. The development of dermatitis in an 
epilepsy patient being treated with oral eosin heralded the treatment of skin tumours 
with topically applied eosin and white light93. This interaction between chemical and 
light was termed ‘photodynamic action.’ 
 
A decade later, the interaction between porphyrins, which had been identified as being 
associated with porphyria and skin sensitivity in the mid 1800s, and light was being 
investigated. Exposure of Paramecium and red blood cells to haematoporphyrin and 
light was found to be lethal. Then in 1975, the combination of haemotoporphyrin 
derivative (HpD), which was synthesised in the 1960s94 and could be administered at 
much smaller doses than crude haematoporphyrin, and red light was found to 
completely eradicate mammary tumour growth95 and bladder carcinoma96 in mice. And 
thus, the foundations for human trials were laid.  
2.2 Mechanism of Action 
PDT requires three components, which individually are non-toxic: the first is the 
photosensitiser, the second is light of a specific wavelength that can activate the 
photosensitiser, and the third is oxygen. When the photosensitiser is activated by light 
of a specific wavelength, by absorbing photons, the photosensitiser is transformed from 
its ground, singlet state into a relatively long-lived, electronically excited, triplet state, 
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via a short-lived, excited, singlet state (see Figure 3). The photosensitiser in its excited, 
triplet state, can then undergo two reactions, both of which result in the formation of 
singlet oxygen, a highly reactive oxygen species97. Firstly, it can react directly with a 
substrate, such as the cell membrane or a molecule and transfer an electron to form free 
radicals, which can interact with oxygen to produce singlet oxygen: this is termed a 
type I reaction. Alternatively, as the excited, triplet state photosensitiser returns to its 
ground, singlet state, it transfers its energy to ground state triplet oxygen, again 
producing singlet oxygen: this is termed a type II reaction. Both type 1 and type II 
reactions occur simultaneously, and the ratio between these processes depends on the 
type of sensitiser used, the concentrations of substrate and oxygen, and the binding 
affinity of the sensitiser for the substrate98. Nevertheless, it is the resulting singlet 
oxygen that then mediates cell death.  
 
 
 
Figure 3 Photodynamic therapy: mechanism of action 
When a photosensitiser is activated by light of a specific wavelength it is transformed from its ground, singlet 
state into a relatively long-lived, electronically excited, triplet state, via a short-lived, excited, singlet state. In 
its excited, triplet state, it can undergo two reactions. Firstly, it can react directly with a substrate, such as the 
cell membrane, to form free radicals, which can interact with oxygen to produce singlet oxygen (1O2): a type I 
reaction. Alternatively, as the excited, triplet state photosensitiser returns to its ground, singlet state, it 
transfers its energy to ground state triplet oxygen (3O2), again producing singlet oxygen: a type II reaction.  
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Cell death mediated by singlet oxygen can occur via three main mechanisms88. Firstly, 
singlet oxygen can kill cells directly. Secondly, singlet oxygen can damage tumour-
associated vasculature, leading to tumour infarction. And finally, this damage that is 
caused can activate an immune response against the tumour. Although the relative 
importance of each for the overall tumour response is yet to be defined, it is clear that 
the combination of all these components is required for long-term tumour control.  
 
The actual extent of photodamage and cytotoxicity that singlet oxygen can impart onto 
a tumour is determined by several factors. These include the type of photosensitiser, its 
extracellular and intracellular localisation, and the total dose administered, as well as 
the total light exposure dose, light fluence rate, oxygen availability, and the time 
between the administration of the drug and light exposure. Having established a vast 
library of photosensitisers and an understanding of the wavelengths of light that can 
activate them and the singlet oxygen that can be produced99, more recent in vitro and in 
vivo studies focus their efforts on studying these variables and finding the optimum 
conditions that lead to maximum tumour kill.  
2.3 Advantages of PDT 
By virtue of its mechanism of action, PDT has several unique advantages over 
conventional therapies. Firstly, PDT is associated with very little toxicity. In the 
absence of light of a specific wavelength, photosensitisers themselves have very little 
effect, with only some causing self-limiting changes to liver function if given at high 
dosages. Its most significant side effect is that of skin and eye photosensitivity, which 
can last from a few hours to a few months depending on the photosensitiser. The 
danger comes from prolonged exposure to direct sunlight, and like sun burn, the effect 
is not immediately noticeable, only becoming apparent a few hours later. Patients must 
be educated about this and are advised to wear dark glasses and to cover areas of 
exposed skin when exposed to bright lights until the drug level in the body has fallen to 
safe levels. If these precautions are adhered to, problems are very rare, and the effects 
of PDT relatively innocuous.  
 
Secondly, the photodynamic effect is largely localised to tumour tissue, leaving the 
surrounding normal tissues relatively untouched. The reasons for this are multifactorial. 
Initially, it was thought that selective uptake of the photosensitiser into the tumour 
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accounted for the selective effect. To some extent this is true. The peak concentration 
of the photosensitiser in tumour often occurs later after drug administration than the 
peak in adjacent normal tissue. In most organs, the ratio of photosensitiser 
concentration in tumour to normal tissue ranges from 2-3:1. This is enough to allow the 
identification of precancerous and cancerous lesions, photodynamic diagnosis (see 
below). However, this is not enough to account for the selectivity of the photodynamic 
effect. It is now recognised that the selective effect comes from careful targeting of the 
activating light100, and also the timing of light delivery to coincide with peak 
photosensitiser concentration in tumour tissue. Furthermore, as singlet oxygen is highly 
reactive with a short half-life, only cells close to the area of its production are affected: 
the half life of singlet oxygen in biological systems is < 0.04 µs and therefore its radius 
of action is < 0.02 µm. Importantly, PDT is a cold photochemical reaction101; there is 
no tissue heating and connective tissues such as collagen and elastin are largely 
unaffected. There is therefore much less risk to the integrity of the underlying 
structures than with thermal laser techniques and surgery, and for this reason, many 
PDT treated areas also heal with more regeneration and less scarring. This is 
particularly attractive when treating lesions of the skin, head and neck, and hollow 
organs, where PDT not only leads to minimal loss of tissue, which can be important 
cosmetically, but also minimal loss of function. 
 
Thirdly, unlike radiation, which is limited by the amount of ionising radiation that 
normal tissues can tolerate over time, PDT is not limited by cumulative toxicity. For 
this reason, PDT has the potential to be given repeatedly, and to be given to tissues that 
have already been exposed to maximum ionising radiation. Lastly, there is little 
evidence for the development of resistance to PDT. Overall, for the treatment of cancer, 
PDT is a safe and complementary adjunct to the conventional therapies of surgery, 
radiation and chemotherapy. 
2.4 Clinical Applications of PDT 
In the clinical setting, PDT requires two steps. Firstly, the photosensitiser is 
administered, either systemically (intravenous or oral), or by topical application. 
Secondly, after a time interval that varies between minutes and days depending on the 
photosensitiser, allowing tissue accumulation of the photosensitiser, the light is applied 
to the site of disease.  
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2.4.1 Photosensitisers 
The first photosensitisers were derived from the naturally occurring, endogenous, 
porphyrins: the first generation. In overcoming some of the photochemical limitations 
associated with these, a second wave of completely synthetic compounds that were still 
based upon the tetrapyrolic structure of the porphyrins was developed: the second 
generation. More recently, the focus has been on targeting approaches to increase 
photosensitiser affinity to tumour tissue, and hence the third generation.  
2.4.1.1 First Generation Photosensitisers 
In 1841, it was discovered that when haemoglobin is subjected to acid hydrolysis, 
removing the protein and iron, a red-purple substance is left. A few years later in 1844, 
the chemical composition of this substance was determined, and it was called 
‘haematin,’ later to be renamed ‘haematoporphyrin,’ after the Greek for purple, 
‘porphyrus.’ Haematoporphyrin was later recognised to confer a powerful 
photosensitive effect, and in the search of a more soluble photosensitiser, it was treated 
with sulphuric acid in acetic acid at room temperature for 15 mins, then precipitated out 
with aqueous sodium acetate, then treated with alkali before neutralisation to a pH of 
7.4. This led to a preparation containing a mixture of di- and oligomeric porphyrins that 
was an extremely powerful photosensitiser, which was called haematoporphyrin 
derivative (HpD). Commercial development led to various proprietary photosensitisers 
of which Photofrin® received the first regulatory approval.  
 
PDT was first approved in 1993 in Canada, using Photofrin® for the prophylactic 
treatment of bladder cancer. As a first generation photosensitiser, it has some 
limitations. Firstly, the wavelength of light needed for activation, 630 nm, does not 
have high tissue penetration, and its depth of effect is limited to 0.5 cm. Secondly, its 
absorption band, measured by the molar absorption coefficient, at this wavelength is 
weak, 1.170 M-1cm-1, therefore its efficiency at transferring energy from light to 
cytotoxic products is moderate, with a quantum yield of singlet oxygen of 0.01-0.0999. 
Another important consideration is that eye and skin photosensitivity persists for many 
weeks and patients who have been treated with Photofrin® have to avoid sunlight for 
4-6 weeks.   
 
Another endogenous porphyrin in commercial use as a photosensitiser is 5-ALA, sold 
as Gliolan®. This is a naturally occurring precursor in the haeme biosynthetic pathway. 
It is a prodrug that is converted endogenously to protoporphyrin IX, which is the 
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photosensitiser. It is versatile in that it can be administered topically, orally, or 
intravenously. Although it can be activated by several wavelengths of light, 546, 630 
and 646 nm, the quantum yield of singlet oxygen at these wavelengths, 0.54, 0.54 and 
0.60, respectively, is modest99. Its depth of use is largely constratined to < 0.2 cm. 
However, one significant benefit is that light sensitivity only lasts 1-2 days. Methyl-
ALA and Hex-ALA have also be manufactured as hydrochlorides and sold as Metvix® 
and Hexvix®, respectively.  
2.4.1.2 Second Generation Photosensitisers 
To overcome the shortcomings of the endogenous porphyrins, a second generation of 
photosensitisere were synthetically developed to have longer activation wavelengths 
and therefore increased depth of effect, higher yields of singlet oxygen, better tumour 
selectivity, and shorter periods of photosensitivity. Their chemical configuration was 
based upon the tetrapyrolic structure of the porphyrin.  
 
One of the most thoroughly investigated class of second generation photosensitiser is 
the chlorins. meta-tetrahydroxyphenyl chlorin (mTHPC), with the generic name 
Temoporfin®, and the proprietary name Foscan, is a synthetic chlorin and a potent 
photosensitiser. It is activated by light with a wavelength of 652 nm and its quantum 
yield of singlet oxygen is 0.399. It has a residual photosensitivity of only 2 weeks.  
 
Other compounds include the benzoporphyrins (Visudyne®) and porphycene 
(ATMPn). Metallated derivative have also been synthesized (Al, AlPcS4; Si, SiNC; 
and Sn, SnEt2), although there is no consistent correlation between metallation and 
increased photodynamic activity102.  
2.4.1.3 Third Generation Photosensitisers 
More recently, targeting strategies have been shown to increase the affinity of the 
photosensitiser for tumour tissue103. There have also been reports of selectivity 
targeting subcellular compartments, including mitochondria104. These targeting 
approaches have led to a third generation of photosensitiser. The potential for these will 
be discussed further in the Conclusion.  
2.4.2 Light sources 
Light sources must provide enough light of an appropriate wavelength, in an acceptable 
treatment time, and with a spatial distribution that matches the target tissue geometry. 
The three main types of light source in use are filtered high-brightness lamps, light 
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emitting diode arrays, and continuous wave lasers. In this way, light can be delivered 
with relative ease to superficial targets, such as the skin and eye, and to hollow organs, 
such as the oesophagus and bronchus.  
 
Delivery of light to solid organs requires more sophistication. In such cases, light can 
be delivered directly into the solid tumour by feeding thin diffusing laser fibres through 
needles placed into the tumour under image guidance: interstitial PDT101. This type of 
treatment requires all light sources to be placed in an equidistant, parallel arrangement 
to ensure even light distribution. There is a clear parallel with interstitial radiotherapy. 
The needles can then be partly withdrawn to expose the fibres such that light from each 
fibre is emitted in a cylindrical distribution. In this way, layers of tumour can be 
treated, resulting in necrosis throughout even very large tumours. The necrotic tissue is 
resorbed rather than sloughing off.  
2.4.3 Clinical Applications 
PDT has mainly been approved for use in treating cancerous and pre-cancerous 
conditions. However, it has also been approved for use in vascular disease and also in 
treating infections.  
2.4.3.1 Cancerous and pre-cancerous conditions 
PDT is a well-established treatment modality in dermatology where it is used to treat 
superficial non-melanoma skin cancers and precancers such as actinic keratosis, 
Bowen’s disease, and basal cell carcinoma105. The photosensitiser commonly used is 
methyl-ALA, which can be applied topically as a cream. Healing is excellent with 
minimal scarring, even over bone where the skin has poor vascularity. Although 
conventional treatments such as surgical excision, cryotherapy, and radiation work 
well, PDT is of special value for lesions in cosmetically and functionally sensitive areas 
such as the head and neck region.  
 
Advanced cancers of the lips, tongue, mouth and pharynx carry great morbidity. Heroic 
surgery is feasible, but is often associated with loss of function (speech, mastication, 
and swallowing), and is markedly disfiguring. Radiation dries saliva production and 
destroys bone. PDT with mTHPC is approved for the treatment of advanced head and 
neck cancers in those who have failed, or would not tolerate, conventional 
treatments101.  
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PDT has also been approved for use in cancerous and precancerous lesions in hollow 
organs. By the time lung cancer becomes symptomatic, it is often too advanced for 
curative treatment. For bulky cancers that are bleeding or causing mechanical 
obstruction of a major airway, palliative endoscopic re-canalisation using PDT 
mediated by Photofrin® is an approved treatment. Furthermore, in early lung cancers 
that have not spread beyond the bronchial wall, PDT is approved for treatment in those 
who are not fit for surgery or chemoradiation106. Barrett’s oesophagus, secondary to 
chronic and excessive reflux, is common and 10-15% of those suffering from it will go 
on to develop dysplasia, which left untreated will progress to oesophageal cancer. If 
detected early enough, this can be treated endoscopically with PDT mediated by 
Photofrin® or radiofrequency ablation. The latter is preferred as it is simpler. However, 
if the cancer has spread to the deeper layers of the oesophageal wall but no further, 
PDT is possible, but radiofrequency is not, in patients deemed unfit for surgery and 
chemoradiation. Hex-ALA has also been approved for the detection of early cancer and 
precancerous lesions of the bladder (photodynamic diagnosis, see below). 
 
Studies into the use of PDT for the treatment of solid organ cancers are ongoing. The 
main challenge is light delivery, as discussed above. Organs being investigated include 
the pancreas, prostate, breast, and bone.  
2.4.3.2 Vascular disease 
Wet age-related macular degeneration is where macular degeneration is exacerbated by 
neovascularisation of the macula. PDT mediated by the photosensitiser Visudyne® has 
been approved in the UK and the US for the treatment of this, and has been shown to 
prevent disease progression for at least 5 years.  
 
Interestingly, preclinical studies have shown that PDT can reduce the stenosis due to 
proliferation of arterial smooth muscle cells after balloon angioplasty without reducing 
the mechanical strength of the artery and without increasing the incidence of 
thrombosis100. Pilot studies of adjuvant PDT after repeat angioplasty for recurrent 
femoral artery stenosis have shown a low incidence of subsequent restenosis. PDT is an 
attractive alternative to drug eluting stents at sites of arterial narrowing suitable for 
balloon angioplasty but unsuitable for stenting107.  
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2.4.3.3 Infection 
PDT using methylene blue as the photosensitiser is an approved treatment for gum 
periodonitis that is used widely, particularly in Canada. With an increasing incidence in 
antibiotic resistant organisms, novel anti-infective therapies are being sought. Studies 
are underway to investigate the use PDT to treat skin infections, including infected 
ulcers and acne. Studies are planned for using PDT to sterilize indwelling items such as 
urinary catheters and the tissue bed if infected joint prostheses have to be removed. 
2.5 Clinical Applications in Neurosurgery 
Gliomas were one of the first pathologies that the effectiveness of PDT was tested in. 
In 1972, haematoporphyrin followed by light therapy was proven to be lethal both to 
glioma cells in culture and in those transplanted subcutaneously in rats108. PDT is 
particularly attractive for use in the brain as its relatively selective action on tumour 
tissue would leave delicate and potentially eloquent brain tissue untouched. 
Overall, this should translate into little risk for the development of short- or long-term 
neurological deficits. 
2.5.1 Photosensitiser Localisation 
There is evidence that photosensitiers are taken up and retained preferentially by 
neoplastic tissue. However, this effect is generally not sufficiently pronounced to allow 
a selective clinical response, except in brain tissue109, where the absence of the BBB 
around the tumour aids this selectivity. The ratio of the concentration in tumour to 
normal brain ranges from 2.5:1 to 4:1 for HpD110,111, is 4:1 for 5-ALA, and 10:1 for 
mTHPC112.  
 
Despite this preferential uptake, there is some injury to the surrounding normal glia and 
neurons113-116, the degree of damage depending on the photosensitiser and its 
concentration, the time interval of sensitisation to light exposure, and the light density. 
In animal models, PDT has been shown to initially cause break down of the BBB, 
swelling of astrocytes and neurones, and after 24 hours, coagulation necrosis in the 
brain surrounding the tumour. Nevertheless, clinically, this translates very rarely into 
temporarily increased intracranial pressure that is non-fatal and amenable to standard 
medical treatment. Overall, therefore, the preferential uptake of photosensitisers into 
brain tumours is significant enough for a selective clinical response. 
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2.5.2 Photodynamic Diagnosis and Fluorescence Guided Resection 
The type I and II reactions that a photosensitiser undergoes as it returns to its ground 
state following excitation by a light of a specific wavelength has been discussed, and 
are what mediate photodynamic-mediated cell death. Additionally, as the photosentiser 
returns to its ground state, it can also release energy in the form of light, fluorescence. 
The preferential uptake of photosensitisers into brain tumours and their ability to 
fluoresce upon excitation by light has been used to delineate the characteristically 
indistinct borders of high-grade gliomas, termed photodynamic diagnosis (PDD), and 
to guide resection, fluorescence-guided resection (FGR).  
 
As discussed above, 5-ALA mediated FGR of high-grade glioma has been evaluated in 
a multi-centre phase III trial34 where FGR was shown to lead to a significantly higher 
frequency of complete resections of contrast-enhancing tumours as shown on early 
postoperative MRI. This translated into a significantly higher 6 month progression-free 
survival, but did not improve overall survival.  
2.5.3 Photodynamic Therapy 
Supported by in vitro117,118 and in vivo studies113,118,119, PDT for gliomas was tested in 
humans. It was applied as an adjunct to surgery, radiotherapy, and chemotherapy in 
patients with high-grade gliomas, as well as other types of intracranial tumours. PDT 
was given intraoperatively: patients were typically given the first generation 
photosensitiser, HpD, prior to surgery, then following either subtotal or gross total 
resection, the tumour cavity was exposed to light from various types of sources.  
 
The earliest reports of PDT being used to treat high-grade gliomas are from the 
1980s120,121. No survival advantage was gained. However, PDT was found to be safe 
and ongoing testing was deemed feasible. Since then, a number of small case series 
were published. A European group presented 11 patients with grade 4 astrocytoma and 
39 patients with recurrent grade 4 astrocytoma treated with PDT122. The median 
survival of those with primary disease was 19 months and the median survival of those 
with recurrent disease was 7 months. A Canadian group reported on 12 patients with 
newly diagnosed, and 37 patients with recurrent, grade 4 astrocytoma treated with 
PDT123. For those with newly diagnosed disease, the median survival was 33 weeks 
with a 1 and 2-year survival of 33 and 0%, respectively. For those with recurrent 
disease, the median survival was 29 weeks with 1 and 2-year survival of 19 and 3%, 
respectively.  
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The largest series examining the effect of PDT on high-grade glioma to date is from 
Australia and reports on 136 patients124. All patients with newly diagnosed tumours had 
standard postoperative radiotherapy and all those with recurrent tumour had been 
previously treated with radiotherapy. Chemotherapy was administered to 29% of 
patients in the study. Focusing on those with grade 4 astrocytoma, which made up over 
60% of the subjects, the median survival for patients with newly diagnosed grade 4 
astrocytoma (n=31) was 14.3 months, with 25% surviving for more than 36 months and 
22% surviving for more than 60 months. Furthermore, for those with recurrent disease 
(n=55), the median survival was 14.9 months from the time of reoperation, with 41% 
surviving beyond 24 months and 37% survival beyond 36 months. PDT was only 
complicated by cerebral oedema in 3 patients, which responded to standard medical 
therapy. There were no deaths associated with PDT.  
 
The European and Australian data are certainly compelling, indicating that PDT 
conferred at least a comparable survival advantage to chemotherapy, with considerably 
less side effects. The difference in findings between the European and Australian 
groups, and that of the studies in the 1980s and the Canadian group, highlights the 
importance of light dose. The mean light dose in the early studies ranged between 0.9 
and 9 J/cm2, and in the Canadian study was 58 ± 17 J/cm2, whereas the mean light dose 
in the European study was up to 260 J/cm2 and in the Australian study was 230 J/cm2.  
Light dosimetry is certainly important and underdosing the total light dose may be an 
important contributing factor to many treatment failures.  
 
Whether the degree of photosensitiser uptake into the tumour is associated with the 
degree of PDT effect is unclear. Work performed by the Australian group demonstrated 
that the greater the uptake of photosensitiser into the tumour, the better the outcome 
following PDT in patients with high-grade astrocytoma125. This would be consistent 
with greater singlet oxygen production, and hence greater tumour kill, with greater 
tumour uptake of photosensitiser. However, this relationship was not demonstrated by 
the European group122. It is possible that a higher tissue concentration of photosensitiser 
leads to greater light absorption and consequently, less light penetration into the deeper 
tissues, and hence, a paradoxically lesser PDT effect.  
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Although encouraging, the case series above are difficult to interpret, as there was no 
uniformity as to the degree of surgical resection or to the radiotherapy or chemotherapy 
regimes, predating our current standard of care with temozolomide chemotherapy, as 
described above. The results from a randomised, phase III trial of PDT for high-grade 
glioma using HpD were reported at an international meeting by the Canadian group 
(Muller et al., Proceedings of the International Photodynamic Symposium, Brixen, 
Italy, 2006). The trial did not reveal a survival advantage with PDT. However, results 
were confounded by the substantial degree of residual tumour left following resection.  
2.5.3 Combining Fluorescence Guided Resection and Photodynamic Therapy 
As discussed, there is increasing evidence to support that the degree of surgical 
resection influences survival32-34. Respecting this concept, and in light of the findings 
from the only phase III trial investigating PDT (Muller et al., Proceedings of the 
International Photodynamic Symposium, Brixen, Italy, 2006), the effect of combining 
FGR and PDT on patients with high-grade glioma has been investigated.  
 
A phase II study involving 22 patients with radiological findings consistent with grade 
4 astrocytoma was undertaken to assess the feasibility and effectiveness of combining 
FGR and intraoperative PDT using the photosensitiser mTHPC126. Patients were given 
the photosensitiser 4 days prior to surgery to allow it time to reach its maximum 
concentration within the tumour. At the time of surgery, gross total resection of the 
tumour was undertaken in the usual fashion. The tumour cavity was then exposed to 
blue light: mTHPC has a strong absorption band in the blue-wavelength range, which 
leads to strong fluorescence in the red part of the visible spectrum, with emission peaks 
at 652 and 718 nm. The resection was then carried out until no fluorescence was 
visible. Once FGR was complete, PDT was performed with light at a wavelength of 
652 nm. From biopsies taken from fluorescent and non-fluorescent areas, PDD with 
mTHPC was found to have a sensitivity and specificity of 87.9% and 95.7%, 
respectively. A gross total resection, assessed by MRI within 48 hours of surgery, was 
demonstrated in 75% of patients who underwent FGR/PDT, but only in 52% of the 
matched pair control group. Furthermore, the median survival for the FGR/PDT group 
was 9 months, compared to 3.5 months in the matched pair control group. Morbidity 
included two severe toxic reactions to sunlight, due to inadvertent exposure to direct 
sunlight, and one patient experienced temporary cerebral oedema, which was 
responsive to standard medical therapies. This study demonstrated that combining FGR 
and PDT is feasible and safe, and together, are likely to confer a survival advantage.  
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A phase III randomised controlled trial was conducted to investigate the effect of 5-
ALA and Photofrin® mediated FGR and PDT in patients with grade 4 astrocytoma127. 
27 patients from a single centre were recruited for this study and 13 were randomised 
to the study group, and 14 to the control group. Those in the study group received 
Photofrin® intravenously 48 hrs prior to surgery. Then 3 hrs prior to surgery, they were 
also given 5-ALA orally. They then underwent gross total resection using standard 
microsurgical techniques, following which blue light was shone into the tumour cavity, 
and FGR was used to maximise tumour resection. Once tumour resection was 
complete, a silicone balloon catheter was inflated to fit the surgical cavity and tunnelled 
out through the skin. Through this catheter, light at a wavelength of 630 nm could be 
delivered via a diode laser into the tumour cavity, with a goal dose of 100 J/cm2. 5 
‘light’ treatments were given: one in the recovery room immediately following surgery, 
then daily for the next 4 days. The patients also received standard radiotherapy, and 
were followed every 3 months. Those in the control group underwent gross total 
resection using standard microsurgical techniques followed by standard radiotherapy. 
The mean survival of the study group was 52.8 weeks compared to 24.6 weeks in the 
control group (p < 0.01). The study group gained on average 20 points on the 
Karnofsky performance score (p < 0.05). There were no differences in complications or 
hospital stay between the two groups. The mean time to tumour progression was 8.6 
months in the study group compared to 4.8 months in the control group (p < 0.05). 
Although this study was conducted in a small population, the results are certainly 
encouraging, demonstrating that in combination, FGR and PDT can confer a survival 
advantage with little morbidity.  
 
The rationale for using two photosensitisers in this phase III trial was that although 5-
ALA produces robust fluorescence, its half-life was too short to mediate PDT over 5 
days. In contrast, Photofrin®, as a result of being a mixture of molecules that tend to 
oligomerise, produces variable fluorescence, and also the fluorescence was noted to be 
very dark red and difficult to see. However, the half-life of Photofrin® allows it to 
mediate PDT over 5 days. The ‘repetitive’ PDT technique used here, otherwise termed 
‘metronomic,’ can be likened to the fractionation of radiotherapy. By having a break 
between ‘treatments,’ oxygen, an essential component for the photodynamic effect, can 
be replenished, as can fresh photosensitiser, repleting drug that has been 
photobleached. 
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The combination of FGR and PDT certainly seems to have a promising effect in the 
treatment of grade 4 astroyctoma. Studies with larger numbers of patients all receiving 
current standard of care with temozolomide chemotherapy are required.  
2.5.4 Limitations of PDT  
PDT has several advantages over conventional therapies. Being a cold photochemical 
process with a relatively selective effect on tumour tissue, preserving the surrounding 
normal brain, leaves little potential for the long term neurocognitive effects that can be 
associated with radiotherapy. Furthermore, compared to chemotherapeutic agents, side 
effects are rare, and residual photosensitivity is short-lived and tolerable with the 
correct precautions. However, PDT remains a focal treatment: light can only penetrate 
a certain distance, and hence, PDT does not address the diffuse nature of high-grade 
astrocytoma. Although PDT can induce a host immune response against the tumour, 
how this contributes to overall tumour control has not been delineated. For PDT to 
truly improve the outcome of high-grade astrocytoma, a novel way of delivering light 
to the diffusely infiltrative tumour cells must be found. This study investigates 
bioluminescence as a novel source. 
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Chapter 3 Bioluminescence, A Novel Method of Light Delivery 
Bioluminescence is the production and emission of light by a living organism. It is a 
type of chemiluminescence, a chemical reaction during which chemical energy is 
converted to light energy. Here, a background on bioluminescence will be given, and 
the possibility of bioluminescence as a light source for PDT will be explored.  
3.1 Bioluminescence 
The ability to generate bioluminescence exists widely in nature, throughout different 
ecosystems, and has evolved for several purposes that include defending against 
predators, hunting prey, and attracting mates. This capacity is most commonly found in 
species from the ocean, such as dinoflagellates, a type of plankton, and jellyfish, such 
as those from the Aequorea species128. Although more rare, terrestrial bioluminescence 
also exists, such as that from fireflies and click bettles.   
 
In the majority of cases, bioluminescence requires two chemicals; one that produces 
light, which is generically termed ‘luciferin,’ and one that catalyses the reaction, which 
is generically termed ‘luciferase.’ Simply, luciferase catalyses the oxidation of 
luciferin, resulting in the generation of light and an inactive molecule, oxyluciferin (see 
Figure 4). 
   
Figure 4 Simplified representation of chemiluminescence 
Chemiluminescence results from the oxygenation of ‘luciferin,’ which is catalysed by ‘luciferase.’ When this 
occurs in a living, biological organism, the reaction is termed bioluminescence. O2 denotes oxygen.  
 
In actuality, the bioluminescence reaction is more complex, and draws parallels with 
the energy transfers that occur with the photodynamic reaction. For example, in a 
system that uses beetle luciferase, luciferin binds to the luciferase and then luciferin 
(LH2) undergoes adenylation to form luciferyl adenylate (LH2.AMP)129. An enzymatic 
base then extracts a proton from the 4-C of LH2 in the LH2.AMP, forming a carbanion, 
which reacts rapidly with oxygen. This results in the formation of a high energy, 
intermediate, dioxetane transition state and the removal of AMP130. Subsequent 
decarboxylation of this intermediate releases energy, which is efficiently transferred 
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into producing a high yield of singlet, excited state oxyluciferin (LO*). When this 
decays to ground state oxyluciferin (LO), a photon is emitted.  
3.1.1 Wavelengths of Bioluminescence 
As a reflection of the diverse habitats in which bioluminescent organisms exist, 
bioluminescence is produced in a range of colours of the visible electromagnetic 
spectrum. Most marine bioluminescence is expressed in the blue-green part of the 
spectrum, as most marine organisms are only sensitive to blue-green colours and are 
unable to process yellow, red, or violet colours. From land, fireflies emit ‘yellow-
green’ light, while the related click beetle emits light that ranges from orange to green. 
Furthermore, due to incident light, terrestrial bioluminescence is often brighter: 
bioluminescent beetles have a quantum yield of light that is much higher than for any 
other system131.  
 
Some bioluminescent organisms will synthesize their own luciferin, such as 
dinoflagellates. However, others not able to synthesize luciferin must acquire it, such as 
some species of midshipman fish that obtain luciferin from the seed shrimp that they 
consume. Through evolution, luciferins have varied very little. In contrast, the enzyme, 
luciferase, is always synthesized by bioluminescent organisms and varies widely in 
different species. It is this variation in the expression of luciferase, in the setting of the 
stability of the luciferin, which underlies the range of bioluminescence in the visible 
electromagnetic spectrum. Interestingly, one organism can generate bioluminescence of 
different colours: the railroad worm (the larva of a beetle) has a head that will glow red 
whilst the body glows green. As only one type of luciferin is ingested, this is thought to 
be due the expression of different luciferases in the different parts of the body, a 
characteristic believed to have evolved to confuse and frighten predators.  
3.1.2 Replicating Bioluminescence 
Since the extensive study of bioluminescence in nature, the genes encoding several 
luciferases from different species have been cloned and are commercially available as 
reporter vectors, which are ready for cell cloning. Such vectors have been optimised for 
mammalian expression and fall into two main classes. First are those that encode 
coelenterazine-utilising luciferases from marine organisms. Coelenterazine is the 
‘luciferin’ that is found in many aquatic organisms. It serves as the substrate for 
luciferases expressed by marine organisms such as Renilla reniformis, the sea pansy, 
and Gaussia, a genus of copepod. Then there are those that encode the benzothiazole 
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luciferin-utilising beetle luciferases from terrestrial organisms such as the firefly and 
click beetle.  
3.1.3 Utilising Bioluminescence: Bioluminescence Imaging 
In the field of tumour research, bioluminescence has gained popularity as a relatively 
inexpensive, fast, and simple method of imaging tumour progression and response to 
treatment in animal models. Several tumour cell lines, such as PC-3M-human prostate, 
A549-human lung, and HT-29-human colon cancer cells have been successfully 
transfected with the firefly luciferase gene (luc): with the addition of d-luciferin, a 
synthetic luciferase substrate, bioluminescence was demonstrated in all cell lines, and 
the degree of bioluminescence correlated highly with the number of cells (r2 = 0.99)132. 
C6 rat glioma cells have also been successfully transfected with not only the firefly 
luciferase gene (luc), but also click beetle luciferases (CBGr68luc and CBRedluc), and 
Renilla reniformis luciferase (hRluc). With the addition of the appropriate luciferin, all 
cells produced bioluminescence, each luciferase generating a bioluminescence in a 
different part of of the visible electromagnetic spectrum133. All these luciferase 
transfected cells lines have been transplanted subcutaneously132, and in the case of the 
C6 transfected cells, into the liver and lungs of mice133, where their ability to 
bioluminesce was maintained when the animals were given intraperitoneal (ip) 
luciferin. The bioluminescence was detected with the Xenogen IVIS system (Xenogen 
Corporation, Alameda, CA). When ready for imaging, the animals were anaesthesised 
with isofluorane, given an ip injection of luciferin, and placed in the imaging chamber, 
which was able to hold several mice and allowed maintenance of inhalational 
anaesthesia. The IVIS 100 cooled CCD camera system was used for emitted light 
acquisition and Living Image software (Xenogen Corp.) was used for data analysis. In 
all models, bioluminescence imaging (BLI) was found to provide a real-time, non-
invasive, quantitative and sensitive analysis of tumour growth, metastasis, and response 
to therapy.  
 
BLI has been developed most prominently in animal models of prostate cancer. 22Rv1 
prostate tumour cells were transfected with luc, and once stable luciferase-expressing 
cells were obtained, they were injected into the left ventricle of a mouse model134. 
Bioluminescence of these transfected tumour cells, after ip injection of luciferin, 
revealed dissemination of tumour to bone, liver, and the adrenals, replicating tumour 
behaviour in humans. Subsequent tumour growth was monitored with BLI. 
Furthermore, BLI has also been used to identify metastases in animal models with 
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already established prostate cancer: injection of a prostate-specific adenovirus vector 
that also carries the luc gene, which can be expressed from an enhanced prostate-
specific antigen promoter (AdPSE-BC-luc), demonstrated that the viral vector was not 
only able to localise to the lung and spinal metastases, but was able to produce 
sufficient bioluminescence to allow their detection once luciferin was given135. This has 
also been achieved using a lentivirus-based vector136. Additionally, a transgenic mouse 
model where the prostate gland is targeted with a vector carrying the luc gene under 
control of a small, but highly active and specific, supra prostate-specific antigen 
promoter, has been developed137. This model enabled real-time, BLI analysis of the 
development and responsiveness of the prostate gland to endogenous and exogenously 
administered androgen. These mice also allowed BLI examination of SV40 T antigen-
induced prostate tumourigenesis and the subsequent tumour response to androgen 
ablation.  
 
Whilst research into the diagnostic potential of bioluminescence is well developed, 
research into its therapeutic potential remains in infancy. 
3.2 Bioluminescence-Mediated Photodynamic Therapy 
Despite the many advantages of PDT, as discussed above, one of its biggest challenges 
lies in the delivery of adequate amounts of light, particularly to deep seated 
malignancies. Although interstitial PDT has tried to address this, light distribution over 
the tumour is not homogenous and if metastatic or infiltrative disease is not identified, 
it goes untreated.  
 
The recognition that bioluminescence might be able to provide a targetable, 
endogenous light source to activate a photosensitiser, bioluminescence-mediated 
photodynamic therapy (bPDT) (see Figure 5), was first made in the 1994, in the search 
for novel ways to treat human immunodeficiency virus (HIV). At that time, although 
three compounds were approved for treatment, drug-resistant viral variants had already 
started to emerge, and there was urgency to finding alternative treatments. Hypericin, a 
naturally occurring photosensitiser, had an innate anti-viral action that was potentiated 
upon illumination. However, the ability to deliver light to such a diffuse blood-borne 
organism was challenging. Carpenter et al.138 conducted an experiment to investigate 
whether a chemiluminescent reaction would be able to provide enough light to activate 
hypericin resulting in anti-viral action. Equine dermal cells were infected with equine 
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infectious anaemia virus and incubated with hypericin, luciferin and luciferase. 
Chemiluminescence was initiated by the addition of ATP. The anti-viral activity of 
hypericin was successfully induced by this chemiluminescence. Moreover, to ensure 
proximity of light source to photosensitiser, a tethered molecule of pseudohypericin–
luciferin, without compromise to the anti-viral action of pseudohypericin was 
subsequently synthesised139.  
 
 
 
Figure 5 Bioluminescence-mediated photodynamic therapy 
Diagramatic representation of bioluminescence-mediated photodynamic therapy: the use of bioluminescence, 
an endogenous light source, to activate a photosensitiser. 
 
Nearly a decade later, in 2003, bioluminescence, generated by the addition of d-
luciferin to luciferase-transfected NIH 3T3 cells, was reported to activate the 
photosensitser, rose bengal, causing significant phototoxicity and cell death140. 
Attempts at replicating this work by incubating two luciferase-transfected tumour cell 
lines with the photosensitisers rose bengal and hypericin in turn, then generating 
bioluminescence with d-luciferin, failed to demonstrate cell kill141. However, the doses 
of d-luciferin used were orders of magnitude less than that used in the first experiment: 
the maximum dose of d-luciferin used in this experiment was 20 µM compared to the 
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500 µM in the first study. The most likely reason for failure was that not enough light 
was generated to activate the photosensitiser. 
 
Overall, the in vitro work demonstrates that enough light can be generated from 
bioluminescence/chemiluminescence to activate a photosensitser and achieve 
phototoxicity. bPDT is particularly attractive for the treatment of high-grade 
astrocytomas. Conventional PDT has been demonstrated to cause significant cell death 
in cell culture and animal models of astrocytoma. However, this has failed to translate 
into a dramatic survival advantage in human studies. The most likely reason for this is 
that high-grade astrocytoma is a diffusely infiltrative disease. Not only is there 
infiltration local to the main tumour bulk, but distant infiltration as well. Although 
conventional PDT is able to make gains in local control, particularly with second-
generation photosensitisers, such as mTHPC, being activated by light of longer 
wavelength, and thus achieving deeper tissue penetration, the areas of distant 
infiltration, that may not even be discernible on imaging, remain elusive. As 
photosensitisers are taken up preferentially by tumour cells, particularly in the brain, 
targetable activation by an endogenous light source, for example, the tumour cell itself, 
may allow these areas of distant infiltration to be overcome.  
 
In the next chapter, the outline of this study into bPDT for high-grade astrocytomas and 
the rationale behind it is described.  
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Chapter 4 Bioluminescence-Mediated Photodynamic Therapy for 
Grade 4 Astrocytoma: Aims and Outline of Study 
The overall goal of this study is to provide proof-of-principle that cells from an 
astrocytoma are amenable to phototoxicity by bPDT. If proof-of-principle is achieved 
in vitro, then attempts at proof-of-principle will be made in vivo.  
4.1 Photosensitisers and Emitters 
In designing this study, the first step was to decide upon which photosensitsers and 
which bioluminescence systems should be used to test the concept of bPDT. The light 
dose achieved by bioluminescence is orders of magnitude less than that delivered by an 
external light source, therefore the ability of bioluminescence to activate a 
photosensitiser cannot solely result from the radiative absorption of the photons from 
bioluminescence by the photosensitiser. Another method of activation must also be 
occurring, and this is likely bioluminescence resonance energy transfer (BRET). BRET 
involves the non-radiative transfer of energy from a donor enzyme, luciferase, to a 
suitable acceptor molecule, the photosensitiser, after substrate, luciferin, oxidation142. 
The transfer of excited-state energy is inversely proportional to the sixth power of the 
distance between donor and acceptor dipoles, providing an effective range of less than 
10 nm143. For these reasons, the chemical characteristics of the chosen photosensitiser 
and emitter for bPDT are of key importance. 
  
In order maximise the radiative absorption of photons from bioluminescence by the 
photosensitiser, the photosensitiser should have an absorption profile that closely 
matches the emission profile of the bioluminescence. Furthermore, the photosensitiser 
should absorb photons efficiently i.e. have a high extinction coefficient, and the 
photosensitiser should have a high quantum yield of singlet oxygen when activated. 
Lastly, to engage BRET, the photosensitiser, luciferase, luciferin and ATP should all 
localise to the same cellular compartment.  
 
In literature searching, two photosensitisers became of particular interest, hypericin and 
mTHPC, both of which were already associated with research into gliomas.  
4.1.1 Hypericin 
Hypericin naturally occurs in the Hypericum plant species, most commonly represented 
by Hypericum perforatum, or St John’s wort. Its recognition as a photosensitiser 
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originates from the search for the constituents responsible for hypericism, a skin 
photosensitivity seen in cattle ingesting large amounts of Hypericum plants growing on 
pastures.  
 
Hypericin has been found to be a potent protein kinase inhibitor without light 
activation. Culture of hypericin with glioma cells led to marked inhibition of growth 
secondary to apoptosis144. Subsequently, photoactivation of hypericin has been shown 
to cause profound cell kill in several glioma cell lines with relatively low light 
doses145,146. Indeed, the potent effect of hypericin mediated PDT has been demonstrated 
in many different tumour cell lines147. Furthermore, PDT with hypericin in rodents 
bearing transplanted tumours that include lymphoma, pancreatic cancer, squamous cell 
carcinoma and bladder cancer have confirmed its potent antitumoural effect147. 
Hypericin’s mediation in the anti-viral effect of bPDT has already been discussed138.  
 
Hypericin has a high extinction coefficient when exited at wavelengths greater than 590 
nm, and has the potential for high singlet oxygen quantum yield99. Its subcellular 
localisation is limited to the cytoplasm148 and it has been observed in all subcellular 
organelles146.  
4.1.2 mTHPC 
mTHPC is a synthetic, chlorin-based, second generation photosensitiser. Found to 
cause profound phototoxicity in both in vitro studies of non tumour149,150, tumour151-155, 
and specifically, glioma cell lines156, as well as in vivo studies of non-glioma 
tumour115,157 and glioma tumour114,158 bearing animal models, it is now approved for the 
clinical treatment of head and neck cancers, and has been investigated in a phase II trial 
of high-grade astrocytoma126.  
 
mTHPC has a high extinction coefficient when exited at wavelengths greater than 652 
nm, and has the potential for high singlet oxygen quantum yield99. The primary sites of 
mTHPC localisation are the Golgi apparatus and endoplasmic reticulum159. 
4.1.3 The Emitters 
As mentioned above, genes encoding several luciferases for different species are now 
commercially available. Four luciferases have been chosen for investigation: hRluc, 
CBG68luc, luc, and CBRluc. hRluc is the coelenterazine-utilising luciferase from 
Renilla reniformis. luc is the benzothiazole luciferin-utilising beetle luciferase from the 
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firefly, and CBG68luc and CBRluc are two different types of click beetle luciferase. 
All vectors were available from the company Promega.  
 
The substrate for hRluc, coelenterazine, is extremely unstable in aqueous solutions and 
has been difficult and inconvenient to use under normal cell culture conditions. Two 
synthetic substrates for hRluc have been developed, EnduRenTM160 and ViviRenTM161 
(Promega Corp.), which have different profiles in the amount of bioluminescence they 
can generate and also how the generation of bioluminescence changes over time. Use 
of these substrates was planned for this study. However, no data reports on the 
localisation of these substrates, or of coelenterazine. d-Luciferin is the substrate for luc, 
CBG68luc and CBRluc, and this has been shown to localise to the cytoplasm140.  
4.1.4 Overlap of Absorption Spectra and Emission Profile 
Through literature searching, the absorption spectra of hypericin and mTHPC, and the 
emission profiles of the bioluminescence generated by hRluc, CBG68luc, luc, and 
CBRluc were obtained. With the aid of computer simulation, the absorption spectra of 
hypericin and mTHPC plotted on the same graph as the emission profiles of the light 
generated by the above luciferases, and the degree of overlap between absorption and 
emission spectra assessed (see Figure 6). 
 
Hypericin was reported to have absorption peaks at 470, 545, and 595 nm162. These 
coincided well with the peak emission wavelengths of hRluc, CBGr68luc and luc, 
which had been shown to be at approximately 480, 540, and 610 nm133 (see Figure 6a). 
mTHPC was reported to have an extremely strong absorption peak in the Soret band 
spanning approximately 390-430 nm, then less intense peaks at 517, 542, 595, and 650 
nm163. Although there was not a peak-to-peak match of the absorption of mTHPC in the 
Soret band with the peak bioluminescence of hRluc at 480 nm, there was reasonable 
overlap of the curves (see Figure 6b). The absorption peaks of mTHPC at 542 and 595 
nm coincided well with peak emission wavelengths of CBGr68luc and luc at 540 and 
610 nm, respectively. The emission peak of CBRluc was found to be subtly longer than 
that of luc. However, the difference was not great enough to afford significant overlap 
with the 650 nm absorption peak of mTHPC.  
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Figure 6 Overlap of the absorption spectra of hypericin (a.) and mTHPC (b.) with the emission spectra of the 
bioluminescence generated by hRluc, CBGr68luc, luc, and CBRluc 
Wavelength of light is represented in nm on the x axis. The y axis represents arbitrary units of absorption and 
emission. Hypericin has absorption peaks at 470, 545, and 595 nm and these coincided well with the peak 
emission wavelengths of hRluc, CBGr68luc and luc, which are at 480, 540, and 610 nm, respectively. mTHPC 
has a strong absorption peak in the Soret band spanning approximately 390-430 nm, then less intense peaks 
at 517, 542, 595, and 650 nm. Although there is not a peak-to-peak match of the absorption of mTHPC in the 
Soret band with the peak bioluminescence of hRluc at 480 nm, there is reasonable overlap of the curves. The 
absorption peaks of mTHPC at 542 and 595 nm coincide well with peak emission wavelengths of CBGr68luc 
and luc at 540 and 610 nm, respectively.  
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4.1.5 Decision Made on Photosensitisers and Emitters 
Based upon these findings, the decision was made to use the photosensitisers hypericin 
and mTHPC for this study. Furthermore, cells would be cloned to express hRluc, 
CBG68luc, and luc.  
 
Hypericin and mTHPC both have the potential for a high extinction coefficient: 44 000 
M-1cm-1 at 527 nm and 22 400 M-1cm-1 at 630 nm, respectively, compared to only 1.17 
M-1cm-1 at 630 nm for Photofrin®. Furthermore, they also have the potential for a 
relatively high quantum yield of singlet oxygen: depending on the wavelength of 
excitation and solvent, approximately 0.3 for both hypericin and mTHPC, compared to 
only 0.01-0.09 for Photofrin®99. Both photosensitisers and d-luciferin seem to co-
localise at the very least to the cytoplasm. There is good overlap between the 
absorption peaks of these photosensitisers and the emission profile of the 
bioluminescence generated by these luciferases as described. Although there is not a 
peak-to-peak match between the absorption peak of mTHPC in the Soret band and the 
emission profile of the bioluminescence generated by hRluc, there is reasonable overlap 
of the curves, and in view of the extremely high intensity of the absorption and the high 
quantum yield of singlet oxygen that mTHPC is capable of, this overlap may be enough 
to mediate a photodynamic effect. 
4.2 Preparing for bPDT 
Several stages of experimentation would need to be completed before embarking on 
bPDT.  
4.2.1 Response to Conventional PDT 
In this stage, the cell lines used would need to be determined, as would the dose of 
photosensitiser, the duration of incubation with the photosensitiser, as well as 
confirmation that these cell lines would be amenable to cell kill by conventional PDT.  
 
It was decided that four cell lines should be tested in this preparatory stage. As the 
pathology of focus is glioma, specifically, grade 4 astrocytoma, two glioma cell lines 
originally sourced from two different human grade 4 astrocytomas were chosen for use, 
U87 and U251. As a comparison neoplastic cell line, MCF-7, derived from a human 
breast adenocarcinoma was chosen. Lastly, if failing an effect being demonstrated in 
tumour cell lines, the NIH 3T3 cell line, derived from mouse fibroblasts, was chosen.  
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The dosages of hypericin and mTHPC used for in vitro experiments are highly variable 
in the literature, ranging between 0.1 – 250 µM for hypericin144-146,148,164-167 and 0.1 – 10 
µg/ml for mTHPC149-156. As discussed above, it remains controversial whether the 
greater the tumour concentration of photosensitiser correlates with increased cell kill 
once activated. However, as the light dose delivered by bioluminescence is orders of 
magnitude less than that from an external light source, photobleaching is not likely 
significant. Thus, in order to maximise the amount of singlet oxygen production, the 
maximum dose of photosensitiser tolerated by each cell line without causing toxicity in 
itself i.e. the dark toxicity, would need to be determined.  
 
Additionally, reported incubation times vary between 4 – 24 hrs for hypericin and 3 – 
24 hrs for mTHPC. It is suggested that the effectiveness of PDT may be influenced by 
an interaction between drug dose and incubation time, with higher drug doses166 and 
longer incubation times155 being associated with aggregate formation; aggregates 
enhance the nonradiative decay of the molecular excited state, thereby reducing the 
efficacy of PDT. Hence, dark toxic doses of the photosensitisers would need to be 
determined for both a short incubation and long incubation time.  
 
Having determined the dark toxic doses of photosensitiser for two incubation times, the 
cell lines would be tested to see if they are amenable to cell kill by conventional PDT. 
This opportunity was also taken to assess the lowest light dose that could achieve 
toxicity, termed the threshold of toxicity. If bPDT was subsequently found to be 
effective, this would give an indication of how much of the bPDT effect was 
attributable to radiative absorption of the photons from bioluminescence by the 
photosensitiser compared to BRET.  
4.2.2 Generating Luciferase-Expressing Cell Lines and Study of Bioluminescence 
Having established whether some or all of the cell lines are amenable to cell kill by 
conventional PDT, a decision would be made on which cell lines to transfect with the 
three luciferase genes: hRluc, CBG68luc, and luc. If successful luciferase-expressing 
cell lines are generated, a study of the character of bioluminescence would be 
undertaken in order to determine the conditions required to produce maximum 
bioluminescence. An understanding of how bioluminescence changes over time would 
also need to be gained. 
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d-Luciferin would be used as the substrate for luc and CBG68luc. As discussed above, 
the substrate for hRluc, coelenterazine, is extremely unstable in aqueous solutions, thus 
two synthetic substrates for hRluc will be tested, EnduRenTM and ViviRenTM (Promega).  
4.3 Bioluminescence mediated Photodynamic Therapy 
4.3.1 in vitro studies 
By this stage of study, the optimum conditions for bPDT should have been determined. 
It is envisaged that stable, luciferase-expressing cell lines would be incubated with 
photosensitiser, then with luciferin, and the degree of cell kill determined. Companion 
control studies would include repeating the experiments in untransfected cells that 
would not express luciferase and also repeating experiments in the presence of 
lycopene, an anti-oxidant, that would prevent the formation of singlet oxygen. The 
opportunity for co-localisation studies would also be taken.  
4.3.2 in vivo studies 
If results from in vitro studies are compelling, then this study would proceed to in vivo 
experiments. Before bPDT could be tested, an animal model with a transplanted, 
luciferase-expressing tumour would need to be generated. The aim would be to 
generate a subcutaneous model in the first instance. The simplicity of the model would 
remove any challenges that the intracerebral microenvironment may pose and would 
also allow serial physical measurements of tumour size to validate BLI. Depending on 
progress and time, an attempt at generating an intracranial model would be undertaken. 
Indeed, luciferase-expressing glioma cells have been successfully transplanted both 
subcutaneously and intracranially into rodents. If successful models can be generated, 
the animals can then be treated with photosensitiser, then given systemic luciferin. 
Outcome measures would include survival, an assessment of tumour size, and 
histopathological examination of the tumour. 
4.4 Statistical Analysis 
Data was entered into GraphPad PRISM® Version 6 (GraphPad Software Inc.) and 
expressed as the mean of observations±standard error (SE). The difference in values 
between groups was determined by analysis of variance (ANOVA) and Student-t-test 
using PRISM®. Results were considered significant when the value of p ≤ 0.05. 
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4.5 Developing Infrastructure 
To investigate such an immature concept as bPDT the co-operation of several 
laboratories was required. The laboratories not only spanned across the University 
College London campus, but also across the University of London campus, and also 
involved independent research institutions. I would like to acknowledge and thank the 
groups and individuals without whom this work could not have been conducted.  
 
University College London National Medical Laser Centre 
In addition to Professor S Bown’s supervision of this project, his team provided the 
expertise in photosensitisers and photodynamic therapy and include Mr C Hopper, Dr S 
Mosse, Dr S Macrobert, Dr J Woodhams, Dr M Austwick, and Ms F Hanaster. 
  
University College London Institute of Neurology, Neuropathology 
Dr S Brandner provided the bench space to perform most of the in vitro work. His team 
includes Ms H Naumann, Dr M Shaked-Rabi, Dr P Rodenas Cuadrado, and Dr A 
Swales. 
  
University College London Institute of Neurology, Prion Centre 
Professor P Jat supervised the DNA and cell cloning work. His team includes Ms P 
Aurora. 
 
University College London Centre for Advanced Biomedical Engineering 
Dr M Lythgoe kindly allowed me access to their luminometer and Dr A Jathoul 
assisted with the generation of the bioluminescence emission spectra. 
 
Queen Mary University of London Institute of Cancer 
Professor S Mather and Dr J Foster oversaw the in vivo work, and their neuropathology 
team cut and processed all the pathological specimens. 
 
Cancer Research UK 
Dr C DaCosta and Dr N Kanu allowed me weekly access to their luminometer. 
 
University of Wisconsin, Madison, Department of Pathology 
Dr S Salamat, whose patient and persistent teaching afforded me the skills to interpret 
histopathological slides of neurological disease, and Dr M Baskaya, who guided me 
through the technical and clinical nuances of the surgical management of grade 4 
astrocytoma.  
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Part 2 Original Work 
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Chapter 5 Materials, General Principles of Cell Culture, and 
Understanding the Cell Lines 
The initial set of experiments focused on becoming familiar with the behaviour of the 
chosen cell lines and finding a valid method to assess cell survival. Lastly, response of 
the cell lines to serum starvation was tested, as several drugs and reagents would be 
constituted in serum free solutions. 
5.1 Materials 
5.1.1 Cells, cell lines and plasmids 
	
Cells and Cell Line Supplier 
C  
CMV-Fluc Gift from Professor G Van der Pluijm, 
Leyden, Netherlands 
CMV-hRluc  
 
J  
JS4 Escherichia coli (E. coli ) Gift from Professor P Jat, Institute of 
Neurology, Queen Square 
 
M  
MCF-7 Gift from Professor M Baum, Department 
of Surgery, University College London 
 
N  
NIH 3T3 Gift from Professor P Jat, Institute of 
Neurology, Queen Square 
 
P  
pcDNA3.1(+) Invitrogen 
pCBG68-control Promega 
 
pGL4.70 [hRluc] vector Promega 
  
 72 
U  
U251 Gift from Dr T Warr, Institute of 
Neurology, Queen Square 
U87 Gift from Professor S Brandner, Institute 
of Neurology, Queen, Square 
 
5.1.2 General Reagents 
 
A  
Agarose Sigma-Aldrich 
Ampicillin Sigma-Aldrich 
 
B  
Bactotryptone  Sigma-Aldrich 
Blue Juice™ Loading Dye Invitrogen 
Bovine Serum Albumin (BSA) New England Biolabs 
Buffer 2 New England Biolabs 
 
C  
Calcium chloride (CaCl2) Sigma-Aldrich 
 
D  
Dimethyl sulfoxide (DMSO) Sigma-Aldrich 
Distilled water Thermo Fischer Scientific 
D-luciferin Caliper Life Sciences 
D-luciferin Promega 
D-luciferin Synchem 
D-MEM/F12 (1:1) (IX), liquid with L-
Glutamine, without HEPES 
GIBCO/Invitrogen 
 
Dulbecco’s Modified Eagle Medium (D-
MEM) (IX), liquid (High Glucose) 
GIBCO/Invitrogen  
 
 
E  
EnduRenTM Promega 
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F  
Fetal Bovine Serum (FBS) GIBCO/Invitrogen  
Formic Acid Sigma-Aldrich 
FuGENE HD Roche 
F-10 Nutrient Mixture (Ham) (1X), 
Liquid 
GIBCO/Invitrogen 
 
G  
Geneticin (Neomycin, G418) Invitrogen 
Glycerol  
 
H  
HindIII restriction endonuclease New England Biolabs 
Hypericin Planta Natural Products 
 
I  
Isopropanol Sigma-Aldrich 
 
L  
Luciferase assay system Promega 
Luria Broth Base Invitrogen  
 
 
M  
Methylthiazolyldiphenyl-tetrazolium 
bromide (MTT) 
Sigma-Aldrich 
 
3-(N-Morpholino)propanesulfonic acid, 
4-Morpholinepropanesulfonic acid 
[MOPS]) 
Sigma-Aldrich 
m-tetrahydroxyphenylchlorin (mTHPC) Biolitec 
 
O  
Oxoid Agar Sigma-Aldrich 
 
P  
Phosphate buffered saline (PBS) Biowhittaker 
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Q  
QIAfilter Plasmid Maxi Kit Qiagen 
QIAfilter Plasmid Mini Kit Qiagen 
 
R  
Renilla Luciferase Assay System Promega 
 
T  
Tris(hydroxymethyl)aminomethane-
ethylenedia-inetetraacetic acid, Tris-
EDTA (TE) buffer 
Sigma-Aldrich 
Trypan Blue Sigma-Aldrich 
 
Trypsin, 0.05% (1x) with ethylenedia-
inetetraacetic acid 4Na, liquid 
(trypsin/EDTA) 
GIBCO/Invitrogen 
T4 DNA ligase USB 
T4 DNA ligase buffer 10 x USB 
 
V  
ViviRen™ Promega 
 
X  
XbaI restriction endonuclease New England Biolabs 
 
Y  
Yeast extract Sigma-Aldrich 
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5.2 Mammalian Cell Culture 
Cells were maintained in the following manner throughout, with alterations in 
methodology mentioned in the appropriate sections. 
5.2.1 Cell Media 
Cell culture media were purchased from Invitrogen and reagents from Biowhittaker and 
Sigma-Aldrich. 
5.2.2 Cell lines 
Four cell lines were used: two human-derived glioma lines, U87 and U251; a breast 
cancer line, MCF-7; and a non-tumour, fibroblast line, NIH 3T3. Each cell line required 
maintenance in a specific culture media, which was enriched with 10% v/v FBS (see 
Table 3). Alternatively, for some experiments, media was enriched with 10% v/v heat 
inactivated FBS. Heat inactivation was achieved by heating FBS to a temperature of 
560C for 45 minutes. 
 
Cell Line Culture Medium Required  
U87 and NIH 3T3 (D-MEM) (1x), liquid (High Glucose) 
with L-glutamine, 4500 mg/L D-Glucose, 
110 mg/L Sodium Pyruvate 
U251 D-MEM/F12 (1:1) (1x), liquid with 
L-Glutamine, without HEPES 
MCF-7 F-10 Nutrient Mixture (Ham) (1x), 
Liquid with L-glutamine 
 
Table 3 Specific media requirements for each cell line 
5.2.3 Cell Culture Conditions 
All cell lines were maintained at 5% CO2, 20% O2, 95% humidity and 370C.  
5.2.4 Sub-culturing of Cells (Passaging of Cells) 
Cells were grown until a sub-confluent state was reached (approximately 80% 
confluence). Media was then removed and the cell monolayer washed with 5 ml of 
PBS. Following aspiration of PBS, cells were detached with 2.5 ml trypsin/EDTA per 
80 cm2 flask at 370C for 2 mins. Once cells were adequately detached, the 
trypsin/EDTA was inactivated with 5 ml of complete media and the contents of the 
flask transferred to a 15 ml tube for centrifugation at 1000 rpm for 5 mins. Following 
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centrifugation, the media was aspirated and the remaining pellet resuspended in an 
appropriate volume of media. Cells were then re-plated at a defined ratio e.g. 1 in 8 of 
the total cells, or counted using a haemocytometer and plated at the required density. 
Table 4 shows the typical frequency of cell passaging and ratio of re-plating required 
for each cell line. 
 
Cell Line Ratio of Re-plating Required  Frequency of Cell Passaging 
U87 1:10 to 1:12 Twice a week 
U251 1:3 to 1:5 Once a week 
MCF-7 1:10 Twice a week 
NIH 3T3 1:12 to 1:14 Twice a week 
 
Table 4 Frequency of cell passaging and ratio of re-plating 
5.2.5 Preservations of cells (Freezing down of cells) 
Cells from a sub-confluent 80 cm2 flask were trypsinised, resuspended in complete 
media and centrifuged at 1000 rpm for 5 minutes to remove any traces of trypsin. 
Following centrifugation, the supernatant was aspirated and the remaining pellet 
resuspended in complete media and counted by haemocytometry. Cells were spun 
down again then resuspended in the appropriate volume of freezing media (40% v/v 
FBS, 40% v/v complete media, and 20% v/v dimethyl sulfoxide [DMSO]) to attain at 
least 1x106 cells per ml. The cell solution was transferred into cryovials (1 ml per vial), 
which were placed in an insulated container containing isopropanol and stored at -800C. 
After 24 hrs, they were transferred to liquid N2. 
5.2.6 Recovery of Frozen Cells (Thawing of cells) 
Cells were retrieved from liquid N2, thawed rapidly at 370C, and transferred into a 15 
ml falcon tube containing 5 ml of complete media. Cells were then centrifuged for 5 
minutes at 1000 rpm to remove DMSO-containing media. Following centrifugation, the 
supernatant was aspirated and the remaining pellet resuspended in 5 ml of complete 
media. The cell suspension was then transferred into an 80 cm2 flask containing 20 ml 
of complete media. The cells were maintained as above until sub-confluence was 
reached, then sub-cultured as described above.   
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Figure 7 Light microscopy images of cell lines U87, U251, MCF-7 and NIH 3T3, original magnification at x20. 
5.3 Cell Viability 
5.3.1 Haemocytometry 
Viable cells were counted using trypan blue staining and a haemocytometer, viewed 
under phase-contrast light microscopy at x10 magnification.  Following resuspension in 
an adequate volume, 20 µl of cell solution was added to an equal volume of trypan 
blue, and 20 µl of the resulting mixture was injected into a haemocytometer. Unstained 
cells, considered as viable, were counted in the outer four quadrants; each quadrant 
having an area of 1 mm2 and the space between the slide and cover slip being 0.1 mm, 
and hence each quadrant representing a volume of 0.1 mm3. The number of cells per ml 
was calculated as follows: 
 
Number of cells per ml = Average number of cells over four quadrants x 2 x 104 
5.3.2 Cell Viability Assay 
The method of transcriptional and translational (MTT) assay is a standard colorimetric 
assay where a yellow (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) 
tetrazole dye is reduced to purple formazan in the mitochondria of living cells168. After 
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incubating cells with the dye for a certain amount of time, a solubilisation solution is 
added to lyse the cells, and release and dissolve the insoluble purple formazan product 
into a coloured solution. The amount of product can then be quantified by measuring its 
optical density at a certain wavelength by a standard, multiwell scanning 
spectrophotometer. The reduction reaction depends upon active reductase enzymes in 
living mitochondria, and hence, the assay is a precise and rapid method for measuring 
cell proliferation and survival. 
 
MTT was dissolved in PBS to make a stock solution of 5 mg/ml and stored at -200C in 
1 ml aliquots, thawing the necessary aliquots for each experiment. To establish optimal 
conditions for the MTT assay, dose-response curves were generated for each cell line. 
Four doses of cells were plated in triplicate in parallel 96 well plates; cell numbers 
ranging between 0.125 and 4 x 104, depending on the proliferation rate of the cell line. 
The cells were allowed to incubate for 72 hrs, representing the longest time of future 
experiments, after which 20 µl of MTT, for U87, MCF7 and NIH 3T3 cells, and 40 µl 
of MTT for U251 cells, were added to each well of one set of plates, and left to 
incubate for 3 hrs at 370C. Media was then aspirated from the wells and 0.1 ml of lysis 
buffer (95% isopropanol and 5% formic acid) was added to each well. The plate was 
placed on a gyrator for 10 mins to ensure complete cell lysis. The optical density (OD) 
of the wells was quantified in a spectrophotometer (TECAN SunriseTM microplate 
reader, XFluor4 software) using a test wavelength of 550 nm and reference wavelength 
of 690 nm. Cells in the second plate were counted by haemocytometry.  
 
Dose-response curves were produced by calculating the mean ± SEM for each triplicate 
set of results and fitting a best-fit line by linear regression analysis. Where the p value 
indicated that the chance of generating such a linear relationship was not significantly 
different from chance, the data was subject to non-linear regression, generating a best-
fit curve. This data was used to determine the number of cells that should be plated for 
future experiments; this number generating an OD and cell count in the linear part of 
the dose-response curve.  
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Figure 8 Increasing cell numbers, as demonstrated by haemocytometry, are appropriately reflected by 
increasing OD, as generated by the MTT assay. 
Linear regression of MTT assay and haemocytometry results generated best-fit lines that were significantly 
different from change for U87, U251 and MCF-7 cells (p = 0.005 and 0.04, p = 0.02 and 0.03, and p = 0.05 and 
0.03, respectively), but no significantly different from chance for NIH 3T3 cells (p = 0.09 and 0.07). For NIH 
3T3 cells, both the best-fit line from linear regression ( ⎯  ) and the best-fit curve from non-linear regression ( 
----) are shown. r2 values are quoted in the figure. Asterisks indicate the degree of significance of the r2 value 
where * p > 0.05, ** p ≤  0.05, *** p < 0.01.  
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Linear regression of results from MTT assays and haemocytometry for U87, U251 and 
MCF-7 cell lines (see Figure 8) produced best-fit lines that were significantly different 
from chance (p = 0.005 and 0.04, p = 0.02 and 0.03, and p = 0.05 and 0.03, 
respectively). However, for NIH 3T3 cells, the best-fit line was not significantly 
different from chance (p = 0.09 and 0.07), hence, non-linear regression analysis was 
used to generate a best-fit curve. Notably, findings from haemocytometry correlated 
well with the MTT assay results; increasing cell numbers being reflected by increasing 
OD (see Figure 8). It was decided that for future experiments 1 x 104 cells for U87 and 
MCF-7 cells, 2 x 104 cells for U251 cells, and 0.25 x 10 4 cells for NIH 3T3 cells would 
be used.  
5.4 Effect of Serum Starvation 
Sub-confluent cells of each cell line were harvested and plated at a density of 1 x 104 
cells for U87 and MCF-7 cells, 2 x 104 cells for U251 cells, and 0.25 x 10 4 cells for 
NIH 3T3 cells, per well of a 96 well plate. After 24 hrs incubation, the media was 
aspirated and cells were washed twice with 0.1 ml of PBS. 0.2 ml of complete media 
was replaced in the control wells, and 0.2 ml of serum free media was placed in test 
wells. Cells were plated in triplicate for each condition, and parallel plates were tested. 
After 48 hrs incubation, an MTT assay was carried out.   
 
All cell lines were sensitive to serum starvation compared to controls (see Figure 9): p 
= 0.01, p = 0.02, p = 0.004, and p < 0.0001 for U87, U251, MCF-7 and NIH 3T3 cells, 
respectively.  
 
Figure 9 Cell lines are sensitive to serum starvation.  
C = control, T = test, serum starved. Asterisks indicate the degree of significance in the difference between the 
OD of the test wells compared to control wells where * p > 0.05, ** p ≤  0.05, *** p < 0.01, **** p < 0.001, 
***** p < 0.0001. 
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5.3 Summary and Discussion 
Four cell lines; two human-derived glioma lines, U87 and U251; a breast cancer line, 
MCF-7; and a non-tumour, fibroblast line, NIH 3T3; were successfully cultured, 
passaged, and stored. The colorimetric MTT assay was found to correlate well with 
haemocytometry in assessing cell viability, and both methods were employed in 
ongoing experimentation. Cell viability studies also allowed a determination of the 
number of cells to be plated for ongoing experimentation: 1 x 104 cells for U87 and 
MCF-7 cells, 2 x 104 cells for U251 cells, and 0.25 x 10 4 cells for NIH 3T3 cells, per 
well of a 96 well plate. Finally, all cell lines were sensitive to serum starvation, thus, 
further experiments required cells to be incubated in complete media, although drugs 
and reagents were constituted in serum free solutions.  
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Chapter 6 Efficacy of Photodynamic Therapy in vitro 
Before testing whether bioluminescence is able to activate a photosensitiser and cause a 
photodynamic effect that leads to cell death, experiments were conducted on the cell 
lines to demonstrate that they were indeed amenable to cell death by conventional PDT.  
These studies included an assessment of the dark toxicity of the photosensitisers, 
hypericin and mTHPC, allowing the maximum sub-lethal doses of the photosensitisers 
in each cell line to be established: bioluminescence produces much less energy than an 
external light source, hence use of the maximum sub-lethal dose of photosensitiser 
allows optimisation of conditions. Furthermore, having incubated the cells with the 
previously established maximum sub-lethal doses of photosensitiser, not only was an 
assessment made of whether the cells were amenable to cell kill by conventional PDT, 
but an assessment of the minimum amount of light required to achieve this cell kill was 
made in order to gauge the susceptibility of each cell line to PDT. Care was taken to 
ensure that all lighting was minimised during all steps involving photosensitisers: 
window blinds were drawn, lights were switched off, and plates were wrapped in 
aluminium foil when placed in the incubator to avoid inadvertent photoactivation.  
6.1 Establishing Dark Toxicity 
Dark toxicity refers to the toxicity of the photosensitiser itself, before the application of 
light.  
6.1.1. Preparation of the Photosensitisers 
Hypericin was purchased as a powder (10 mg per vial) and stored at -200C. Before each 
experiment, the powder was brought to room temperature and a stock solution of 1mM 
was freshly made by dissolving 0.5 mg of drug (molecular weight 504.45) in 1 ml of 
DMSO. This was then sterile filtered once. mTHPC was purchased as a 4 mg/ml 
solution and stored at 40C. Before each experiment, the solution was brought to room 
temperature and a predetermined volume of drug was sterile filtered.  
6.1.2 Dark toxicity 
To establish the maximum, sub-lethal drug dose, sub-confluent cells of each cell line 
were harvested and plated at a density of 1 x 104 cells for U87 and MCF-7 cells, 2 x 104 
cells for U251 cells, and 0.25 x 10 4 cells for NIH 3T3 cells, per well of a 96 well plate. 
Following 24 hrs incubation in standard cell culture conditions, media was aspirated 
and replaced with 0.1 ml of complete media.  
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Varying concentrations of hypericin were made up in serum free media from the stock 
solution and 0.1 ml added to the wells, each concentration in triplicate, to give final 
concentrations ranging from 0.00160-200 µM. Similarly, varying concentrations of 
mTHPC were made up in serum free media and 0.1 ml added to the wells, each 
concentration in triplicate, to give final concentrations ranging from 0.400-50.0 µg/ml. 
Cells were incubated with each drug in standard cell culture conditions for two 
durations: 4 or 24 hrs with hypericin, and 3 or 24 hrs with mTHPC. They were then 
washed twice with 0.1 ml of PBS. 0.2 ml of complete media were replaced in the wells 
and after a further 24 hrs incubation, an MTT assay was conducted. Control cells were 
similarly treated, but instead of drug, they were incubated with 0.1 ml of serum free 
media.  
 
A dose that caused a significant reduction in OD compared to control (p ≤ 0.05) was 
considered toxic. Several experiments were conducted using different concentrations of 
drug in order to establish the maximum possible sub-lethal dose. Illustrative results are 
presented below:  in some cases, two experiments on a particular cell line are shown to 
best demonstrate how the maximum sub-lethal dose was determined. Drug dosages are 
expressed to 3 significant figures. 
6.1.3 Hypericin, Short Incubation 
For short incubation (4 hrs) with hypericin (see Figure 10), the maximum, sub-lethal 
dose was determined to be 12.5 µM (p > 0.05) for U87 cells, 0.200 µM (p > 0.05) for 
U251 cells, and 25.0 µM (p > 0.05) for MCF-7 and NIH 3T3 cells. 
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Figure 10 Establishing the maximum, sub-lethal dose of hypericin when incubating with cells for 4 hrs. 
Asterisks indicate the degree of significance of the difference in OD between the specified dose and control, 
where * p > 0.05, ** p ≤  0.05, *** p < 0.01, **** p < 0.001. Drug dosages are expressed to 3 significant figures. 
For short incubation (4 hrs) with hypericin, the maximum, sub-lethal dose was determined to be 12.5 µM (p > 
0.05) for U87 cells, 0.200 µM (p > 0.05) for U251 cells, and 25.0 µM (p > 0.05) for MCF-7 and NIH 3T3 cells. 
Two experiments on NIH 3T3 cells are shown to clearly demonstrate that doses ≤  25.0 µM are not toxic, but 
doses > 25.0 µM are.   
6.1.4 Hypericin, Long Incubation 
For long incubation (24 hrs) with hypericin (see Figure 11), the maximum, sub-lethal 
dose for U87 and NIH 3T3 cells was determined to be 10.0 µM, which was an 
arbitrarily chosen dose between the toxic 12.5 µM (p < 0.01) and the non-toxic 6.25 
µM (p > 0.05) doses. 0.00160 µM (p > 0.05) was the determined maximum, sub-lethal 
dose for U251 cells and 12.5 µM (p > 0.05) for MCF-7 cells. 
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Figure 11 Establishing the maximum, sub-lethal dose of hypericin when incubating with cells for 24 hrs. 
Asterisks indicate the degree of significance of the difference in OD between the specified dose and control, 
where * p > 0.05, ** p ≤  0.05, *** p < 0.01, **** p < 0.001. Drug dosages are expressed to 3 significant figures. 
For long incubation (24 hrs) with hypericin, the maximum, sub-lethal dose was determined to be 10.0 µM for 
U87 and NIH 3T3 cells, 0.00160 µM (p > 0.05) for U251 cells, and 12.5 µM (p > 0.05) for MCF-7 cells. 
6.1.5 mTHPC, Short Incubation 
For short incubation (3 hrs) with mTHPC (see Figure 12), the maximum, sub-lethal 
dose determined for U251 cells was 25.0 µg/ml (p > 0.05). Where a certain dose of 
drug demonstrated inconsistent toxicity, a lower, though consistently sub-lethal dose 
was determined to be the maximum, sub-lethal dose: 25.0 µg/ml was inconsistently 
toxic (p < 0.001 vs p > 0.05) for U87 and MCF-7 cells, hence 12.5 µg/ml (p > 0.05) 
was the determined maximum, sub-lethal dose. For NIH 3T3 cells, a dose of 25.0 
µg/ml caused a 32.3% reduction in OD (p > 0.05), but as the 95% CI (-0.0833 to 0.398) 
trended towards significance, this dose was considered toxic, and a dose of 12.5 µg/ml 
(p > 0.05) was set as the maximum, sub-lethal dose.  
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 Figure 12 Establishing the maximum, sub-lethal dose of mTHPC when incubating with cells for 3 hrs.  
Asterisks indicate the degree of significance of the difference in OD between the specified dose and control, 
where * p > 0.05, ** p ≤  0.05, *** p < 0.01, **** p < 0.001. Drug dosages are expressed to 3 significant figures. 
For short incubation (3 hrs) with mTHPC, the maximum, sub-lethal dose determined to be 25.0 µg/ml (p > 
0.05) for U251 cells and 12.5 µg/ml (p > 0.05) for U87, NIH 3T3, and MCF-7 cells. Two experiments on U87 
and NIH 3T3 cells demonstrated the inconsistent toxicity of the 25 µg/ml dose on these two cells lines.   
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6.1.6 mTHPC, Long Incubation 
For long incubation (24 hrs) with mTHPC (see Figure 13), the maximum sub-lethal 
dose was determined to be 2.50 µg/ml (p > 0.05) for U87 cells and 5.00 µg/ml p (> 
0.05) for U251 cells. 10.0 µg/ml was inconsistently toxic to MCF-7 cells p < 0.001 vs p 
> 0.05), hence 5.00 µg/ml (p > 0.05) was the determined maximum sub-lethal dose for 
this cell line. For NIH 3T3 cells, a dose of 5.00 µg/ml caused a 35.8 % reduction in OD 
(p > 0.05), but as the 95% CI (-0.107 to 0.246) trended towards significance, this dose 
was considered toxic, and a dose of 2.50 µg/ml (p > 0.05) became the test dose of 
choice.  
 
Figure 13 Establishing the maximum, sub-lethal dose of mTHPC when incubating with cells for 24 hrs. 
Asterisks indicate the degree of significance of the difference in OD between the specified dose and control, 
where * p > 0.05, ** p < 0.05, *** p < 0.01, **** p < 0.001. Drug dosages are expressed to 3 significant figures. 
For long incubation (24 hrs) with mTHPC, the maximum sub-lethal dose was determined to be 2.50 µg/ml for 
U87 and NIH 3T3 cells, and 5.00 µg/ml for U251 and MCF-7 cells. Two experiments on MCF-7 cells 
demonstrated the inconsistent toxicity of a 10.0 µg/ml dose.  
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The maximum sub-lethal doses determined for hypericin and mTHPC incubating for 
short (4 hrs for hypericin, 3 hrs for mTHPC) and long (24 hrs) durations with each cell 
line are summarised in Table 5. 
  
 Hypericin Dose µM mTHPC Dose µg/ml 
Incubation 
Time 
4 Hrs 24 Hrs 3 Hrs 24 Hrs 
U87 12.5 10.0 12.5 2.50 
U251 0.200 0.00160 25.0 5.00 
MCF7 25.0 12.5 12.5 5.00 
NIH 3T3 25.0 10.0 12.5 2.50 
 
Table 5 Maximum sub-lethal doses of photosensitisers for the appropriate incubation times. Drug dosages are 
expressed to 3 significant figures.  
The literature does not report experiments specifically aimed at establishing the 
maximum sub-lethal dose for the photosensitiers hypericin and mTHPC in these 
particular cell lines and under these particular conditions. However, the range of doses 
established here for both incubation times do lie within the ranges that have been 
reported for use for photodynamic therapy in vitro (as cited in section 4.2.1): 0.1 – 250 
µM for hypericin and 0.1 – 10 µg/ml for mTHPC. Furthermore, as would be expected, 
the maximum sub-lethal dose at the longer incubation time is less than that for the 
shorter incubation time for both drugs in all cell lines. It is noted that the maximum 
sub-lethal dose of hypericin in the U251 cell line is orders of magnitude less than that 
of the other cell lines. Although this could be a spurious result, it was replicated. The 
literature does not report hypericin being used with the U251 cell line for verification.  
6.2 Conventional Photodynamic Therapy 
Before investigating the efficacy of bPDT, the toxicity of conventional PDT was 
confirmed. The threshold of toxicity, the lowest light dose at which toxicity was 
achieved in cells that had been incubated with photosensitiser, was also noted.  
 
Sub-confluent cells of each cell line were harvested and plated at a density of 1 x 104 
cells for U87 and MCF-7 cells, 2 x 104 cells for U251 cells, and 0.25 x 10 4 cells for 
NIH 3T3 cells, per well of a 96 well plate. Following 24 hrs incubation in standard cell 
culture conditions, media was aspirated and replaced with 0.1 ml of complete media. 
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Wells were designated as either control or test. Control wells were further divided into 
pure ‘control’ wells, which were exposed to neither drug nor light; ‘drug only’ wells, 
which were exposed only to drug, but no light; and ‘light only’ wells, which were 
exposed only to light, but no drug. ‘Test’ wells were exposed to both drug and light. 
Each condition was tested in triplicate.  
 
Photosensitisers were made up in 0.1 ml of serum free media and added to ‘drug only’ 
and ‘test’ wells to give a final concentration equal to the maximum sub-lethal 
concentrations, as established above (see Table 5). ‘Control’ and ‘light only’ wells 
received 0.1 ml of serum free media. After the appropriate incubation time (4 and 24 
hrs for hypericin, 3 and 24 hrs for mTHPC), all wells were washed twice with 0.1 ml of 
PBS, following which 0.2 ml of complete media was added to each well. ‘Light only’ 
and ‘test’ wells were then exposed to varying durations of blue light illumination 
(Lumisource, maximum output at 420 nm 7 mWcm-2, Biotech, Oslo, Norway), ranging 
from 1 sec to 500 secs (120 secs x 7 mWcm-2 equivalent to 840 mJcm-2). Cells were 
then replaced in standard cell culture conditions for a further 24 hrs, after which an 
MTT assay was performed.  
 
Regarding ‘light only’ wells, the mean OD for each exposure time was compared. In 
most circumstances, there was no significant difference between these groups, and in 
no circumstances did light cause a significant fall in OD (see Appendix A1). In a few 
circumstances, light did cause a significant increase in OD, indicating stimulation of 
cell growth. For ease of interpretation, the mean OD of the ‘light only’ wells exposed 
to the longest duration of light i.e. the greatest fluence of light, was used as the overall 
‘light only’ control for comparison with the other conditions.  
 
The OD for each condition, ‘drug only,’ ‘light only,’ and ‘test,’ was compared to 
‘control’ wells.  A significant reduction in OD compared to ‘control’ (p ≤ 0.05) was 
considered toxic. 
6.2.1 Hypericin, Short Incubation 
For short incubation (4 hrs) with hypericin (see Figure 14), all cells lines were 
amenable to toxicity from conventional PDT and a clear dose-response was seen with 
increasing doses of light. The threshold of toxicity was 50 secs light illumination (350 
mJcm-2) for U87 and NIH 3T3 cells, resulting in the OD falling to 27.6% (p < 0.0001) 
and 3.77% (p < 0.0001) of control, respectively. Although light seemed to stimulate 
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growth in NIH 3T3 cells, these cells demonstrated toxicity from a photodynamic effect. 
The threshold of toxicity was 180 secs of light illumination (1260 mJcm-2) for U251 
cells, resulting in the OD falling to 61.8% (p < 0.0001) of control. Examining the effect 
of 5 and 50 secs light illumination on U251 cells, p values would indicate that the 
reduction in OD to 87.4% (p < 0.0001) and 89.0% (p ≤ 0.05) of control for cells 
exposed to ‘drug only’ and ‘test’ cells exposed to 5 secs light illumination, 
respectively, was significant. However, as the fall in OD was small, and the trend was 
strongly towards no significant difference compared to control (95% CI 0.0185 to 
0.159 and 0.00365 to 0.151, respectively), these variations were not considered 
significantly different from control. Although light seemed to stimulate growth in 
MCF-7 cells, these cells demonstrated toxicity from a photodynamic effect, and the 
threshold of toxicity was 20 secs light illumination (140 mJcm-2), resulting in the OD 
falling to 35.4% (p < 0.0001) of control.  
6.2.2 Hypericin, Long Incubation 
For long incubation (24 hrs) with hypericin (see Figure 15), all cell lines were 
amenable to toxicity from conventional PDT, except U251 cells, and in those cell lines 
amenable to toxicity from PDT, a dose-response was also demonstrated. The threshold 
of toxicity was 50 secs light illumination (350 mJcm-2) for U87 cells, resulting in the 
OD falling to 23.5% (p < 0.0001) of control, and 20 secs light illumination (140 mJcm-
2) for MCF-7 cells, resulting in the OD falling to 61.6% (p < 0.0001) of control. The 
addition of ‘drug only’ seemed to lead to slight cell growth in these two cell lines 
compared to control (p ≤ 0.05). However, the degree of growth was small and the 95% 
CI indicated a strong trend towards no significant difference compared to control 
(138.2%, -0.364 to -0.0672, and 118.5%, -0.128 to -0.00286, respectively), and 
therefore these differences were treated as being not significantly different to control. 
Furthermore, U87 cells exposed to ‘drug’ then 5 secs light illumination seemed to 
undergo growth stimulation (OD 134% of control, p < 0.01). However, as this degree 
of stimulation was small and the 95% CI strongly trended towards no significant 
difference compared to control (- 0.0339 to - 0.0423), this was considered not 
significantly different from control. Regarding NIH 3T3 cells, the threshold of toxicity 
was 20 secs light illumination (140 mJcm-2), which led to a fall in OD to 36.6% of 
control (p < 0.0001). Although ‘test’ cells exposed to 5 and 10 secs light illumination 
led to a fall in OD to 62.0% and 53.6% of control (p < 0.01 and p < 0.001, respectively, 
when compared to control), when compared to cells that had received ‘drug only,’ this 
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fall was not significantly different, and thus, the toxicity seen in these test cells were 
likely due to dark toxicity. 
 
 
 
 
Figure 14 The effect of conventional PDT on cells lines incubated with hypericin for 4 hrs.  
C = control, D = drug only, L = light only. Numbers on the x axis refer to the time in secs that cells incubated 
with drug were exposed to light, and represent the ‘test’ wells. Asterisks indicate the degree of significance of 
the difference in OD between each condition and control, where * p > 0.05, ** p ≤  0.05, *** p < 0.01, **** p < 
0.001, ***** p < 0.0001. All cell lines were amenable to toxicity from conventional PDT and demonstrated a 
clear dose-response. The threshold of toxicity was 50 secs of light illumination (350 mJcm-2) for U87 and NIH 
3T3 cells; 180 secs of light illumination (1260 mJcm-2) for U251 cells; and 20 secs light illumination (140 
mJcm-2) for MCF-7 cells.  
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Figure 15 The effect of conventional PDT on cells lines incubated with hypericin for 24 hrs.  
C = control, D = drug only, L = light only. Numbers on the x axis refer to the time in secs that cells incubated 
with drug were exposed to light, and represent the ‘test’ wells. Asterisks indicate the degree of significance of 
the difference in OD between each condition and control, where * p > 0.05, ** p ≤  0.05, *** p < 0.01, **** p < 
0.001, ***** p < 0.0001. For NIH 3T3 cells, the diamonds indicate the degree of significance of the difference 
in OD between each condition and ‘drug only’ cells, where !p > 0.05, !!p ≤  0.05, !!!p < 0.01, !!!!p < 
0.001, !!!!!p < 0.0001. All cell lines were amenable to toxicity from conventional PDT, except for the U251 
cell line. Of the cell lines amenable to PDT, a dose-response was demonstrated. The threshold of toxicity was 
50 secs of light illumination (350 mJcm-2) for U87 cells, and 20 sec light illumination (140 mJcm-2) for MCF-7 
an NIH 3T3 cells.  
6.2.3 mTHPC, Short Incubation 
For short incubation (3 hrs) with mTHPC (see Figure 16), all cells lines were amenable 
to toxicity from conventional PDT and a clear dose-response was seen with increasing 
doses. The threshold of toxicity was 3 secs light illumination (21 mJcm-2) for U87 cells, 
resulting in the OD falling to 70.7% (p < 0.001) of control; and 1 sec light illumination 
(7 mJcm-2) for U251 cells, resulting in the OD falling to 41.7% of control (p < 0.0001). 
The threshold of toxicity was 20 secs light illumination (140 mJcm-2) for MCF-7 cells, 
resulting in the OD falling to 66.0% (p < 0.001) of control: although exposure of these 
cells to ‘drug’ then 1 sec of light seemed to cause stimulation of growth (124%, p ≤ 
0.05), the degree of growth was small, and the 95% CI trended towards no significant 
C D L 5 10 20 50
0.0
0.2
0.4
0.6
0.8
1.0
Time of Light Illumination, secs
O
D
 55
0 
- 6
90
U87 Cells
***
*
**
*
*
*****
C D L 5 50 500
0.0
0.2
0.4
0.6
0.8
1.0
Time of Light Illumination, secs
O
D
 55
0 
- 6
90
U251 Cells
*
**
*
* *
C D L 5 10 20 50
0.0
0.1
0.2
0.3
0.4
0.5
Time of Light Illumination, secs
O
D
 55
0 
- 6
90
MCF-7 Cells
**
*
*
*
*****
*****
C D L 5 10 20 50
0.0
0.5
1.0
1.5
2.0
Time of Light Illumination, secs
O
D
 55
0 
- 6
90
NIH 3T3 Cells
*
*
*** ****
*****
*****
!
!
!!!
!!!!!
 93 
difference compared to control (- 0.0965 to - 0.000815), and thus this effect was 
considered as such. Although exposure of NIH 3T3 cells to ‘light only’ caused 
stimulation of cell growth, toxicity to PDT was indeed demonstrated and the threshold 
of toxicity was 3 secs light illumination (21 mJcm-2), resulting in the OD falling to 
38.3% (p < 0.0001) of control. 
 
 
  
  
Figure 16 The effect of conventional PDT on cell lines incubated with mTHPC for 3 hrs.  
C = control, D = drug only, L = light only. Numbers on the x axis refer to the time in secs that cells incubated 
with drug were exposed to light, and represent the ‘test’ wells. Asterisks indicate the degree of significance of 
the difference in OD between each condition and control, where * p > 0.05, ** p ≤  0.05, *** p < 0.01, **** p < 
0.001, ***** p < 0.0001. All cell lines were amenable to toxicity from conventional PDT and demonstrated a 
clear dose-response. The threshold of toxicity was 3 secs of light illumination (21 mJcm-2) for U87 and NIH 
3T3 cells; 1 sec of light illumination (7 mJcm-2) for U251 cells; and 20 secs light illumination (140 mJcm-2) for 
MCF-7 cells.  
6.2.4 mTHPC, Long Incubation 
For long incubation (24 hrs) with mTHPC (see Figure 17), all cell lines were amenable 
to toxicity from conventional PDT and a clear dose-response was seen with increasing 
doses of light. The threshold of toxicity was 3 secs light illumination (21 mJcm-2) for 
U87, U251 and NIH 3T3 cells, resulting in the OD falling to 51.5% of control (p < 
0.01), 10.6% of control (p < 0.0001), and 30.3% of control (p < 0.0001), respectively. 
Although exposure of U251 cells to ‘light only’ seemed to cause toxicity with the OD 
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91.5% of control (p ≤ 0.05), this fall in OD was small and the 95% CI trended strongly 
towards no significant difference to control (0.00341 to 0.116), and hence was treated 
as such. Similarly, although exposure of MCF-7 cells to ‘drug’ then 5 secs light seemed 
to cause toxicity (OD 82.2% of control, p ≤ 0.05), the fall in OD was small and the 
95% CI trended strongly towards no significant difference to control (0.00202 to 
0.206), and hence was treated as such. The threshold of toxicity was 20 secs light 
illumination (140 mJcm-2) for MCF-7 cells, resulting in the OD falling to 53.4% of 
control (p < 0.0001). 
 
 
 
 
Figure 17 The effect of conventional PDT on cell lines incubated with mTHPC for 24 hrs. 
C = control, D = drug only, L = light only. Numbers on the x axis refer to the time in secs that cells incubated 
with drug were exposed to light, and represent the ‘test’ wells. Asterisks indicate the degree of significance of 
the difference in OD between each condition and control, where * p > 0.05, ** p ≤  0.05, *** p < 0.01, **** p < 
0.001. ***** p < 0.0001. All cell lines were amenable to toxicity from conventional PDT and demonstrated a 
clear dose-response. The threshold of toxicity was 3 secs light illumination (21 mJcm-2) for U87, U251 and 
NIH 3T3 cells. The threshold of toxicity was 20 secs light illumination (140 mJcm-2) for MCF-7 cells. 
All cells lines were amenable to cell kill by conventional PDT (see Table 6). Regarding 
the use of hypericin as the photosensitiser, U251 cells seemed the most resistant to 
PDT: exposure to light after short incubation with hypericin was associated with the 
highest threshold of toxicity and after long incubation with hypericin had no effect at 
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all. However, this is most likely a reflection of the unusually low maximum sub-lethal 
dose of photosensitiser that could be used rather than an inherent resistance to PDT. 
There are no reports of U251 cells being used for PDT with hypericin as a 
photosenstiser. MCF-7 and NIH 3T3 cells had comparable responses to PDT, with 
similar thresholds of toxicity: although NIH 3T3 cells had a higher threshold of toxicity 
than MCF-7 after short incubation with hypericin, the resultant cell kill was profound. 
Apart from U251 cells, U87 cells incubated with hypericin were the most resistant to 
cell kill by conventional PDT, although the degree of cell kill achieved at the threshold 
of toxicity was profound. There was no marked difference in the effect to PDT between 
short or long incubation with hypericin.  
 
Regarding the use of mTHPC as a photosensitiser, U251 cells were the most 
susceptible to cell kill by conventional PDT, having the lowest threshold of toxicity 
after short incubation with the photosensitiser, and having the most profound cell kill 
after long incubation with photosensitiser at a threshold of toxicity comparable to other 
cell lines. MCF-7 cells were the least susceptible to cell kill by conventional PDT, 
having the highest threshold of toxicity. U87 and NIH 3T3 cells had similar thresholds 
of toxicity. However, a greater degree of cell kill was achieved in NIH 3T3 for both 
photosensitiser incubation times. Longer incubation with mTHPC seemed to provide 
some advantage, with mildly increased cell kill at similar fluences. This would be 
consistent with the photosensitiser forming aggregates after 24 hr incubation155, which 
are associated with less photodynamic efficacy149,166,169.  
 
PDT with mTHPC as the photosensitiser was more effective than with hypericin, with 
lower thresholds of toxicity achieved for all cell lines, except for the MCF-7 cell line, 
which had a similar threshold of toxicity after incubation with both photosensitiers at 
short and long incubation times.  
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 Hypericin, Threshold of 
Toxicity, mJcm-2  (% of control) 
mTHPC, Threshold of Toxicity, 
mJcm-2 (% of control) 
Incubation 
Time 
4 Hrs 24 Hrs 3 Hrs 24 Hrs 
U87 350 (27.6) 350 (23.5) 21 (70.7) 21 (51.5) 
U251 1260 (61.8) - 7 (41.7) 21 (10.6) 
MCF7 140 (35.4) 140 (61.6) 140 (66.0) 140 (53.4) 
NIH 3T3 350 (3.77) 140 (36.6) 21 (38.3) 21 (30.3) 
 
Table 6 Summary of the threshold of toxicity for each cell line 
The threshold of toxicity i.e. the lowest light dose at which toxicity was achieved is reported for each 
photosensitiser and both their incubation times in each cell line. The percentage cell survival is noted in 
brackets.  
6.3 Summary and Discussion 
Before testing the concept of bPDT, cell lines were tested to investigate their response 
to conventional PDT.  This provided an opportunity to establish their dark toxicity and 
to note the lowest light doses at which toxicity can be achieved, the threshold of 
toxicity, providing an estimation of the relative susceptibility of the cell lines to PDT.  
 
Maximum sub-lethal doses of the photosensitisers at two incubation times were 
established in all cell lines. All cell lines were amenable to cell kill by PDT. Results 
from the U251 cell line incubated with hypericin were unreliable. Although MCF-7 
cells incubated with hypericin were least resistant to cell kill by PDT, when incubated 
mTHPC, were the most resistant to PDT. Based on these results, the decision was made 
to proceed with the U87 and NIH 3T3 cell lines for ongoing experimentation. 
Furthermore, for studies involving their incubation with photosensitisers, their 
maximum sub-lethal dose for the appropriate incubation time would be used.  
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Chapter 7 Generating Bioluminescent Cell Lines and Characterising 
Bioluminescence 
The aim was to produce cell lines that would generate bioluminescence at three 
different wavelengths. Plasmids containing firefly (luc), click beetle (CBG68luc), and 
Renilla (hRluc) luciferase, which would produce bioluminescence with peak emission 
wavelengths at 560 nm, 537 nm and 480 nm, respectively, were cloned for cell 
transfection.  
 
A brief overview of the DNA cloning process is illustrated in Figure 18. As a plasmid 
containing firefly luciferase, CMV-luc, had been kindly donated by Professor G Van 
der Pluijm, only plasmids containing click beetle and Renilla luciferase, CMV-
CBG68luc and CMV-hRluc respectively, had to be generated. In short, click beetle and 
Renilla luciferase genes were purchased as vectors, along with a backbone vector, and 
these vectors were multiplied by bacterial transformation. Once multiplied and 
extracted, the vectors underwent digestion by specific restriction endonucleases. The 
luciferase genes could then be ligated into the backbone vector, thereby forming the 
desired plasmids. 
 
 
 Figure 18 An overview of DNA cloning.  
The luciferase genes, CBG68luc and hRluc, were purchased as vectors, pCBG68 and pGL4.70[hRluc], 
respectively. These vectors, along with the backbone vector pcDNA3.1(+), were multiplied by bacterial 
transformation. Once extracted, the vectors underwent digestion by specific restriction endonucleases. The 
resulting luciferase genes could then be ligated into the backbone vector, forming the desired plasmids.  
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A more detailed description of the DNA cloning process will now be given and results 
presented, with specific protocols regarding bacterial and DNA manipulation 
considered in the following sections. 
7.1 DNA Cloning 
7.1.1 Vectors and plasmids 
The luciferase genes of CBG68luc and hRluc were purchased as vectors, pCBG68 and 
pGL4.70[hRluc] respectively, from Promega (see Appendix 2). A pcDNA3.1(+) 
backbone vector containing an origin of replication for E.Coli, a CMV promoter, and 
sequences for ampicillin and neomycin resistance, was purchased from Invitrogen (see 
Appendix 2). CMV-luc, a plasmid containing firefly luciferase in a pcDNA3.1(+) 
backbone, ready for cell transfection, was kindly given by Professor G Van der Pluijm.  
7.1.2 Cloning CMV-CBG68luc and CMV-hRluc  
Copies of pCBG68, pGL4.70[hRluc], and pcDNA3.1(+) were multiplied by bacterial 
transformation. For each vector, several bacterial colonies were selected for large-scale 
preparation and an example of the yields are given below (see Table 7). 
 
Sample Yield, ηg/µl 
pCBG68luc 1 1212.30 
pCBG68luc 2 1518.90 
pGL4.0[hRluc] 1 3690.54 
pGL4.0[hRluc] 2 2756.77 
pcDNA3.1(+) 3933.25 
 
Table 7 An example of the DNA yields from bacterial transformation and large-scale preparation of vectors 
pCBG68, pGL4.70[hRluc], and pcDNA3.1(+), in preparation for cloning CMV-CBG68luc and CMV-hRluc  
pCBG68 has HindIII and XbaI restriction endonuclease recognition sites on the 5’ and 
3’ ends of the luciferase gene, respectively (see Appendix 2). Similarly, 
pGL4.70[hRluc] has HindIII and BamHI recognition sites. pcDNA3.1(+) also has these 
recognition sites in a forward orientation in its multiple cloning region. pCBG68 and 
one sample of pcDNA3.1(+) were digested with the restriction endonucleases HindIII 
and XbaI, and pGL4.70[hRluc] and another sample of pcDNA3.1(+) were digested 
with Hind III and BamHI. Successful digestion was confirmed with gel electrophoresis 
(see Figure 19). 
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Figure 19 Gel electrophoresis demonstrating successful digestion of pCBG68, pGL4.70[hRluc], and 
pcDNA3.1(+).  
Two different exposures of the same gel are shown. Columns from left to right: 1 Kb DNA ladder; undigested 
pCBG68 (5248 bp); undigested pGL4.70[hRluc] (3653 bp); pCBG68 digested with HindIII and XbaI 
(CBG68luc = 1628 bp); pcDNA3.1(+) digested with HindIII and XbaI (5168 bp); pGL4.70[hRluc] digested 
with HindIII and BamHI (hRluc = 1058 bp); pcDNA3.1(+) digested with HindIII and BamHI (5230 bp).  
Repeat gel electrophoresis was performed and the digested pcDNA3.1(+), CBG68luc 
and hRluc fragments were isolated, then extracted from the agarose gel. Another gel 
was run to confirm successful isolation of pcDNA3.1(+), and the CBG68luc and hRluc 
inserts (see Figure 20). CBG68luc and hRluc were then ligated with the similarly 
digested pcDNA3.1(+) to produce CMV-CBG68luc and CMV-hRluc, respectively. 
Two negative controls were made by ligating HindIII/XbaI-digested pcDNA3.1(+) with 
itself, and ligating HindIII/BamHI-digested pcDNA3.1(+) also with itself. Competent 
bacteria were then transformed with each of these plasmids. The positive control was 
bacteria transformed with CMV-luc given by Professor G Van der Pluijm. 16-18 
colonies of bacteria transformed with CMV-CBG68luc were seen after 24 hr 
incubation. No colonies were seen with bacteria transformed with CMV-hRluc, or the 
negative controls. Multiple colonies were seen with the positive control. Results 
indicated successful cloning of CMV-CBG68luc, but failure to clone CMV-hRluc.  
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Figure 20 Gel electrophoresis confirming successful isolation of digested pcDNA3.1(+), and CBG68luc and 
hRluc inserts. 
Columns from left to right: 1 Kb DNA ladder; CBG68luc insert (1628 bp); pcDNA3.1(+) digested with 
HindIII and XbaI (5168 bp); hRluc insert (1058 bp); pcDNA3.1(+) digested with HindIII and BamHI (5230 
bp).  
10 colonies of CMV-CBG68luc transformants were harvested for small-scale plasmid 
preparation. Plasmid obtained from each colony underwent digestion with HindIII, 
XbaI or both. Gel electrophoresis of these samples showed that all colonies, except for 
colony 9, contained the CBG68luc insert (see Figure 21).  
 
  
 
Figure 21 Gel electrophoresis of CMV-CBG68luc from 10 transformants.  
A 1 kb ladder is seen in the far left column of each gel. For each transformant, three digests are seen; one 
digested with HindIII only, one digested with XbaI only, and the last digested with both HindIII and XbaI. All 
transformants, except for colony 9 (third transformant in the top row of the second gel), are seen to contain 
the CBG68luc insert.  
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A repeat attempt was made to clone CMV-hRluc, following the steps described above. 
Gel electrophoresis confirmed successful digestion of pGL4.70[hRluc] and 
pcDNA3.1(+) with HindIII and BamHI (see Figure 22).  However, ligation of hRluc 
into pcDNA3.1(+) and transformation into competent bacteria yielded no 
transformants. It was suspected that the SV40 late polyA signal just downstream to the 
hRluc gene was interfering with gene expression. Further examination of the 
pGL4.70[hRluc] sequence revealed an XbaI site at the 3’ end of the hRluc gene, 
upstream to the SV40 late polyA signal. Steps described above were repeated to clone 
CMV-hRluc, but this time digesting pGL4.70[hRluc] with HindIII and XbaI. Gel 
electrophoresis revealed successful enzyme digestion (see Figure 23). The hRluc insert 
was ligated into pcDNA3.1(+) that had previously been successfully digested with 
HindIII and XbaI (see Figure 19 and Figure 20), then transformed into competent 
bacteria. This yielded 4 colonies, indicating successful cloning of CMV-hRluc. The 
negative control was ligating HindIII/XbaI-digested pcDNA3.1(+) with itself, then 
transforming this into competent bacteria, which yielded no colonies. The positive 
control was bacteria transformed with CMV-luc, which yielded multiple colonies.  
 
 
 
Figure 22 Gel electrophoresis demonstrating successful digestion of pGL4.70[hRluc], and pcDNA3.1(+) with 
HindIII and BamHI 
Two different exposures of the same gel are shown. Columns from left to right: 1 Kb DNA ladder; 
pGL4.70[hRluc] digested with HindIII and BamHI (hRluc = 1058 bp); pcDNA3.1(+) digested with HindIII 
and BamHI (5230 bp). 
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Figure 23 Gel electrophoresis of pGL4.0[hRluc] digested with HindIII and XbaI 
Columns from left to right: 1 Kb DNA ladder; pGL4.70[hRluc] successfully digested with HindIII and XbaI 
(hRluc = 1058 bp). 
All 4 colonies were picked for small-scale plasmid preparation. Plasmid obtained from 
each colony underwent digestion with HindIII, XbaI or both. Gel electrophoresis of 
these samples showed that all colonies, except for colony 2, contained the hRluc insert 
(see Figure 24). 
 
  
Figure 24 Gel electrophoresis of CMV-hRluc from 4 transformants.  
A 1 kb ladder is seen in the far left column of each gel. For each transformant, three digests are seen; one 
digested with HindIII only, one digested with XbaI only, and the last digested with both HindIII and XbaI. All 
transformants, except for colony 2 (second transformant of the first gel), are seen to contain the hRluc insert.  
7.1.3 Preparing DNA for Cell Cloning 
Bacterial transformants of a colony demonstrating the presence of CBG68luc and 
hRluc inserts were used for large-scale plasmid preparation, to produce a stock of 
CMV-CBG68luc and CMV-hRluc. Similarly, a stock of CMV-luc was also generated. 
The yields obtained are shown below (see Table 8).  
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Sample Yield, ηg/µl 
CMV-luc 6021.39 
CMV-CBG68luc 4149.39 
CMV-hRluc 3479.97 
 
Table 8 An example of the DNA yields from large-scale preparation plasmids CMV-luc, CMV-CBG68luc, and 
CMV-hRluc.  
As a final check, samples of CMV-CBG68luc and CMV-hRluc obtained were digested 
with HindIII only, XbaI only, and both endonucleases. Gel electrophoresis showed that 
CBG68luc and hRluc inserts were present, respectively (see Figure 25). 
 
 
 
Figure 25 Gel electrophoresis of CMV-CBG68luc and CMV-hRluc showing the presence of CBG68luc and 
hRluc inserts, respectively. 
Columns from left to right: 1 Kb DNA ladder; CMV-CBG68luc digested with HindIII only, CMV-CBG68luc 
digested with XbaI only; CMV-CBG68luc digested with HindIII and XbaI (CBG68luc = 1628 bp); CMV-
hRluc digested with HindIII only, CMV-hRluc digested with XbaI only; CMV-hRluc digested with HindIII 
and XbaI (hRluc = 1058 bp). 
Protocols followed for bacterial and DNA manipulation will now be described.   
7.2 Bacterial Manipulations 
7.2.1 Bacterial Strains 
The JS4 E. coli strain was used for plasmid manipulation and preparation. JS4 is a 
recA1 derivative of MC1061 and has the following genotype: F-araD139, Δ(ara, 
leu)7697, Δ(lac)χ74, galU, galK, hsdR2 (rk- mk-), mcrA, mcrBC, rpsL(Strr) thi, recA.  
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7.2.2 Media and Bacterial Growth 
E. coli cells were grown in LB Broth (25g/L Luria Broth Base) or Super Broth (32 g/L 
bactotryptone, 20 g/L yeast extract, 10 g/L MOPS). 15 g/L of agar (Oxoid) was added 
to LB medium when preparing LB agar plates. To make up the media, all the 
components were dissolved in dd H2O and autoclaved for 20 min at 1210C. When 
required, ampicillin was added to give a final concentration of 100 µg/ml. 
7.2.3 Preparation of Competent Bacteria 
The JS4 bacteria kindly given had already been made competent using the following 
method. 5 ml of LB medium was inoculated with a single bacterial colony and 
incubated overnight with shaking at 370C. The subsequent culture was decanted into 
500 ml of LB medium and grown at 370C with aeration for 2.0-2.5 hr until the optical 
density (OD) reading at 600 nm (OD600) reached 1.0-1.2 (mid-exponential phase). 
Bacteria were then harvested by centrifugation at 2500 rpm for 20 min; resuspended in 
5 ml of ice-cold, 0.1 molar (M) calcium chloride (CaCl2); and placed on ice for 20 min. 
Bacteria were centrifuged again and resuspended in 5 ml of ice-cold 85:15 solution 0.1 
M CaCl2  and glycerol. 1 ml aliquots were placed in liquid N2-chilled 1.5 ml microfuge 
tubes and stored at -800C.  
7.2.4 Bacterial Transformation 
1 ml of frozen, competent, JS4 bacteria was thawed on ice. Once thawed, 0.9 ml of ice-
cold 0.1 M CaCl2 was added and 0.1 ml of this mixture was then added to each DNA 
sample to be transformed. The DNA/bacteria samples were placed on ice for 30 min 
followed by heat shock at 420C for 90 sec. The transformations were returned to ice 
where 1 ml of LB medium was added to each specimen, which were then incubated at 
370C for 30 min. Each sample was plated on pre-warmed, 10 cm2, LB agar plates 
containing ampicillin, at a final concentration of 100 µg/ml, and incubated overnight at 
370C. A negative control plated with competent, JS4 bacteria that had not been 
transformed was also prepared.  
7.3 DNA Manipulations 
7.3.1.DNA Preparation 
All vector and plasmid preparations, both small and large scale, were carried out using 
QIAGEN kits, following manufacturer instructions. 
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7.3.1.1 Small Scale Plasmid Preparation 
All solutions and buffers used were from the QIAfilter Plasmid Mini Kit, QIAGEN. All 
centrifugation occurred at a speed of 13 000 rpm.  
 
Liquid cultures of transformed bacteria picked from single colonies and transferred to 5 
ml of LB medium containing ampicillin, were grown with vigorous shaking at 370C 
overnight. 1.5 ml samples were then transferred to 2 ml microfuge tubes and 
centrifuged for 30 sec. The resultant pellet was resuspended in 250 µl of buffer P1 (50 
mM Tris/HCl, pH 8.0, 10 mM EDTA and 100 mg/ml RNAse A, stored at 40C), 
following which 250 µl of buffer P2 (200 mM NaOH and 1 % SDS) was added and 
gently mixed by inversion. 350 µl of solution buffer N3 (3.0 M sodium acetate, pH5.5) 
was then added and also mixed by inversion. The samples were centrifuged for 10 min 
and the supernatant transferred to a QIAprep spin column. The column was centrifuged 
for 1 min and the flow-through discarded. The column was then washed with 0.75 ml 
of buffer PE and centrifuged again for 1 min. The flow-through was again discarded 
and the column centrifuged for an additional 2 min to remove any residual buffer.  
DNA was then eluted with 50 µl of buffer EB. After 1 min, the column was centrifuged 
for 1 min. The flow-through DNA was collected and stored at -200C. 
7.3.1.2 Large Scale Plasmid Preparation 
All solutions and buffers used were from the QIAfilter Plasmid Maxi Kit, QIAGEN.  
 
200 ml of Super Broth containing 100 µg/ml of ampicillin was inoculated with an 
overnight culture of transformed bacteria from a single colony. After incubation at 
370C with vigorous shaking for 24h, bacteria were harvested at 6000 rpm for 15 min at 
40C using a Sorvall GS3 rotor. The bacterial pellet was resuspended in 10 ml of buffer 
P1. 10 ml of buffer P2 was then added. After incubation at room temperature for 5 min, 
10 ml of chilled, neutralisation buffer P3 was added and the resultant lysate transferred 
to a QIAfilter cartridge. Following incubation at room temperature for 10 min, the 
lysate was transferred to a pre-equilibrated QIAGEN-tip 500 column (equilibration 
buffer QBT: 750 mM NaCl, 50 mM MOPS, pH 7.0, 15 % ethanol v/v, and 0.15 % 
Triton X-100) and allowed to enter the resin under gravity. The column was then 
washed twice with 30 ml of Buffer QC (1 M NaCl, 50 mM MOPS, pH 7.0, and 15 % 
ethanol). DNA was eluted with 15 ml of elution buffer OF (1.25 M NaCl, 50 mM Tris-
HCl, pH 8.5, and 15 % ethanol) and precipitated in 10.5 ml of isopropanol at room 
temperature. Centrifugation was then performed at 40C 8000 rpm for 15 min using a 
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Sorvall SS-34 rotor, the only deviation from the standard protocol. The DNA pellet was 
washed with 1 ml 70% ethanol, transferred to a 1.5 ml vial, and centrifuged at 11 000 
rpm for 5 min. Having decanted away the supernatant, the pellet was allowed to air dry, 
then redissolved in 0.1-0.2 ml of TE.  
7.3.2 DNA Quantification 
To determine DNA concentration, the OD of the solution was measured at 260 nm 
(OD260) using a BioRad spectrophotometer (Bio-Rad Smart SpecTM 3000 
Spectrophotometer). The DNA concentration was calculated using the relationship 1 
OD unit at 260 nm = 50 µg/ml DNA.  
7.3.3 Restriction Digests 
Restriction digests of DNA plasmids were performed using restriction endonculeases 
from New England Biolabs. 5 µg of DNA was used for digestion. For HindIII and XbaI 
digestions, 3 µl of 10x buffer 2 (10 mM Tris-HCl, 50 mM NaCl, 10 mM MgCl2, 1 mM 
DTT, pH 7.9 at 250C) was added to the DNA. For HindIII and BamHI digestions, 3 µl 
of 10x buffer 3 (50 mM Tris-HCl, 100 mM NaCl, 10 mM MgCl2, 1 mM DTT, pH 7.9 
at 250C) was added to the DNA. To the DNA/buffer mix, 0.5 µl of 100x BSA and 1 µl 
of each enzyme was added, with ddH20 being used to make a total volume of 30 µl. 3 
hr incubation at 370C was performed for all digestion reactions, followed by 
inactivation at 700C for 20 min. After resting at 40C for a few minutes, the digests were 
stored at -200C. 
7.3.4 DNA-Agarose Gel Electrophoresis 
DNA fragments were loaded with 1x DNA loading buffer (BlueJuiceTM, 65% (w/v) 
sucrose, 10 mM Tris-HCl [pH 7.5], 10 mM EDTA, and 0.3 % (w/v) bromophenol blue) 
and fractionated by electrophoresis on 1 % (w/v) agarose gels prepared in 1x TAE (40 
mM Tris-acetate and 2 mM EDTA) with 0.5 µg/ml ethidium bromide. Electrophoresis 
in 1x TAE was carried out in electrophoresis tanks and DNA fragments were separated 
at a constant voltage of 70 V for a minimum of 30 min. Samples were loaded alongside 
5 µl 1 Kb DNA ladder. Ethidium bromide stained DNA fragments were then visualised 
on a UVP (Dual Density UV transilluminator) and an image produced and printed with 
a Sony video graphic printer.  
7.3.5 Extraction of DNA from Agarose Gels 
DNA restriction fragments were separated on agarose gels with the electrophoresis 
running a constant voltage of 50 V for 1 hr. The resulting fragments were viewed with 
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a long wavelength UV emission transilluminator and the desired band isolated with a 
scalpel. DNA was then purified using the QIAquickGel Extraction Kit (QIAGEN), 
following instructions in the QIAquick Spin Handbook (QIAGEN): all centrifugation 
took place at 13 000 rpm for 1 min. To dissolve the gel, 3 volumes of buffer QG were 
added to the gel slice, which was then incubated at 500C for 10 min. Once dissolved, 1 
gel volume of isopropanol was mixed with the sample, which was then transferred to a 
QIAquick spin column and centrifuged. To remove all traces of agarose, a further 0.5 
ml of buffer QG was added to the column, which was centrifuged again.  As a wash, 
0.75 ml of buffer PE was added to the column and centrifuged. To elute the DNA, 30 
µl of buffer EB was added to the column and centrifuged.  
7.3.6 Ligation 
15 µl ligation reactions were performed using 1 µl T4 DNA Ligase and 1.5-2 µl 10x 
ligation buffer (500 mM Tris-HCl pH7.5, 100 mM MgCl2, 100 mM DTT, 10 mM ATP, 
and 250 µg/ml BSA). A ratio of 2:1 for vector DNA:insert DNA was used. Final 
samples were centrifuged at 13 000 rpm for 1 min, then stored overnight at 160C.  
7.4 Cell Cloning: Generating Stable Luciferase-Expressing Cell Lines  
U87 cells were transfected with CMV-luc, CMV-CBG68luc and CMV-hRluc to 
generate monoclonal and polyclonal lines. NIH 3T3 cells were transfected with CMV-
luc to generate monoclonal and polyclonal lines.  
 
A brief overview of the cell cloning process is illustrated in Figure 26. In short, cells 
were transfected with the desired plasmid using a transfection agent. After 48 hours of 
incubation, the standard culture media was replaced with a neomycin-containing, 
selection media. After further incubation, surviving cells, presumably those 
successfully transfected with plasmid, were either allowed to grow to 80% confluence, 
thereby generating a polyclonal line, or were harvested, replated such as to allow single 
cells to form colonies, each colony then being harvested and allowed to grow to 80% 
confluence, thereby generating monoclonal lines.  
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Figure 26 An overview of cell cloning.  
Cells were transfected with the desired plasmid using a transfection agent. After 48 hours of incubation, the 
standard culture media was replaced with a neomycin-containing, selection media. After further incubation, 
surviving cells, were either allowed to grow to 80% confluence, thereby generating a polyclonal line, or were 
harvested, replated such as to allow single cells to form colonies, each colony then being harvested and 
allowed to grow to 80% confluence, thereby generating monoclonal lines.  
A more detailed description of the cell cloning process now follows.  
7.4.1 DNA Transfection of Cells 
Cells were harvested by trypsinisation, plated at a density of 1.5x106 cells per well of a 
24 well plate, and incubated overnight. The transfection reagent, FuGENE HD, 
mediated transfection of cells with luciferase-containing plasmids. A series of 1 ml 
tubes were filled with 200 ml of serum free media. Pre-determined amounts of plasmid, 
then FuGENE HD was added to each tube at ratios of 3:1 and 3:2 FuGENE 
HD:plasmid, and immediately shaken. The mixture was left to incubate for 15 mins at 
room temperature. The contents were then added to appropriately labelled wells. There 
were also two controls: cells to which only serum free media was added, and those to 
which only FuGENE HD in serum free media was added. The cells were then placed in 
an incubator.  
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7.4.2 Transient Transfection 
After 48 hrs of incubation, media was aspirated from the transfected cells, and the wells 
were washed with 0.5 ml of PBS. Cells were then prepared for a luciferase assay, as 
below.  
7.4.3 Selection of Stable Transfectants 
Following 48 hrs of incubation, media was aspirated from the transfected cells and 
replaced with complete media containing 1 mg/ml of neomycin. Cells were then 
incubated for a further 5 days.    
7.4.4 Isolation of Monoclonal Luciferase-Expressing Lines 
After transfection, selection with 1 mg/ml of neomycin, and 5 days of incubation, 
surviving cells were trypsinised and transferred from the 24 well plate to a 10 cm2 
plate. Cells were maintained in selection media; fresh media being changed every 3-4 
days. Once individual colonies had established, single colonies were picked using 
sterile cloning discs. Media was aspirated from the dish. Trypsin-soaked cloning discs 
(0.5 cm2 diameter) were then placed over the colonies. Following 1-2 mins incubation 
at 370C, discs, now holding the detached colony, were retrieved with a Pasteur pipette 
on light suction and transferred to individual wells of a 24 well plate containing fresh 
selection media. Cells were allowed to attach to the wells at 370C overnight, following 
which the discs were removed with a Pasteur pipette on light suction. Each colony was 
allowed to grow to 80% confluence, then progressively expanded into T80 cm2 flasks.  
7.4.5 Generation of Polyclonal Luciferase-Expressing Lines 
Once cells had been transfected and exposed to selective media, they were allowed to 
grow to 80% confluence in the wells of the 24 well plate. Cells in each well were then 
progressively expanded into T80 cm2 flasks.  
7.4.6 Cell Culture of Luciferase-Expressing Lines 
Monoclonal and polyclonal luciferase-expressing cell lines were sub-cultured and 
maintained in similar cell culture conditions as described in Chapter 6. The only 
exception was that luciferase-expressing cell lines were maintained in complete media 
containing 1 mg/ml neomycin at all times. 
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7.5 Characterising Bioluminescence 
The degree of bioluminescence produced by each luciferase-expressing cell line 
generated was studied using two methods, the luciferase assay and the live cell assay.  
7.5.1 Luciferase Assay 
7.5.1.1 Preparation of Reagents 
For CMV-luc and CMV-CBG68luc transfected cell lines, the luciferase assay was 
carried out using the Luciferase Assay System from Promega. The assay reagent was 
prepared by adding the vial of luciferase assay substrate with the luciferase assay buffer 
provided. The reagent was divided into 0.5 ml aliquots and stored at -700C. Before each 
experiment, the appropriate volume of reagent was thawed and allowed to equilibrate 
to room temperature, and 4 volumes of distilled water was added to 1 volume of the 5x 
luciferase assay lysis buffer provided, to make a 1x lysis buffer.   
 
For CMV-hRluc transfected cell lines, the Renilla Luciferase Assay System from 
Promega was used. The reagent was prepared before each experiment by adding 1 
volume of the 100x Renilla luciferase assay substrate to 100 volumes of the Renilla 
luciferase assay buffer provided. The 5x Renilla luciferase assay lysis buffer provided 
was prepared as above, to make a 1x lysis buffer. 
7.5.1.2 Preparation of Cells 
When analysing the effect of transient transfection, 48 hrs after transfection, cells were 
prepared in the wells that they had been transfected in. For stable transfectants, cells 
were harvested, following trypsinization, and plated at a density of 1x104 cells per well 
of a 24 well plate and allowed to incubate for 24 hrs. All cell lines tested were at the 
same passage number.  
7.5.1.3 The assay 
Media was aspirated from wells and cells washed with PBS. 0.1 ml of 1x lysis buffer 
was then added to each well and the plate rocked at room temperature for 5 mins, 
ensuring complete cell lysis. The lysate was stored at -200C. When ready to run the 
assay, the lysate was thawed and 5 µl lysate was transferred into the wells of a white, 
half area, Corning 96 well plate. 25 µl reagent was then added to each well and 
bioluminescence measured immediately on a luminometer. For transient transfectants, 
there were three controls, untransfected cells (C), untransfected cells that had been 
exposed to serum free media (CM), untransfected cells that had been exposed to serum 
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free media and FuGENE HD (CFu). For stable transfectants, the only control was 
untransfected cells.  
 
The method of cell transfection using the transfection reagent FuGENE HD was 
successful, as demonstrated by conducting a luciferase assay on U87 and NIH 3T3 cells 
transiently transfected with CMV-luc (see Figure 27). For U87 cells, there was no 
significant difference in light production between a 3:1 (28 200 ± 11 500 RLU) or 3:2 
(27 800 ± 4 370 RLU) FuGENE HD:plasmid ratio (p > 0.05). However, for NIH 3T3 
cells, a 3:1 FuGENE HD:plasmid ratio produced significantly more light (12 200 ± 1 
950 RLU) compared to a 3:2 FuGENE HD:plasmid ratio (4 910 ± 934 RLU), 
indicating a more efficient transfection (p < 0.01) with a 3:1 FuGENE HD:plasmid 
ratio. Transfection of U87 cells produced more light than transfection of NIH 3T3 cells. 
There was no significant between the three controls, C, CM and CFu, for each cell line.  
 
 
 
Figure 27 Luciferase Assay of U87 and NIH 3T3 transiently transfected with CMV-luc.  
C = untransfected cells only; CM = untransfected cells exposed to serum free media only; CFu = untransfected 
cells exposed to serum free media and FuGENE HD; 3:1, ratio of FuGENE HD:plasmid ; 3:2, ratio of 
FuGENE HD:plasmid. Asterisks indicate the degree of significance compared to C where * p > 0.05, ** p ≤  
0.05, *** p < 0.01, **** p < 0.001.  The diamonds represent the degree of significance between the two test 
conditions where !p > 0.05, !! p ≤  0.05,  !!! p < 0.01, !!!! p < 0.001. For U87 cells, there was no significant 
difference in light production between a 3:1 (28 200 ±  11 500 RLU) or 3:2 (27 800 ±  4 370 RLU) FuGENE 
HD:plasmid ratio (p > 0.05). However, for NIH 3T3 cells, a 3:1 FuGENE HD:plasmid ratio produced 
significantly more light (12 200 ±  1 950 RLU) compared to a 3:2 FuGENE HD:plasmid ratio (4 910 ±  934 
RLU) (p < 0.01). 
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Furthermore, stable, monoclonal U87-luc and NIH 3T3-luc transfectants were 
successfully generated (see Figure 28). For U87-luc, all cell lines generated significant 
amounts of light compared to control (A1, 90 100 ± 8 010 RLU; B1, 84 200 ± 3 030 
RLU; B2, 73 600 ± 2 380 RLU; D1, 94 300 ± 3 340 RLU; E1, 161 000 ± 9 210 RLU; p 
< 0.0001). There was no significant difference in light production between cell lines 
A1, B1, B2 and D1. However, E1 produced significantly more light compared to the 
other cell lines (p < 0.0001). For NIH 3T3-luc cells, two of three lines, E1 and F1, 
produced significant amounts of light compared to control (E1, 1 410 ± 270 RLU; F1, 1 
680 ± 94.3, p < 0.001), with no significant difference between the two cell lines.  
 
Stable polyclonal U87-luc and NIH 3T3-luc cells were also generated (see Figure 28). 
For U87-luc cells, 1 way ANOVA analysis of the data indicated that one cell line, P6, 
produced a significant amount of light compared to control (447 000 ± 34 700 RLU, p 
< 0.001). However, cell lines P4 and P5 produced 51 200 ± 3 670 RLU and 15 100 ± 1 
590 RLU of light, respectively. Although p values did not reach significance, this was 
likely due to the orders of magnitude difference in light generated by the P6 cell line. 
When P6 was excluded from analysis, the light generated by the P4 and P5 cell lines 
became significant compared to control (p < 0.001). For NIH 3T3-luc cells, four out of 
the eight polyclonal lines produced a significant amount of light compared to control 
(A2, 3 420 ± 303 RLU; γ3, 4 670 ± 387 RLU; D4, 1 150 ± 114 RLU; E4, 2 750 ± 191 
RLU; p < 0.001).  
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Figure 28 Luciferase assay of monoclonal and polyclonal U87-luc cell lines and NIH 3T3-luc cell lines 
C = untransfected cells. The remaining ‘test’ conditions represent the various cell lines generated. Asterisks 
indicate the degree of significance in RLU of the test conditions compared to control, where * p > 0.05, ** p ≤  
0.05, *** p < 0.01, **** p < 0.001, ***** p < 0.0001. Diamonds indicate the degree of significance in RLU 
between the test conditions, where !p > 0.05, !!p ≤  0.05, !!!p < 0.01, !!!!p < 0.001, !!!!!p < 0.0001. 
Regarding U87-luc polyclonal cells, ^^^^ indicate p < 0.001 compared to control having excluded P6 from the 
analysis. All U87-luc monoclonal cell lines generated significantly more light than control, with no significant 
difference between cell lines A1, B1, B2, D1; but with cell line E1 producing significantly more light than the 
rest of the cell lines. For NIH 3T3-luc monoclonal cells, 2 cell lines, E1 and F1, produced significantly more 
light than control. 3 U87-luc polyclonal lines produced significant amounts of light, with the P6 cell line 
generating orders of magnitude more light than cell lines P4 and P5. 4 NIH 3T3-luc polyclonal lines produced 
significantly more light than control.  
Stable U87-CBG68luc monoclonal and polyclonal lines were generated (see Figure 
29). Regarding monoclonal cells, the E1 cell line produced significant amounts of light 
(378 000 ± 39 300 RLU, p < 0.001) compared to control. On initial 1 way ANOVA 
analysis, the light produced by cell line γ2 (9 480 ± 968 RLU) did not reach 
significance. However, this was likely due to the orders of magnitude difference in 
light generated by the E1 cell line. When E1 was excluded from analysis, the light 
generated by the γ2 cell line became significant (p < 0.001). All U87-CBG68luc 
polyclonal cell lines generated significant amounts of light compared to control (P1 78 
500 ± 3140 RLU, P2 113 000 ± 7 220, P3 36 900 ± 4 760 RLU, P4 36 400 ± 2 940, P5 
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43 520 ± 4 160, P6 81 800 ± 4 190 RLU, P7 33 500 ± 3 340, and P8 58 000 ± 3 530 
RLU, p < 0.001). 
 
 
Figure 29 Luciferase assay of U87-CBG68luc monoclonal and polyclonal lines 
C = untransfected cells. The remaining ‘test’ conditions represent the various cell lines generated. Asterisks 
indicate the degree of significance in RLU compared to C where * p > 0.05, ** p ≤  0.05, *** p < 0.01, **** p < 
0.001. ^^^^ indicate p < 0.001 compared to control having excluded E1 from the analysis. U87-CBG68luc E1 
cells generated significant amounts of light compared to control. When E1 cells were removed from analysis 
the amount of light produced by the γ2 cell line also reached significance. All polyclonal cell lines generated 
significant amounts of light compared to control.  
Stable U87-hRluc monoclonal and polyclonal lines were generated (see Figure 30). 
Regarding monoclonal cells, cell line E produced significant amounts of light (713 000 
± 72 200 RLU, p < 0.001) compared to control. On initial 1 way ANOVA analysis, the 
light produced by cell lines D (46 800 ± 13 400 RLU) and I (89 400 ± 10 600 RLU) did 
no reach significance. However, this was likely due to the orders of magnitude 
difference in light generated by cell line E. When E was excluded from the analysis, the 
light generated by cell lines D and I became significant (p < 0.001). U87-hRluc 
polyclonal cell lines also generated significant amounts of light compared to control. 
Initial analysis revealed that cell lines P2, P4 and P6 generated a light signal 
significantly different to control (151 400 ± 2 800 RLU, p < 0.01; 415 000 ± 61 600 
RLU, p < 0.001; and 178 000 ± 22 100 RLU, p < 0.001, respectively). When these cell 
lines were removed from analysis, so comparing signal of similar orders of magnitude, 
signal from cell lines P1, P3, P5 and P7, also reached significance (39 600 ± 3 250 
RLU, 34 700 ± 3 850 RLU, 80 300 ± 4 160 RLU, and 40 200 ± 3 810 RLU, 
respectively, p < 0.001).  
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Figure 30 Luciferase assay of U87-hRluc monoclonal and polyclonal lines 
C = untransfected cells. The remaining ‘test’ conditions represent the various cell lines generated. Asterisks 
indicate the degree of significance in RLU compared to C where * p > 0.05, ** p ≤  0.05, *** p < 0.01, **** p < 
0.001. ^^^^ indicate p < 0.001 compared to control having excluded cell lines generating signal of a higher 
order of magnitude from the analysis. U87-hRluc cell line E generated significant amounts of light compared 
to control. When cell line E was removed from analysis the amount of light produced by cell lines D and I 
reached significance. Polyclonal cell lines P2, P4 and P6 were found to generate significant amounts of light. 
After removing these from the analysis, cell lines P1, P3, P5 and P7, were also found to generate significant 
amounts of light.  
Overall, more polyclonal than monoclonal cell lines capable of bioluminescence were 
generated: as described in detail above, 4 NIH 3T3-luc polyclonal cell lines capable of 
bioluminescence were generated compared to 2 NIH 3T3-luc monoclonal lines; and 
similarly, 8 U87-CBG68luc polyclonal cell lines were generated compared to 2 
monoclonal lines; and 7 U87-hRluc polyclonal cell lines were generated compared to 3 
monoclonal lines. The only exception was the U87-luc cell line, where 5 U87-luc 
monoclonal cell lines capable of bioluminescence were generated compared to 3 
polyclonal lines. Furthermore, regarding U87 luciferase transfected cells (see Figure 
31), although more polyclonal cell lines producing bioluminescence in the order of 
hundreds of thousands of RLU were generated compared to monoclonal lines, at least 1 
monoclonal line was generated that was capable of producing an exceptional amount of 
light (U87-CBG68luc E1, 378 000 ± 39 300 RLU, p < 0.001; and U87-hRluc E, 713 
000 ± 72 200 RLU, p < 0.001). Again, U87-luc was the exception: with U87-luc P6, a 
polyclonal line, producing an exceptional amount of light (447 000 ± 34 700 RLU, p < 
0.001) compared to the monoclonal lines. Consistent with the transient transfectants, 
much greater bioluminescence was produced by U87 luciferase-transfected cells 
compared to NIH-3T3 luciferase-transfected cells, whether monoclonal or polyclonal. 
For this reason, ongoing characterisation of bioluminescence was carried out in the 
U87 transfected cells only. 
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Figure 31 Summary of the Luciferase Assays carried on U87-luc, U87-CBG68luc and U87-hRluc monoclonal 
and polyclonal lines.  
C = untransfected cells. Asterisks indicate the degree of significance in RLU of the test conditions compared 
to control, where * p > 0.05, ** p ≤  0.05, *** p < 0.01, **** p < 0.001, ***** p < 0.0001. Although more 
polyclonal cell lines producing bioluminescence in the order of hundreds of thousands of RLU were generated 
compared to monoclonal lines, at least 1 monoclonal line was generated that was capable of producing an 
exceptional amount of light (U87-CBG68luc E1 378 000 ±  39 300 RLU, p < 0.001;and U87-hRluc E, 713 000 ±  
72 200 RLU, p < 0.001). Again, U87-luc was the exception with U87-luc P6, a polyclonal line, producing an 
exceptional amount of light (447 000 ±  34 700 RLU, p < 0.001) compared to the monoclonal lines.  
7.5.2 Live Cell Assay 
U87-luc and U87-hRluc cells were chosen to test the live cell assay.  
7.5.2.1 Preparation of Reagents 
For U87-luc cells, d-luciferin was used as the substrate. A 5 mM stock solution of d-
luciferin (molecular weight = 318.4) was made by dissolving it in PBS. The solution 
was stored in 1 ml aliquots at -200C.  
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For U87-hRluc cells, EnduRenTM was used as the substrate. A 60 mM stock solution 
was made by dissolving the substances in tissue grade DMSO. The solution was stored 
in 1 ml aliquots at -200C. 
7.5.2.2 Preparation of Cells 
Cells were harvested and plated in white, flat bottom, tissue culture treated, 96 well 
plates (Sigma), at a density of 1x104 cells per well. Cells were replaced into the 
incubator. 
7.5.2.3 The Assay 
After 24 hrs incubation, media was aspirated from each well and replaced with 0.1 ml 
of complete media. 5 mM of d-luciferin was added to U87-luc cells and 60 mM of 
EnduRenTM was added to U87-hRluc cells, making final concentrations of 2.5 mM and 
30 mM, respectively. Each cell line was tested in triplicate. The bioluminescence from 
the U87-luc cells was measured immediately after the substrate was added, whereas 
that from U87-hRluc cells was measured after 1 hour incubation with the substrate. The 
control was untransfected cells to which substrate was added.  
 
Bioluminescence generated by U87-luc monocloncal cell lines was compared (see 
Figure 32). The live cell assay demonstrated that all cell lines produced 
bioluminescence that was significantly different from control.  Cell lines A1 and D1 
produced the most light (35 000 ± 2 060 RLU and 36 600 ± 2 440 RLU, respectively), 
with no significant difference between them. Cell lines B1, B2 and E1 produced 
significantly less light (20 300 ± 1 550 RLU, 16 200 ± 1 080 RLU, and 22 700 ± 1 020 
RLU, respectively) than cell lines A1 and D1, although there was no significant 
difference between them.  The luciferase assay was not predictive of the results of the 
live cell assay (see Figure 32): in contrast to the live cell assay, the luciferase assay 
demonstrated that E1 generated significantly more light than the other cell lines (161 
000 ± 9 210 RLU, p < 0.0001), as discussed above. Furthermore, the luciferase assay 
generated 2.5 to 7 fold more light than the live cell assay. 
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Figure 32 U87-luc Monoclonal Cells: Comparing the Live Cell Assay with the Luciferase Assay 
C = untransfected cells. Asterisks indicate the degree of significance in RLU of the test conditions compared 
to control, where * p > 0.05, ** p ≤  0.05, *** p < 0.01, **** p < 0.001, ***** p < 0.0001. Diamonds indicate the 
degree of significance in RLU between the test conditions, where !p > 0.05, !!p ≤  0.05, !!!p < 0.01, !!!!p < 
0.001, !!!!!p < 0.0001. The live cell assay demonstrated that cell lines A1 and D1 produced the most light 
with no significant difference between them. Cell lines B1, B2 and E1 produced significantly less light in 
comparison, although there was no significant difference between them.  In contrast, the luciferase assay 
showed that E1 produced significantly more light than control and the other cell lines. Furthermore, the 
luciferase assay generated 2.5 to 7 fold more light than the live cell assay.  
Bioluminesence generated by U87-hRluc monoclonal cell lines was also compared (see 
Figure 33). Cell line E was seen to produce significantly more light than control (89 
300 ± 4 820 RLU, p < 0.001. On initial 1 way ANOVA analysis, the light produced by 
cell lines γ, D and I did not reach significance. However, this was likely due to the 
orders of magnitude difference in light generated by cell line E. When cell line E was 
excluded from analysis, the light generated by cell lines γ, D and I (3 880 ± 115 RLU, 1 
400 ± 122 RLU, and 4 240 ± 122 RLU, respectively) became significantly greater than 
control, p < 0.001. With U87-hRluc monoclonal cells, the luciferase assay was more 
predictive of the live cell assay (see Figure 33): the luciferase assay also demonstrated 
that cell line E produced significantly more light than the other cell lines, and that once 
cell line E was removed from analysis, the light produced by cell lines D and I would 
become significant, as described above. However, in contrast to the live cell assay, 
even with cell line E removed from the analysis, the bioluminescence from cell line γ 
was not significantly different from control in the luciferase assay. Again, the luciferase 
assay generated a whole order of magnitude more light than the live cell assay.  
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Figure 33 U87-hRluc Monoclonal Cells: Comparing the Live cell Assay with the Luciferase Assay 
C = untransfected cells. Asterisks indicate the degree of significance in RLU of the test conditions compared 
to control, where * p > 0.05, ** p ≤  0.05, *** p < 0.01, **** p < 0.001, ***** p < 0.0001.  ^^^^ indicate p < 
0.001 compared to control having excluded cell lines generating signal of a higher order of magnitude from 
the analysis.  The live cell assay demonstrated that cell line E produced significantly more light than control. 
On initial 1 way ANOVA analysis, the light produced by cell lines γ , D and I did not reach significance. 
However, when cell line E was excluded from analysis, the light generated by cell lines γ , D and I became 
significantly greater than control, p < 0.001. The luciferase assay demonstrated similar results, although, even 
with excluding cell line E from the analysis, cell line γ  was not seen to produce significant amounts of light. 
The luciferase assay was seen to generate a whole order of magnitude more light than the live cell assay. 
The luciferase assay generates significantly more bioluminescence than the live cell 
assay, and this is demonstrated across two different cell lines. In the lysis process, the 
luciferase-containing plasmids that have been transfected but have not been 
incorporated into the cellular DNA are now exposed to the nuclear enzymes that 
mediate transcription and translation, and hence more luciferase can be generated, and 
stronger bioluminescence achieved with the addition of substrate. Moreover, there may 
be poor correlation between the luciferase assay and live cell assay as the amount of 
plasmid that has not been incorporated into the cellular DNA will be unpredictable. 
Further contributing to the poor correlation between the two assays, some cells from 
this glioma derived cell line may express a transporter pump170 that causes efflux of 
luciferase, reducing the bioluminescence generated, and this would not be reflected by 
the luciferase assay.  
 
For the purposes of investigating bPDT, the live cell assay is a more accurate measure 
of the light that would be available to mediate a photodynamic effect in a live, 
luciferase-producing cell. For this reason, the live cell assay was used for the remainder 
of the experiments.  
U87-hRluc Cells: Live Cell  Assay
C γ D E F I
0
25000
50000
75000
100000
^^ ^^ ^^ ^^
****
* ^^ ^^
Cell Lines
R
el
at
iv
e 
Li
gh
t U
ni
ts
, R
LU
U87-hRluc Cells: Luciferase Assay
C A B γ D E F G I J
0
200000
400000
600000
800000 ****
^^ ^^ ^^ ^^
* * * * * *
Cell Lines
R
el
at
iv
e 
Li
gh
t U
ni
ts
, R
LU
 120 
7.5.3 Generating Optimal Bioluminescence 
Having successfully generated luciferase-transfected U87 cell lines that were capable 
of bioluminescence, the conditions required to generate optimal bioluminescence were 
studied. The maximum, non-toxic dose of substrate was established. Then using this 
dose of substrate, the effect of substrate manufacturer, substrate solvent, and cell 
culture conditions on bioluminescence were investigated.  
7.5.3.1 d-Luciferin Toxicity 
U87-luc and U87-CBG68luc cells were harvested and plated in 96 well plates at a 
density of 1x104 cells per well. Cells were replaced into the incubator. After 24 hrs 
incubation, media was aspirated from each well and replaced with 0.1 ml of complete 
media. d-Luciferin was diluted in varying amounts of PBS and 0.1 ml was added to 
give final concentrations ranging from 0.313 to 5 mM. Control cells had 0.l ml of PBS 
added. Cells were incubated overnight, to replicate test conditions, and an MTT assay 
was subsequently conducted. The toxicity of d-luciferin from three different 
manufacturers, Promega, Caliper Life Sciences (CLS) and Synchem was compared.  
 
2.5 mM was the maximum dose of d-luciferin, from all manufacturers, that could be 
tolerated by U87-luc cells (see Figure 34).  2.5 mM of d-luciferin only cause mild 
toxicity in U87-CBG68luc cells (68.1% of control, p < 0.01, 95% CI 0.0591 – 0.275).  
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Figure 34 d-Luciferin Toxicity 
C = control. Numbers on the x axis refer to the dose of d-luciferin. Asterisks indicate the degree of 
significance of the difference in OD between each condition and control, where * p > 0.05, ** p ≤  0.05, *** p < 
0.01, **** p < 0.001, ***** p < 0.0001.  2.5mM was the maximum dose of d-luciferin, from all manufacturers, 
tolerated by U87-luc cells. However, this dose did cause toxicity in U87-CBG68luc cells, but this was only mild 
(68.1% of control, p < 0.01, 95% CI 0.0591 – 0.275).  
7.5.3.2 EnduRenTM Toxicity 
U87-hRluc cells were harvested and plated in 96 well plates at a density of 1x104 cells 
per well. Cells were replaced into the incubator. After 24 hrs incubation, media was 
aspirated from each well and replaced with 0.1 ml of complete media. EnduRenTM was 
diluted in varying amounts of PBS and 0.1 ml was added to give final concentrations of 
37.5, 75, 150, 300 and 600 µM. Control cells had 0.1 ml of PBS added. The plate was 
incubated overnight and an MTT assay then conducted.  
 
A dose of 75 µM was found to cause minimal toxicity (98.6% of control, p < 0.05, 95% 
CI 0.0269 – 0.26) (see Figure 35).  
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Figure 35 EnduRenTM Toxicity 
C = control. Numbers on the x axis refer to the dose of EndurenTM. Asterisks indicate the degree of 
significance of the difference in OD between each condition and control, where * p > 0.05, ** p ≤  0.05, *** p < 
0.01, **** p < 0.001, ***** p < 0.0001.  75 µM was found to only cause minimal toxicity (98.6% of control, p < 
0.05, 95% CI 0.0269 – 0.26), and hence, the manufacturer recommended test dose of 60 µM was chosen for 
future testing.  
7.5.3.3 ViviRenTM Toxicity 
ViviRenTM is another substrate for Renilla luciferase that produces bioluminescence 
that has different properties to that produced by EnduRenTM. It was therefore 
investigated as a possible alternative to EnduRenTM.  
 
Three conditions using the substrate ViviRenTM were tested. U87-hRluc cells were 
harvested and plated in 96 well plates at a density of 1x104 cells per well. Cells were 
replaced into the incubator. After 24 hrs incubation, media was aspirated from each 
well and replaced with 0.1 ml of complete media.  Firstly, ViviRenTM was diluted in 
varying amounts of PBS and 0.1 ml of ViviRenTM was added to give final 
concentrations of 3.75, 7.5, 15, 30 and 60 µM. Control cells had 0.l ml of PBS added. 
The plate was incubated overnight and an MTT assay then conducted. Secondly, the 
initial experiment was repeated, but instead of incubating the cells overnight with 
ViviRenTM, the incubation period was for only 1 hour, after which an MTT assay was 
conducted. Thirdly, cells were prepared as for the initial ViviRenTM toxicity experiment 
with similar doses of drug added. However, the plate was then incubated for 1 hr, 
following which the cells were washed twice with PBS and 0.1 ml of complete media 
replaced. 0.1 ml of EnduRenTM was then added to give a final concentration of 30 µM. 
The plate was incubated for a further 24 hrs, following which an MTT assay was 
performed. Control cells were treated similar to test cells, but instead of substrate, they 
received 0.1 ml of PBS. 
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Following incubation with ViviRenTM for 24 hrs (see Figure 36), 7.5 µM of ViviRenTM 
was found to be the maximum non-toxic dose (81.3 % of control, p > 0.05, 95% CI -
0.0451 – 0.269). However, by shortening the incubation time with ViviRenTM to 1 hr, 
the maximum non-toxic dose increased to 30 µM: although the difference in OD550-690 
between control and cells incubated with 30 µM ViviRenTM was found to be 
significantly different, p < 0.01, the OD of cells incubated with 30 µM ViviRenTM was 
only 74.8% of control and the 95% CI 0.0585 – 0.181. In support of this, when 
incubating with ViviRenTM for 1 hr, followed by incubation with 30 µM EnduRenTM, 
use of 30 µM of ViviRenTM under these conditions caused no significant toxicity (105% 
of control, p > 0.05, 95% CI -0.151 – 0.100).  
 
 
Figure 36 ViviRenTM Toxicity 
C = control. Numbers on the x axis refer to the dose of VivirenTM. Asterisks indicate the degree of significance 
of the difference in OD between each condition and control, where * p > 0.05, ** p ≤  0.05, *** p < 0.01, **** p 
< 0.001, ***** p < 0.0001.  When incubating with VivirenTM for 24 hrs, the maximum non-toxic dose was 7.5 
µM (81.3 % of control, p > 0.05, 95% CI -0.0451 – 0.269). By shortening the incubation time with VivirenTM 
to 1 hour, the maximum non-toxic dose was increased to 30 µM (74.8% of control, p < 0.01, 95% CI 0.0585 – 
0.181). Additionally, when incubating with ViviRenTM for 1 hr, followed by incubation with 30 µM 
EnduRenTM, use of 30 µM of ViviRenTM under these conditions caused no significant toxicity (105% of 
control, p > 0.05, 95% CI -0.151 – 0.100).  
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7.5.3.5 Effect of Substrate Manufacturer 
d-Luciferin is produced by a number of manufacturers, which include Promega, CLS, 
and Synchem. These experiments were conducted to study if the amount of 
bioluminescence generated by the d-luciferin produced by these manufacturers 
differed. 
 
U87-luc and U87-CBG68luc cells were harvested and plated in white, flat bottom, 
tissue culture treated, 96 well plates (Sigma), at a density of 1x104 cells per well. Cells 
were replaced into the incubator. After 24 hrs incubation, media was aspirated from 
each well and replaced with 0.1 ml of complete media. Live cell assays were then 
performed using a final concentration of 2.5 mM d-luciferin from each manufacturer 
and the resulting bioluminescence compared (see Figure 37).  
 
In U87-luc cells, the bioluminescence generated by d-luciferin from Promega was 
slightly greater than that generated by CLS, the latter being 83.8% (p ≤ 0.05) and 
88.3% (p < 0.001) of that generated by Promega in B1 and D1 cell lines, respectively. 
In contrast, the bioluminescence generated by d-luciferin from Synchem was 
considerably less than that of Promega and CLS (1.31% and 1.90%, p < 0.0001, of the 
bioluminescence generated by Promega, in the B1 and D1 cell lines respectively). In 
U87-CBG68luc cells, there was no significant difference in the bioluminescence 
generated by d-luciferin from Promega and CLS. d-luciferin from Synchem was not 
tested in U87CBG68luc cells in view of its poor performance in U87-luc cells.  
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Figure 37 Effect of Substrate Manufacturer on Bioluminescence 
Cell lines are identified on the x axis. Asterisks indicate the degree of significance of the difference in RLU 
generated by d-luciferin from each of the manufacturers CLS and Synchem, compared to the RLU generated 
by the d-luciferin from Promega, where * p > 0.05, ** p ≤  0.05, *** p < 0.01, **** p < 0.001, ***** p < 0.0001.  
In U87-luc cells, the bioluminescence generated by d-luciferin from Promega was slightly greater than that 
generated by CLS, the latter being 83.8% (p ≤  0.05) and 88.3% (p < 0.001) of that generated by Promega in 
B1 and D1 cell lines, respectively. In contrast, the bioluminescence generated by d-luciferin from Synchem 
was considerably less than that of Promega and CLS (1.31% and 1.90%, p < 0.0001, of the bioluminescence 
generated by Promega, in the B1 and D1 cell lines respectively). In U87-CBG68luc cells, there was no 
significant difference in the bioluminescence generated by d-luciferin from Promega and CLS.  
7.5.3.6 Effect of Substrate Solvent 
In the experiments thus far, the substrates have been diluted in PBS. The effect on 
bioluminescence generated by diluting the substrates in PBS and serum free media was 
compared. Furthermore, the effect of phenol red in serum free media on 
bioluminesence was also investigated.  
 
U87-luc and U87-hRluc cells were harvested and plated in white, flat bottom, tissue 
culture treated, 96 well plates (Sigma), at a density of 1x104 cells per well. Cells were 
replaced into the incubator. After 24 hrs incubation, media was aspirated from each 
well and replaced with 0.1 ml of complete media. Live cell assays were then performed 
using final concentrations of 2.5 mM d-luciferin and 60 µM of EnduRenTM for U87-luc 
and U87-hRluc cells, respectively. The effect of diluting d-luciferin and EnduRenTM 
with either PBS or serum free media on bioluminescence to make these final 
concentrations was compared. Furthermore, in U87-luc cells, the effect of diluting d-
luciferin in serum free media without phenol red on bioluminescence was also studied 
(see Figure 38).  
 
For U87-luc cells, diluting d-luciferin in serum free media generated significantly less 
bioluminescence than diluting the substrate in PBS: diluting substrate in serum free 
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media generated 54.1% of the bioluminescence that was achieved by diluting the 
substrate in PBS (p<0.01). Furthermore, there was no significant difference in the 
bioluminescence generated by using either serum free media or serum free media 
without phenol red to dilute the substrate (54.1% vs 58.5% of the bioluminescence 
achieved by diluting the substrate in PBS, p > 0.05). Similarly, for U87-hRluc cells, 
diluting EnduRenTM in serum free media generated significantly less bioluminsence 
than diluting the subtrate in PBS: diluting substrate in serum free media generated 
54.3% of the bioluminescence achieved by diluting the substrate in PBS (p < 0.001).  
 
 
 
Figure 38 The Effect of Substrate Solvent on Bioluminescence 
Solvent is identified on the x axis, where PBS is phosphate buffered saline, SFM is serum free media, and 
SFM – PR is serum free media without phenol red. Asterisks indicate the degree of significance of the 
difference in RLU generated by using the different solvents compared to using PBS as the solvent, where * p 
> 0.05, ** p ≤  0.05, *** p < 0.01, **** p < 0.001, ***** p < 0.0001.  The diamond indicates the degree of 
significance of the difference in RLU generated by using SFM-PR compared to SFM, where !  p > 0.05. For 
U87-luc and U87-hRluc cells, diluting d-luciferin in serum free media generated significantly less 
bioluminescence than diluting the substrate in PBS (54.1%, p < 0.01, and 54.3%, p < 0.001, respectively, of the 
bioluminescence that was achieved by diluting the substrate in PBS). Furthermore, in U87-luc cells there was 
no significant difference in the bioluminescence generated by using either serum free media or serum free 
media without phenol red to dilute the substrate (54.1% vs 58.5% of the bioluminescence achieed by diluting 
the substrate in PBS, p > 0.05).  
7.5.3.7 Effect of Cell Culture Media 
Finally, the effect of cell culture media on bioluminescence generated was investigated. 
Cells were cultured in complete media or with complete media made with heat-
inactivated serum (see section 5.2.2).  
 
U87-luc cells were grown under standard cell culture conditions in either standard 
complete media or complete media made with heat-inactivated serum. For the latter, an 
aliquot of cells was directly thawed, then passaged in complete media with heat-
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inactivated serum. Cells were then harvested and plated in white, flat bottom, tissue 
culture treated, 96 well plates (Sigma), at a density of 1x104 cells per well, in their 
appropriate media. Cells were replaced into the incubator. After 24 hrs incubation, 
media was aspirated from each well and replaced with 0.1 ml of the appropriate 
complete media. Live cell assays were then performed using final concentrations of 2.5 
mM d-luciferin (see Figure 39). 
 
Culturing U87-luc cells in heat-inactivated serum led to a significant decline in the 
bioluminescence generated: cells cultured in heat-inactivated serum generated 60.0% of 
the bioluminescence that was achieved by cells grown in standard media, p < 0.01.  
 
 
Figure 39 The Effect of Cell Culture Media on Bioluminescence 
The cell culture media is identified on the x axis, where RS is regular, standard, complete media and HIS 
complete media with heat-inactivated serum. Asterisks indicate the degree of significance of the difference in 
RLU generated by cells cultured in complete media with heat-inactivated serum compared to those cultured 
in standard complete media, where * p > 0.05, ** p ≤  0.05, *** p < 0.01, **** p < 0.001, ***** p < 0.0001. 
Culturing U87-luc cells in heat-inactivated serum led to a significant decline in the bioluminescence, 
generating 60.0% of the bioluminesence that was achieved by cells grown in standard media, p < 0.01. 
7.5.4 Characterising Bioluminescence 
Having established the optimal conditions necessary to achieve maximal 
bioluminescence, the properties of the bioluminescence itself was studied: dose-
response curves were generated for each of the substrates d-luciferin, EnduRenTM, and 
ViviRenTM, then a study of how bioluminescence decays over time was conducted. 
Finally, the emission profiles of the bioluminescence generated by firefly and Renilla 
luciferase from cells of this model were compared to the absorption spectra of the 
photosensitisers, hypericin and mTHPC. 
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7.5.4.1 Dose-Response 
U87-luc and U87-hRluc cells were harvested and plated in white, flat bottom, tissue 
culture treated, 96 well plates (Sigma), at a density of 1x104 cells per well. Cells were 
replaced into the incubator. After 24 hrs incubation, media was aspirated from each 
well and replaced with 0.1 ml of complete media. Live cell assays were then performed 
using increasing doses of substrate: for U87-luc cells, d-luciferin was added to give 
final concentrations of 0.313, 0.625, 1.25 and 2.50 mM; for U87-hRluc cells, 
EnduRenTM and ViviRenTM were added to give final concentrations of 1.50, 7.00, 15.0, 
30.0 and 60.0 µM. 0.1 ml of PBS was added to control cells.  
 
The dose-response curves (see Figure 40) for d-luciferin and EnduRenTM revealed that 
the maximum, non-toxic doses established, 2.5 mM and 60 µM respectively, produced 
maximum bioluminescence, 9 270 ± 427 RLU and 24 700 ± 1092 RLU respectively. 
Furthermore, there was little advantage to increasing the dose of EnduRenTM beyond 30 
µM, the dose used in combination with ViviRenTM in section 8.5.3.3, which produced 
25 800 ± 1330 RLU of bioluminescence. The dose-response curve for ViviRenTM 
demonstrated that a maximum bioluminescence of 151 000 ± 5630 RLU was achieved 
with 60 µM ViviRenTM. In contrast, this was significantly greater than the 
bioluminescence achieved with the maximum, non-toxic doses of 7.50 µM with 24 hr 
incubation and 30 µM with 1 hr incubation, which produced 30 200 ± 1 560 RLU and 
99 300 ± 18 100 RLU respectively.  
 
Finally, the maximum bioluminescence achieved with EnduRenTM was approximately 3 
times more than that of d-luciferin. Moreover, the maximum bioluminescence achieved 
with ViviRenTM was 6 times more than that of EnduRenTM. Although the maximum, 
non-toxic doses of ViviRenTM generated less bioluminescence than the maximum 
possible bioluminescence, the bioluminescence generated by these doses was still 
substantially greater than the maximum bioluminescence achieved by d-luciferin and 
EnduRenTM: 7.50 µM of ViviRenTM generated 3 and 1.2 times more bioluminescence 
than that possible with d-luciferin and EnduRenTM respectively; and 30 µM generated 
11 and 4 times more bioluminescence than that possible with d-luciferin and 
EnduRenTM respectively. 
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Figure 40 Dose-Response of Substrate 
The maximum, non-toxic doses established for d-luciferin and EnduRenTM, 2.5 mM and 60 µM respectively, 
produced the maximum possible bioluminescence. Furthermore, there was little advantage to increasing the 
dose of EnduRenTM beyond 30 µM. For ViviRenTM, although the maximum, non-toxic doses, 7.50 µM with 24 
hr incubation and 30 µM with 1 hr incubation, did not generate the maximum possible bioluminescence, 
which was achieved with 60 µM, the bioluminescence achieved with these doses still exceeded the maximum 
achieved with d-luciferin and EnduRenTM.  
7.5.4.2 Change in Bioluminescence Over Time 
U87-luc and U87-hRluc cells were harvested and plated in white, flat bottom, tissue 
culture treated, 96 well plates (Sigma), at a density of 1x104 cells per well. Cells were 
replaced into the incubator. After 24 hrs incubation, media was aspirated from each 
well and replaced with 0.1 ml of complete media. d-Luciferin was added to U87-luc 
cells to give a final concentration of 2.5 mM. The plate was then placed in the 
luminometer and bioluminescence measured at 2.5, 15, 30, 45 and 60 mins after the 
addition of substrate. EnduRenTM was added to U87-hRluc cells to give a final 
concentration of 60 µM. The plate was then placed in the luminometer and 
bioluminescence measured at 90, 150 and 210 mins after the addition of substrate. The 
plate was kept incubated between readings. ViviRenTM was added to U87-hRluc cells to 
give a final concentration of 60 µM. The plate was then placed in the luminometer and 
bioluminescence measured at 2 and 60 mins after the addition of substrate. The plate 
was replaced in the incubator between readings. Results were plotted and a best-fit line 
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calculated. Experimental design was limited by access to the luminometer. Although, 
not a comprehensive study of the change in bioluminescence over time, the aim of the 
experiments was to confirm that the substrates behaved in our model in a similar way 
to that reported in the literature.  
 
Bioluminescence from d-luciferin is reported to peak at approximately 3 mins, then 
falls and plateaus to a level that persists for at least 20 mins140. Consistent with this, our 
study (see Figure 41) demonstrated peak bioluminescence (21 100 ± 280 RLU) 
occurring close to 2.5 mins, before falling off to a plateau that was sustained for at least 
1 hr (16 000 ± 420 RLU).  
 
EnduRenTM has been shown to generate a bioluminescence that peaks at approximately 
90 mins, which then remains constant for more than 24 hours, and in some cell lines, 
this can persist for up to 3 days160. Consistent with this, our study (see Figure 41) 
showed a slower time to peak bioluminescence compared to d-luciferin, with high 
levels of bioluminescence (89 300 ± 4 820 RLU) demonstrated at 90 mins. Although 
this level of bioluminescence was not sustained, it decayed gradually and still remained 
at a high level (47 600 ±1 730 RLU) at 210 mins. 
 
Peak bioluminescence generated by ViviRenTM has been shown to occur within 2 mins 
of the substrate being added to cells161. The bioluminescence then gradually decays 
over time. The peak bioluminescence achieved with ViviRenTM is approximately 10 
times greater than that achieved with EnduRenTM. Furthermore, if a cell line is exposed 
to either VivRenTM or EnduRenTM, after 45 mins the level of bioluminescence generated 
with each substrate becomes similar and remains so for at least 60 mins. Our study (see 
Figure 41) confirmed the rapid peak of bioluminescence, 986 000 ± 96 900 RLU at 2 
mins, which was also 10 times that of the peak bioluminescence achieved with 
EnduRenTM (89 300 ± 4 820 RLU). In contrast to the literature, in our model, the fall in 
bioluminescence with ViviRenTM was more rapid, reaching 25 700 ± 189 RLU at 60 
mins, with little overlap of a plateau phase for EnduRenTM.  
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Figure 41 Change in Bioluminescence Over Time 
Peak bioluminescence from d-luciferin occurred at approximately 2.5 mins (21 100 ±  280 RLU), then fell to a 
plateau that persisted for at least 1 hour (16 000 ±  420 RLU).  Bioluminescence generated by EnduRenTM 
peaked later at approximately 90 mins (89 300 ±  4 820 RLU), then gradually decayed, with high levels still at 
210 mins  (47 600 ±1 730 RLU). Bioluminescence from ViviRenTM peaked quickly, 986 000 ±  96 900 RLU at 2 
mins, then fell rapidly, reaching 25 700 ±  189 RLU at 60 mins. Overall, the change in bioluminescence 
generated by the substrates was similar to that reported in the literature. 
7.5.4.3 Comparing the Emission Profile of Bioluminescence with the Absorption Spectra 
of the Photosensitisers 
According to the luciferase assay described above, lysates of U87-luc and U87-hRluc 
cells were prepared to obtain emission profiles of firefly luciferase and Renilla 
luciferase, respectively. U87-luc and U87-hRluc cells were plated at a density of 1x104 
cells and 1x105 cells, respectively, per well of a 24 well plate, and allowed to incubate 
for 24 hrs. Media was then aspirated from the wells and cells washed with PBS. 0.1 ml 
of 1x lysis buffer was then added to each well and the plate rocked at room temperature 
for 5 mins, ensuring complete cell lysis. 20 µl of lysate was transferred into the wells of 
a white, half area, Corning 96 well plate. 100 µl of d-luciferin and EnduRenTM was then 
added to each well of U87-luc and U87-hRluc lysate, respectively. The luminometer 
plates were then placed in turn into a fluorometer (Thermo Electro Corp). Signal was 
captured between 400 and 800 nm, and a 3 sec integration time was set to allow the 
signal to equilibrate.  
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The absorption spectra of hypericin (0.5 mg/ml in DMSO) and mTHPC (0.5 mg/ml in 
PBS) were recorded in a CARY 1E Varian spectrophotometer. The background 
absorption profile of DMSO and PBS were subtracted to yield the absorption spectrum 
of hypericin and mTHPC, respectively.  
 
Results from the emission profiles and the absorption spectra were normalised to the 
maximum value. Each emission profile was then plotted against the absorption spectra 
of both photosensitisers (see Figure 42). The peak bioluminescence from the oxidation 
of d-luciferin by firefly luciferase was found to lie between 546 – 574 nm, with the 
maximum at approximately 560 nm, as expected from the literature140. There was 
reasonable overlap of this emission profile with the absorption spectra of hypericin and 
mTHPC, both consistent with that reported in the literature155,166, with peak emission 
coinciding with the absorption peaks of hypericin at 557 nm and that of mTHPC at 550 
nm.  The peak bioluminescence from oxidation of EnduRenTM by Renilla luciferase 
was found to lie between 451 – 505 nm, with the maximum at approximately 487 nm, 
which corresponds well to the reported 480 nm in the literature171. This emission profile 
overlapped poorly with the absorption spectrum of hypericin. There was some overlap 
with the absorption spectrum of mTHPC, although peak emission did not coincide with 
any peak of absorption.  
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Figure 42 Emission profiles of firefly luciferase and Renilla luciferase compared to the Absorption Spectra of 
Hypericin and mTHPC 
The peak bioluminescence of firefly luciferase lay between 546 – 574 nm, with the maximum at approximately 
560 nm, which overlapped well with the absorption peaks of hypericin at 557 nm and mTHPC at 550 nm.  The 
peak bioluminescence of Renilla luciferase lay between 451 – 505 nm, with the maximum at approximately 
487 nm, which did not overlap well with the absorption peaks of hypericin or mTHPC. 
7.6 Summary and Discussion 
U87 cells were successfully transfected to produce stable firefly luciferase, click beetle 
luciferase, and Renilla luciferase-expressing cell lines, U87-luc, U87-CBG68luc, and 
U87-hRluc, respectively. The bioluminescence generated was tested with luciferase and 
live cell assays. The live cell assay was deemed a more accurate measure of the light 
that would be available to mediate a photodynamic effect in a live cell, and hence, this 
assay was used in the experiments henceforth to quantify bioluminescence.  
 
For U87-luc cells, d-luciferin is the appropriate substrate. The maximum tolerated dose 
of 2.5 mM was also found to be the dose that produced maximum bioluminescence. 
Promega was found to produce a substrate that generated higher levels of 
bioluminescence compared to that obtained from other vendors. Dissolving the 
substrate in PBS generated higher levels of bioluminescence than using serum free 
media as a solvent. There was no gain in bioluminescence in culturing cells in heat-
inactivated serum. The bioluminescence generated by adding d-luciferin to U87-luc 
cells was seen to peak within minutes, then fall to a plateau that remained stable for at 
least 1 hr. Based on these findings, in the experiments henceforth, d-luciferin was 
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purchased from Promega, dissolved in PBS, added to cells maintained in complete 
media to achieve a final dose of 2.5 mM, and incubated with the cells for 24 hrs. d-
Luciferin was also used similarly for U87-CBG68luc cells.  
 
Two substrates were tested in U87-hRluc cells, EnduRenTM and ViviRenTM. Although 
the maximum tolerated dose of EnduRenTM was 75 µM and the manufacturer 
recommended dose is 60 µM, its dose response curve showed that there was little to be 
gained in the level of bioluminescence going beyond 30 µM. Furthermore, dissolving 
EnduRenTM in PBS produced superior levels of bioluminescence compared to using 
serum free media as a solvent. The bioluminescence produced by EnduRenTM was seen 
to gradually peak then gradually fall to a plateau that would likely maintain high levels 
of bioluminescence over days. Based on these findings, in the experiments henceforth, 
EnduRenTM was dissolved in PBS, added to cells maintained in complete media to 
achieve a final dose of 30 µM, and incubated with the cells for 24 hours.  
 
The maximum tolerated dose of ViviRenTM was 7.5 µM for 24 hrs incubation and 30 
µM for 1 hr incubation. Although neither dose achieved maximum bioluminescence, 
the bioluminescence of both doses still exceeded the maximum bioluminescence that 
could be achieved with EnduRenTM. Furthermore, the bioluminescence achieved with 
ViviRenTM peaked within minutes, and decayed extremely quickly. If a bPDT effect 
could be demonstrated with EnduRenTM following the conditions above, to optimise the 
bioluminescence, cells could be incubated with 30 µM of ViviRenTM for 1 hr, followed 
by 30 µM of EnduRenTM for 24 hrs, which has been shown not to be toxic. 
 
There was good overlap of the emission profile of the bioluminescence generated by 
the oxidation of d-luciferin by firefly luciferase with the absorption spectra of hypericin 
and mTHPC, hence studies started with U87-luc cells. If successful, studies would 
proceed with U87-CBG68luc cells: although an emission profile of the 
bioluminescence generated by the oxidation of d-luciferin by click beetle luciferase 
was not obtained, the literature indicates reasonable overlap between this and the 
absorption spectra of the photosensitsers. Finally, experiments would be repeated with 
U87-hRluc cells with the understanding that the overlap of the emission profile of the 
bioluminescence generated by the oxidation of EnduRenTM by Renilla luciferase with 
the absorption spectra of the photosensitisers was suboptimal. If this model worked, 
then optimising it using ViviRenTM would be an option.  
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Chapter 8 Using Bioluminescence to Mediate Photodynamic 
Therapy in vitro 
Having successfully produced luciferase-expressing cell lines and having established 
the optimal conditions for generating bioluminescence, studies proceeded to investigate 
whether the bioluminescence generated from these cell lines could activate a 
photosensitiser to cause a photodynamic effect that would lead to cell death: 
bioluminescence-mediated photodynamic therapy (bPDT). Encouraged by the overlap 
of the emission profile of the bioluminescence generated by the oxidation of d-luciferin 
by firefly luciferase with the absorption spectra of hypericin and mTHPC, studies 
started with U87-luc cells. If successful, studies would proceed with U87-CBG68luc 
cells. Finally, experiments would be repeated with U87-hRluc cells with the 
understanding that the overlap of the emission profile of the bioluminescence generated 
by the oxidation of EnduRenTM by Renilla luciferase with the absorption spectra of the 
photosensitisers was suboptimal. 
8.1 Variation in Methodology 
In these experiments, there were some variations in the details of the methodology 
followed thus far, and these are as follows.   
8.1.1 Culture Media 
All luciferase-expressing cell lines were maintained in complete media containing 1 
mg/ml neomycin at all times. This will still be referred to as ‘media’ for ease of 
discussion. 
8.1.2 Use of the Live Cell Assay 
A live cell assay was conducted once a week on the cell lines being tested to ensure 
that the cells continued to generate stable bioluminescence.   
8.1.3 Cell Viability: Use of the Growth Assay 
In addition to the MTT assay and haemocytometry, as described above, cell viability 
was also assessed by a growth assay. Where a growth assay was planned, cells were 
plated in parallel plates that were treated similarly. When ready for the initial cell 
viability assessment with an MTT assay and/or haemocytometry, the plate designated 
for a growth assay was treated as follows. Media was aspirated from the wells, which 
were then washed twice with 0.1 ml of PBS. 0.04 ml of trypsin was added to the wells, 
which were allowed to incubate for 1 min until the cells had detached. The cells of each 
well were then resuspended in 0.1 ml of media then transferred to the wells of a 12 well 
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plate. Additional complete media was added to each well to achieve a total volume of 
1.5 ml. The cells were left to incubate until the control cells had reached 
subconfluence, typically 5 days, after which the surviving cells were counted by 
haemocytometry. Media was changed every other day.  
8.2 U87-luc Cell Line 
Subconfluent U87-luc cells were harvested following trypsinisation, plated at a density 
of 1x104 cells per well of a 96 well plate, and allowed to adhere over 24 hrs at 370C. 
Media was then aspirated from the wells and 0.1 ml of fresh complete media replaced. 
Wells were designated as either control or test.  
 
Control wells were further divided into pure ‘control’ wells, which were exposed to 
neither photosensitiser nor d-luciferin; ‘drug only’ wells, which were exposed only to 
photosensitiser but not d-luciferin; and ‘light only’ wells, which were exposed only to 
d-luciferin but not photosensitiser. For experiments with hypericin, controls also 
included, ‘DMSO only’ wells that were only exposed to DMSO but not photosensitiser 
or d-luciferin, and ‘DMSO+light’ wells that were exposed to DMSO and d-luciferin but 
not to photosensitiser, to account for the DMSO that hypericin was reconstituted in. 
‘Test’ wells were exposed to both photosensitiser and d-luciferin.  
 
0.1 ml of photosensitiser was added to the appropriate wells to give final concentrations 
of either 12.5 µM or 10.0 µM of hypericin for 4 hrs and 24 hrs incubation respectively, 
or 12.5 µg/ml or 2.5 µg/ml of mTHPC for 3 hrs and 24 hrs incubation respectively. For 
experiments with hypericin, DMSO was added to‘DMSO only’ and ‘DMSO+light’ 
controls at this time: the same proportion of DMSO as hypericin stock solution used to 
give the desired concentration of hypericin was added to serum free media to give a 
final volume of 0.1 ml to be added to each well. The remaining wells had 0.1 ml of 
serum free media added. After incubating for the appropriate time, all wells were 
washed twice with 0.1 ml PBS and 0.1 ml of fresh complete media was replaced. 0.1 
ml of d-luciferin was then added to the appropriate wells to give a final concentration 
of 2.5 mM. Remaining wells had 0.1 ml of PBS added. Cells were allowed to incubate 
for a further 20-24 hrs, following which cell viability was assessed by haemocytometry, 
MTT assay, and/or growth assay. Each condition was tested in triplicate. Experiments 
were repeated a minimum of three times. The most representative results are shown. 
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Experiments were conducted in the two monoclonal lines that generated the greatest 
amount of bioluminescence, the monoclonal line that generated the least 
bioluminescence, and the polyclonal line that generated the most bioluminescence. 
Furthermore, as another control, experiments were repeated in U87 cells that had not 
been transfected with CMV-luc.  
8.2.1 Hypericin, Short Incubation 
Incubation with hypericin for 4 hrs, then subsequent incubation with d-luciferin (see 
Figure 43), led to > 50% cell death in all U87-luc (3 monoclonal and 1 polyclonal) cell 
lines. Specifically, incubation with photosensitiser then d-luciferin led to a fall in the 
cell population to 48.8 ± 7.42%, 45.2 ± 2.76%, 40.5 ± 1.33%, and 40.5 ± 2.44% of 
control (p < 0.0001) in the U87-luc D1, A1, B1 monoclonal cell lines, and the 
polyclonal cell line, respectively.  
 
 
Figure 43 The effect of incubating U87-luc cell lines with hypericin for 4 hrs followed by d-luciferin, as 
demonstrated by the MTT assay 
C = control, D = drug only, L = d-luciferin only, D+L = cells exposed to drug and d-luciferin. Asterisks 
indicate the degree of significance of the difference in OD between each condition and control, where * p > 
0.05, ** p ≤  0.05, *** p < 0.01, **** p < 0.001, ***** p < 0.0001. Incubation with hypericin for 4 hrs, then d-
luciferin, led to > 50% cell death in all U87-luc (3 monoclonal and 1 polyclonal) cell lines: in this way, there 
was a fall in the cell population to 48.8 ±  7.42%, 45.2 ±  2.76%, 40.5 ±  1.33%, and 40.5 ±  2.44% of control (p < 
0.0001) in U87-luc D1, A1, B1 monoclonal cell lines, and the polyclonal cell line, respectively.  
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The effect of the interaction between hypericin and d-luciferin was confirmed by 
haemocytometry and growth assay in U87-luc monoclonal and polyclonal lines (see 
Figure 44). In the monoclonal cell line, incubation with hypericin for 4 hrs followed by 
exposure to d-luciferin led to a fall in the cell population to 61.5 ± 4.68% of control (p 
< 0.01). This fall was more pronounced in the growth assay, where these ‘test’ cells 
were found to be 55.3 ± 4.16% of control (p < 0.0001). Similarly, in the polyclonal cell 
line, incubation with hypericin for 4 hrs followed by exposure to d-luciferin led to a fall 
in the cell population to 34.3 ± 2.48% of control (p < 0.0001), and this fall was again 
found to be more profound on the growth assay where test cells were 13.0 ± 2.48% of 
control (p < 0.0001). These experiments were also performed with DMSO controls: 
there was no significant difference between these and other controls, demonstrating that 
DMSO was an inactive solvent, supporting the contention that it was an interaction 
between hypericin and d-luciferin that led to cell death. 
 
The experiment was repeated in U87 cells that had not been transfected with CMV-luc: 
thus, these were cells that would not produce bioluminescence with the addition of d-
luciferin. In this experiment, incubation of cells with hypericin for 4 hrs then d-
luciferin did not lead to significant cell death (see Figure 45). This demonstrates that it 
is not the chemical interaction between hypericin and d-luciferin that leads to cell 
death, but the interaction between hypericin and the bioluminescence generated by the 
addition of d-luciferin that is the cause of cell death: bioluminescence-mediated 
photodynamic therapy (bPDT). 
 
Furthermore, a dose-response with bPDT was demonstrated: increasing the dose of d-
luciferin, which has been shown to increase the degree of bioluminescence (see Figure 
40), increased the degree of cell death (see Figure 46): incubating U87-luc cells with 
hypericin for 4 hrs, followed by incubating the cells with 0.625 mM of d-luciferin led 
to a fall in the cell population to 69.0 ± 4.70% of control (p > 0.05), incubating the cells 
with 1.25 mM of d-luciferin led to a fall to 62.2% ± 3.60% of control (p ≤ 0.05), and 
incubating the cells with 2.50 mM led to a fall to 29.3% ± 2.26% of control (p < 
0.0001). 
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Figure 44 The effect of incubating U87-luc cell lines with hypericin for 4 hrs followed by d-luciferin, as 
demonstrated by haemocytometry and growth assay 
C = control, D = drug only, DMSO = DMSO only, L = d-luciferin only, DMSO+L = cells exposed to DMSO 
and d-luciferin, D+L = cells exposed to drug and d-luciferin. Asterisks indicate the degree of significance of 
the difference in cell number between each condition and control, where * p > 0.05, ** p ≤  0.05, *** p < 0.01, 
**** p < 0.001, ***** p < 0.0001. Following incubation with hypericin for 4 hrs, then exposure to d-luciferin, 
the cell population fell to 61.5 ±  4.68% (p < 0.01) and 34.3 ±  2.48% of control (p < 0.0001), in monoclonal and 
polyclonal cell lines respectively. On growth assay, this fall was more profound, with the test cell population 
falling to 55.3 ±  4.16% (p < 0.0001) and 13.0 ±  2.48% of control (p < 0.0001), in monoclonal and polyclonal 
cell lines respectively. Notably, there was no significant difference between DMSO controls and other 
controls, demonstrating that DMSO was indeed an inactive solvent. 
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Figure 45 Effect of incubating U87 cells that have not been transfected with CMV-luc with hypericin for 4 hrs 
then d-luciferin 
C = control, D = drug only, L = d-luciferin only, D+L = cells exposed to drug and d-luciferin. Asterisks 
indicate the degree of significance of the difference in OD between each condition and control, where * p > 
0.05, ** p ≤  0.05, *** p < 0.01, **** p < 0.001, ***** p < 0.0001. In cells that do not have the ability to 
produce bioluminescence with the addition of d-luciferin, no significant cell death occurred when the cells 
were incubated with hypericin for 4 hrs then d-luciferin.  
 
 
Figure 46 The dose-response of bPDT, demonstrated in a monoclonal U87-luc cell line incubated with 
hypericin for 4 hrs 
C = control, D = drug only, L = d-luciferin only. Numbers on the x axis refer to the dose of d-luciferin that 
cells incubated with drug were exposed to, and represent the ‘test’ wells. Asterisks indicate the degree of 
significance of the difference in OD between each condition and control, where * p > 0.05, ** p ≤  0.05, *** p < 
0.01, **** p < 0.001. ***** p < 0.0001. A dose-response with bPDT was demonstrated: increasing the dose of 
d-luciferin, and hence the amount of bioluminescence, increased the degree of cell death: following 4 hrs 
incubation with hypericin, incubation with 0.625 mM, 1.25 mM, and 2.50 mM of d-luciferin led to a fall in the 
cell population to 69.0 ±  4.70% of control (p > 0.05), 62.2% ±  3.60% of control (p ≤  0.05), and 29.3% ±  2.26% 
of control (p < 0.0001), respectively. 
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8.2.2 Hypericin, Long Incubation 
Incubation with hypericin for 24 hrs, then subsequent incubation with d-luciferin (see 
Figure 47), led to > 50% cell death in all U87-luc (3 monoclonal and 1 polyclonal) cell 
lines. Specifically, incubation with photosensitiser then d-luciferin led to a fall in the 
cell population to 26.1 ± 2.29% (p < 0.0001), 32.1 ± 5.22% (p < 0.0001), 26.1 ± 2.49% 
(p < 0.0001), and 27.3 ± 0.46% (p < 0.001) of control, in the U87-luc D1, A1, B1 
monoclonal cell lines, and the polyclonal cell line, respectively.  
 
 
Figure 47 The effect of incubating U87-luc cell lines with hypericin for 24 hrs followed by d-luciferin, as 
demonstrated by the MTT assay 
C = control, D = drug only, L = d-luciferin only, D+L = cells exposed to drug and d-luciferin. Asterisks 
indicate the degree of significance of the difference in OD between each condition and control, where * p > 
0.05, ** p ≤  0.05, *** p < 0.01, **** p < 0.001, ***** p < 0.0001. Incubation with hypericin for 24 hrs, then d-
luciferin, led to > 50% cell death in all U87-luc (3 monoclonal and 1 polyclonal) cell lines: in this way, there 
was a fall in the cell population to 26.1 ±  2.29% (p < 0.0001), 32.1 ±  5.22% (p < 0.0001), 26.1 ±  2.49% (p < 
0.0001), and 27.3 ±  0.46% (p < 0.001) of control in U87-luc D1, A1, B1 monoclonal cell lines, and the 
polyclonal cell line, respectively.  
The effect of the interaction between hypericin and d-luciferin was confirmed by 
haemocytometry and growth assay in U87-luc monoclonal and polyclonal lines (see 
Figure 48). In the monoclonal cell line, incubation with hypericin for 24 hrs followed 
by exposure to d-luciferin led to a fall in the cell population to 31.4 ± 3.34% of control 
(p < 0.0001). This fall was also reflected in the growth assay, where these ‘test’ cells 
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were found to be 34.6 ± 3.74% of control (p < 0.0001). Similarly, in the polyclonal cell 
line, incubation with hypericin for 24 hrs followed by exposure to d-luciferin led to a 
fall in the cell population to 34.0 ± 3.72% of control (p < 0.0001), and this fall was 
found to be more profound on the growth assay where test cells were 17.8 ± 3.32% of 
control (p < 0.0001). In the growth assay of the polyclonal cell line, there was a mild 
fall in the ‘drug only’ cells to 70.0 ± 4.23% of control (p < 0.01), which was not 
thought to contribute significantly to the overall result. These experiments were also 
performed with DMSO controls: there was no significant difference between these and 
other controls, demonstrating that DMSO was an inactive solvent, supporting the 
contention that it was an interaction between hypericin and d-luciferin that led to cell 
death. 
 
The experiment was repeated in U87 cells that had not been transfected with CMV-luc: 
thus, these were cells that would not produce bioluminescence with the addition of d-
luciferin. In this experiment, incubation of cells with hypericin for 24 hrs then d-
luciferin did not lead to significant cell death (see Figure 48). This demonstrates that it 
is not the chemical interaction between hypericin and d-luciferin that leads to cell 
death, but the interaction between hypericin and the bioluminescence generated by the 
addition of d-luciferin that is the cause of cell death: bioluminescence-mediated 
photodynamic therapy (bPDT). 
 
Furthermore, a dose-response with bPDT was demonstrated: increasing the dose of d-
luciferin, which has been shown to increase the degree of bioluminescence (see Figure 
40), increased the degree of cell death (see Figure 50): incubating U87-luc cells with 
hypericin for 24 hrs, followed by incubating the cells with 0.625 mM of d-luciferin led 
to a fall in the cell population to 50.4 ± 2.55% of control (p < 0.0001), incubating the 
cells with 1.25 mM of d-luciferin led to a fall to 37.0% ± 2.20% of control (p < 
0.0001), and incubating the cells with 2.50 mM led to a fall to 15.2% ± 0.580% of 
control (p < 0.0001). 
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Figure 48 The effect of incubating U87-luc cell lines with hypericin for 24 hrs followed by d-luciferin, as 
demonstrated by haemocytometry and growth assay 
C = control, D = drug only, DMSO = DMSO only, L = d-luciferin only, DMSO+L = cells exposed to DMSO 
and d-luciferin, D+L = cells exposed to drug and d-luciferin. Asterisks indicate the degree of significance of 
the difference in cell number between each condition and control, where * p > 0.05, ** p ≤  0.05, *** p < 0.01, 
**** p < 0.001, ***** p < 0.0001. Following incubation with hypericin for 24 hrs, then exposure to d-luciferin, 
the cell population fell to 31.4 ±  3.34% (p < 0.0001) and 34.0 ±  3.72% of control (p < 0.0001), in monoclonal 
and polyclonal cell lines respectively. On growth assay, this fall persisted, with the test cell population falling 
to 34.6 ±  3.74% (p < 0.0001) and 17.8 ±  3.32% of control (p < 0.0001), in monoclonal and polyclonal cell lines 
respectively. Notably, there was no significant difference between DMSO controls and other controls, 
demonstrating that DMSO was indeed an inactive solvent. The mild fall in the ‘drug only’ cells in the growth 
assay of the polyclonal cell line to 70.0 ±  4.23% of control (p < 0.01), was not thought to contribute 
significantly to the overall result. 
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Figure 49 Effect of incubating U87 cells that have not been transfected with CMV-luc with hypericin for 24 
hrs then d-luciferin 
C = control, D = drug only, L = d-luciferin only, D+L = cells exposed to drug and d-luciferin. Asterisks 
indicate the degree of significance of the difference in OD between each condition and control, where * p > 
0.05, ** p ≤  0.05, *** p < 0.01, **** p < 0.001, ***** p < 0.0001. In cells that do not have the ability to 
produce bioluminescence with the addition of d-luciferin, no significant cell death occurred when the cells 
were incubated with hypericin for 24 hrs then d-luciferin.  
 
 
Figure 50 The dose-response of bPDT, demonstrated in a monoclonal U87-luc cell line incubated with 
hypericin for 24 hrs 
C = control, D = drug only, L = d-luciferin only. Numbers on the x axis refer to the dose of d-luciferin that 
cells incubated with drug were exposed to, and represent the ‘test’ wells. Asterisks indicate the degree of 
significance of the difference in OD between each condition and control, where * p > 0.05, ** p ≤  0.05, *** p < 
0.01, **** p < 0.001. ***** p < 0.0001. A dose-response with bPDT was demonstrated: increasing the dose of 
d-luciferin, and hence the amount of bioluminescence, increased the degree of cell death: following 24 hrs 
incubation with hypericin, incubation with 0.625 mM, 1.25 mM, and 2.50 mM of d-luciferin led to a fall in the 
cell population to 50.4 ±  2.55%, 37.0 ±  2.20%, and 15.2 ±  0.580% of control (p < 0.0001), respectively. 
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Experiments thus far show that the bioluminescence generated by the addition of d-
luciferin to luciferase-producing cells was able to activate a photosensitiser, hypericin, 
and mediate a photodynamic effect resulting in significant cell death: bPDT. In some 
cases, the growth assay revealed a more profound fall in cell survival than appreciated 
on initial haemocytometry. The longer incubation with hypericin led to a more 
profound fall in cell survival.  
 
In order to investigate bPDT further, experiments were repeated but with a different 
photosensitiser, mTHPC. Having provided proof of principle above, experiments with 
mTHPC were performed in two cell lines, a monoclonal and a polyclonal line.  
8.2.3 mTHPC, Short Incubation 
Incubation with mTHPC for 3 hrs, then subsequent incubation with d-luciferin (see 
Figure 51), did not seem to lead to significant cell death when using the MTT assay as 
an assessment of cell viability. However, when assessing cell viability using 
haemocytometry, the test cell population was seen to fall to 22.1 ± 3.32% of control (p 
< 0.0001). Furthermore, the test cell population in the growth assay was seen to be 49.8 
± 3.03% of control (p < 0.0001).  
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Figure 51 The effect of incubating a U87-luc monoclonal cell line with mTHPC for 3 hrs followed by d-
luciferin, as demonstrated by the MTT assay, haemocytometry and growth assay 
C = control, D = drug only, L = d-luciferin only, D+L = cells exposed to drug and d-luciferin. Asterisks 
indicate the degree of significance of the difference in OD or cell number between each condition and control, 
where * p > 0.05, ** p ≤  0.05, *** p < 0.01, **** p < 0.001, ***** p < 0.0001. Incubation with mTHPC for 3 
hrs, then subsequent incubation with d-luciferin, did not seem to lead to significant cell death when using the 
MTT assay as an assessment of cell viability. However, when assessing cell viability using haemocytometry 
and the growth assay, the test cell population was seen to fall to 22.1 ±  3.32% and 49.8 ±  3.03% of control (p < 
0.0001) respectively.  
The reason for the disparity between results from the MTT assay and the cell counting 
techniques, haemocytometry and growth assay, was unclear. Experiments were 
repeated, but this time using U87-luc monoclonal cells that had been cultured and 
passaged 4 times in complete media made with heat inactivated serum (see Figure 52). 
In this cell population, incubation with mTHPC for 3 hrs, then exposure to d-luciferin, 
again did not seem to lead to significant cell death when using the MTT assay as an 
assessment of cell viability. However, when assessing cell viability using 
haemocytometry, the test cell population was seen to fall to 47.2 ± 8.17% of control (p 
< 0.01). Furthermore, the test cell population in the growth assay was seen to have 
fallen more profoundly to 21.8 ± 4.00% of control (p < 0.0001).  
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Figure 52 The effect of incubating a U87-luc monoclonal cell line, which has been passaged in complete media 
made with heat inactivated serum, with mTHPC for 3 hrs followed by d-luciferin, as demonstrated by the 
MTT assay, haemocytometry and growth assay 
C = control, D = drug only, L = d-luciferin only, D+L = cells exposed to drug and d-luciferin. Asterisks 
indicate the degree of significance of the difference in OD or cell number between each condition and control, 
where * p > 0.05, ** p ≤  0.05, *** p < 0.01, **** p < 0.001, ***** p < 0.0001. Incubation with mTHPC for 3 
hrs, then subsequent incubation with d-luciferin, did not seem to lead to significant cell death when using the 
MTT assay as an assessment of cell viability. However, when assessing cell viability using haemocytometry 
and the growth assay, the test cell population was seen to fall to 47.2 ±  8.17% (p < 0.01) and 21.8 ±  4.00 % (p 
< 0.0001) of control respectively.  
 
The experiment was then repeated in a U87-luc polyclonal line. Incubation with 
mTHPC for 3 hrs, then subsequent incubation with d-luciferin (see Figure 53), again 
did not seem to lead to significant cell death when using the MTT assay as an 
assessment of cell viability. However, when assessing cell viability using 
haemocytometry, the test cell population was seen to fall to 25.8 ± 4.00% of control (p 
< 0.0001). Furthermore, the test cell population in the growth assay was seen to have 
fallen more profoundly to 4.26 ± 1.57% of control (p < 0.0001).  
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Figure 53 The effect of incubating a U87-luc polyclonal cell line with mTHPC for 3 hrs followed by d-
luciferin, as demonstrated by the MTT assay, haemocytometry and growth assay 
C = control, D = drug only, L = d-luciferin only, D+L = cells exposed to drug and d-luciferin. Asterisks 
indicate the degree of significance of the difference in OD or cell number between each condition and control, 
where * p > 0.05, ** p ≤  0.05, *** p < 0.01, **** p < 0.001, ***** p < 0.0001. Incubation with mTHPC for 3 
hrs, then subsequent incubation with d-luciferin, did not seem to lead to significant cell death when using the 
MTT assay as an assessment of cell viability. However, when assessing cell viability using haemocytometry 
and the growth assay, the test cell population was seen to fall to 25.8 ±  4.40% and 4.26 ±  1.57% of control (p < 
0.0001) respectively.  
 
The experiment was then repeated, but this time using U87-luc polyclonal cells that had 
been cultured and passaged 4 times in complete media made with heat inactivated 
serum (see Figure 54). In this cell population, incubation with mTHPC for 3 hrs, then 
exposure to d-luciferin, again did not seem to lead to significant cell death when using 
the MTT assay as an assessment of cell viability. However, when assessing cell 
viability using haemocytometry, the test cell population was seen to fall to 9.55 ± 
2.26% of control (p < 0.0001). Furthermore, the test cell population in the growth assay 
was seen to have fallen more profoundly to 5.59 ± 1.62% of control (p < 0.0001). In the 
growth assay, there was a mild fall in the ‘light only’ control to 79.7 ± 3.70% of control 
(p < 0.01), which was not considered to have contributed significantly to the overall 
effect on the test cells.  
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Figure 54 The effect of incubating a U87-luc polyclonal cell line, which has been passaged in complete media 
made with heat inactivated serum, with mTHPC for 3 hrs followed by d-luciferin, as demonstrated by the 
MTT assay, haemocytometry and growth assay 
C = control, D = drug only, L = d-luciferin only, D+L = cells exposed to drug and d-luciferin. Asterisks 
indicate the degree of significance of the difference in OD or cell number between each condition and control, 
where * p > 0.05, ** p ≤  0.05, *** p < 0.01, **** p < 0.001, ***** p < 0.0001. Incubation with mTHPC for 3 
hrs, then subsequent incubation with d-luciferin, did not seem to lead to significant cell death when using the 
MTT assay as an assessment of cell viability. However, when assessing cell viability using haemocytometry 
and the growth assay, the test cell population was seen to fall to 9.55 ±  2.26% and 5.59 ±  1.62 % of control (p 
< 0.0001) respectively. In the growth assay, there was a mild fall in the ‘light only’ control to 79.7 ±  3.70% of 
control (p < 0.01), which was not considered to contribute significantly to the overall effect on the test cells.  
 
8.2.4 mTHPC, Long Incubation 
Incubation with mTHPC for 24 hrs, then subsequent incubation with d-luciferin (see 
Figure 55), did not seem to lead to significant cell death when using the MTT assay as 
an assessment of cell viability. However, when assessing cell viability using 
haemocytometry, the test cell population was seen to fall to 43.8 ± 4.41% of control (p 
< 0.0001). Furthermore, the test cell population in the growth assay was seen to be 59.7 
± 7.48% of control (p < 0.01).  
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Figure 55 The effect of incubating a U87-luc monoclonal cell line with mTHPC for 24 hrs followed by d-
luciferin, as demonstrated by the MTT assay, haemocytometry and growth assay 
C = control, D = drug only, L = d-luciferin only, D+L = cells exposed to drug and d-luciferin. Asterisks 
indicate the degree of significance of the difference in OD or cell number between each condition and control, 
where * p > 0.05, ** p ≤  0.05, *** p < 0.01, **** p < 0.001, ***** p < 0.0001. Incubation with mTHPC for 24 
hrs, then subsequent incubation with d-luciferin, did not seem to lead to significant cell death when using the 
MTT assay as an assessment of cell viability. However, when assessing cell viability using haemocytometry 
and the growth assay, the test cell population was seen to fall to 43.8 ±  4.41% and 59.7 ±  7.48% of control (p < 
0.0001) respectively.  
Similarly, incubation of a U87-luc polyclonal cell line with mTHPC for 24 hrs, then d-
luciferin (see Figure 56), led to a fall in cell population to 31.9 ± 3.65% of control (p < 
0.0001). Furthermore, this fall was also reflected in the growth assay, where these ‘test’ 
cells were found to be 31.1 ± 6.56% of control (p < 0.0001).  
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Figure 56 The effect of incubating a U87-luc polyclonal cell line with mTHPC for 24 hrs followed by d-
luciferin, as demonstrated by haemocytometry and growth assay 
C = control, D = drug only, L = d-luciferin only, D+L = cells exposed to drug and d-luciferin. Asterisks 
indicate the degree of significance of the difference in cell number between each condition and control, where 
* p > 0.05, ** p ≤  0.05, *** p < 0.01, **** p < 0.001, ***** p < 0.0001. Incubation with mTHPC for 24 hrs, 
then subsequent incubation with d-luciferin, led to fall in the cell population to 31.9 ±  3.65% and 31.1 ±  
6.56% of control (p < 0.0001) as demonstrated by haemocytometry and growth assay respectively. 
 
These experiments show that bioluminescence, generated by the addition of d-luciferin 
to luciferase-producing cells, can activate another photosensitiser, mTHPC, and 
mediate a photodynamic effect causing significant cell death; another demonstration of 
bPDT. In contrast to hypericin, the shorter incubation with mTHPC led to a more 
profound fall in cell survival. Similar to experiments with hypericin, in the majority of 
cases, the growth assay demonstrated a more profound fall in cell survival than that 
seen on initial haemocytometry, which was what was typically seen when cells were 
incubated with mTHPC for 3 hrs.  
 
The reason for the MTT assay not providing an accurate indication of cell viability in 
this model is not clear. It was a phenomenon seen consistently in monoclonal as well as 
polyclonal cell lines, so not a characteristic inherent to the monoclonal line. It is not 
surprising that culturing cells in heat inactivated serum, which inactivates complement, 
did not improve the efficacy of the assay, as the reaction of the assay does not interact 
with the complement cascade.  
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8.3 U87-CBG68luc 
Having successfully demonstrated the concept of bPDT in U87-luc cells, experiments 
proceeded in a different cell line, U87-CBG68luc, but still using the same substrate to 
generate bioluminescence, d-luciferin.  
8.3.1 Hypericin, Short Incubation 
Incubation with hypericin for 4 hrs, then subsequent incubation with d-luciferin (see 
Figure 57), led to a fall in the cell population to 20.0 ± 2.22% of control (p < 0.001). 
Having already shown that DMSO is an inactive solvent, experiments were only 
performed with a ‘DMSO+L’ control: there was no significant difference between this 
and other controls, confirming that DMSO was indeed an inactive solvent, supporting 
the contention that it was an interaction between hypericin and d-luciferin that led to 
cell death. 
 
 
Figure 57 The effect of incubating U87-CBG68luc cells with hypericin for 4 hrs followed by d-luciferin, as 
demonstrated by the MTT assay 
C = control, D = drug only, L = d-luciferin only, DMSO+L = cells exposed to DMSO and d-luciferin, D+L = 
cells exposed to drug and d-luciferin. Asterisks indicate the degree of significance of the difference in OD 
between each condition and control, where * p > 0.05, ** p ≤  0.05, *** p < 0.01, **** p < 0.001, ***** p < 
0.0001. Incubation with hypericin for 4 hrs, then d-luciferin, led to a fall in the cell population to 20.0 ±  2.22% 
of control (p < 0.001) in a U87-CBG68luc polyclonal cell line.  
8.3.2 Hypericin, Long Incubation 
Incubation with hypericin for 24 hrs, then subsequent incubation with d-luciferin (see 
Figure 58), led to a fall in the cell population to 25.4 ± 12.0% of control (p < 0.01). 
Having already shown that DMSO is an inactive solvent, experiments were only 
performed with a ‘DMSO+L’ control: there was again no significant difference 
between this and other controls, confirming that DMSO was indeed an inactive solvent, 
supporting the contention that it was an interaction between hypericin and d-luciferin 
that led to cell death. 
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Figure 58 The effect of incubating U87-CBG68luc cells with hypericin for 24 hrs followed by d-luciferin, as 
demonstrated by the MTT assay 
C = control, D = drug only, L = d-luciferin only, DMSO+L = cells exposed to DMSO and d-luciferin, D+L = 
cells exposed to drug and d-luciferin. Asterisks indicate the degree of significance of the difference in OD 
between each condition and control, where * p > 0.05, ** p ≤  0.05, *** p < 0.01, **** p < 0.001, ***** p < 
0.0001. Incubation with hypericin for 24 hrs, then d-luciferin, led to a fall in the cell population to 25.4 ±  
12.0% of control (p < 0.01) in a U87-CBG68luc polyclonal cell line.  
8.3.3 mTHPC Short Incubation 
Incubation with mTHPC for 3 hrs, then subsequent incubation with d-luciferin (see 
Figure 59), did not lead to cell death when using the MTT assay as an assessment of 
cell viability. When assessing cell viability using haemocytometry, the test cell 
population was seen to fall to 57.1 ± 5.83% of control, which trended towards 
significance (95% CI -0.301 to 6.30, p > 0.05). 
 
 
Figure 59 The effect of incubating a U87-CBG68luc polyclonal cell line with mTHPC for 3 hrs followed by d-
luciferin, as demonstrated by the MTT assay, haemocytometry and growth assay 
C = control, D = drug only, L = d-luciferin only, D+L = cells exposed to drug and d-luciferin. Asterisks 
indicate the degree of significance of the difference in OD or cell number between each condition and control, 
where * p > 0.05, ** p ≤  0.05, *** p < 0.01, **** p < 0.001, ***** p < 0.0001. Incubation with mTHPC for 3 
hrs, then subsequent incubation with d-luciferin, did not lead to significant cell death when using the MTT 
assay as an assessment of cell viability. When assessing cell viability using haemocytometry, the test cell 
population was seen to fall to 57.1 ±  5.83%, which trended towards significance (p > 0.05, 95% CI -0.301 to 
6.30). 
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8.3.4 mTHPC Long Incubation 
Incubation with mTHPC for 24 hrs, then subsequent incubation with d-luciferin (see 
Figure 60), did not lead to significant cell death when assessed by MTT assay or 
haemocytometry. Although there was a significant fall in cell survival to 59.5 ± 3.80% 
of control (p < 0.01) when using the MTT assay, this was not significantly different 
from the ‘drug only’ or ‘light only’ controls, 82.4 ± 9.17% and 73.9 ± 4.06% of control, 
respectively. Similarly, although there was a significant fall in cell survival to 38.7 ± 
4.44% of control (p < 0.0001) when using haemocytometry, this was not significantly 
different from the ‘light only’ control, 55.0 ± 3.53%.  
 
 
Figure 60 The effect of incubating a U87-CBG68luc polyclonal cell line with mTHPC for 24 hrs followed by d-
luciferin, as demonstrated by the MTT assay, haemocytometry and growth assay   
C = control, D = drug only, L = d-luciferin only, D+L = cells exposed to drug and d-luciferin. Asterisks 
indicate the degree of significance of the difference in OD or cell number between each condition and control, 
where * p > 0.05, ** p ≤  0.05, *** p < 0.01, **** p < 0.001, ***** p < 0.0001. Incubation with mTHPC for 24 
hrs, then subsequent incubation with d-luciferin, did not lead to significant cell death when assessed by MTT 
assay or haemocytometry: although there was a significant fall in cell survival to 59.5 ±  3.80% (p < 0.01) and 
38.7 ±  4.44% (p < 0.0001) of control respectively, this was not significantly different to the ‘drug only’ and 
‘light only’ controls of the MTT assay, and the ‘light only’ control from haemocytometry.  
 
These experiments show that the bioluminescence generated by the oxidation of d-
luciferin by click beetle luciferase, can activate the photosentiser, hypericin, and 
mediate a photodynamic effect causing significant cell death; another demonstration of 
bPDT. However, such bioluminescence is not able activate the photosensitiser, 
mTHPC, to mediate a photodynamic effect to cause cell death. Further testing with 
different monoclonal and polyclonal lines, and cell viability assessments with 
haemocytometry and growth assay were not pursued due to time contraints.  
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8.4 U87-hRluc 
So far, it has been established that the bioluminescence produced by U87-luc and U87-
CBG68luc cells using d-luciferin as a substrate can activate a photosensitiser to 
mediate a photodynamic effect and cause significant cell death, bPDT. Here, the 
concept of bPDT is tested in a completely different model, using U87-hRluc cells and 
the substrate EnduRenTM. The U87-hRluc monoclonal line E was chosen for testing, as 
it was the cell line that produced maximum bioluminescence. The substrate used was 
30 µM of EnduRenTM. Cell viability was assessed by haemocytometry and growth 
assay.  
8.4.1 Hypericin, Short Incubation 
Incubation with hypericin for 4 hrs, then subsequent incubation with EnduRenTM (see 
Figure 61), did not lead to a fall in the test cell population. Furthermore, no cell kill was 
evident on delayed testing with the growth assay. 
 
 
Figure 61 The effect of incubating U87-hRluc cells with hypericin for 4 hrs followed by EnduRenTM, as 
demonstrated by haemocytometry and growth assay 
C = control, D = drug only, L = EnduRenTM only, DMSO+L = cells exposed to DMSO and EnduRenTM, D+L = 
cells exposed to drug and EnduRenTM. Asterisks indicate the degree of significance of the difference in cell 
number between each condition and control, where * p > 0.05, ** p ≤  0.05, *** p < 0.01, **** p < 0.001, ***** 
p < 0.0001. Incubation with hypericin for 4 hrs, then EnduRenTM, did not lead to a fall in cell population on 
initial testing by haemocytometry or delayed testing by growth assay. 
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8.4.2 Hypericin, Long Incubation 
Incubation with hypericin for 24 hrs, then subsequent incubation with EnduRenTM (see 
Figure 62), did not lead to a fall in the test cell population. Furthermore, no cell kill was 
evident on delayed testing with the growth assay. 
 
Figure 62 The effect of incubating U87-hRluc cells with hypericin for 24 hrs followed by EnduRenTM, as 
demonstrated by haemocytometry and growth assay 
C = control, D = drug only, L = EnduRenTM only, DMSO+L = cells exposed to DMSO and EnduRenTM, D+L = 
cells exposed to drug and EnduRenTM. Asterisks indicate the degree of significance of the difference in cell 
number between each condition and control, where * p > 0.05, ** p ≤  0.05, *** p < 0.01, **** p < 0.001, ***** 
p < 0.0001. Incubation with hypericin for 24 hrs, then EnduRenTM, did not lead to a fall in cell population on 
initial testing by haemocytometry or delayed testing by growth assay. 
8.4.3 mTHPC, Short Incubation 
Incubation with mTHPC for 3 hrs, then subsequent incubation with EnduRenTM (see 
Figure 63), did not lead to a fall in the test cell population. Furthermore, no cell kill was 
evident on delayed testing with the growth assay. 
 
Figure 63 The effect of incubating U87-hRluc cells with mTHPC for 3 hrs followed by EnduRenTM, as 
demonstrated by haemocytometry and growth assay 
C = control, D = drug only, L = EnduRenTM only, D+L = cells exposed to drug and EnduRenTM. Asterisks 
indicate the degree of significance of the difference in cell number between each condition and control, where 
* p > 0.05, ** p ≤  0.05, *** p < 0.01, **** p < 0.001, ***** p < 0.0001. Incubation with mTHPC for 3 hrs, then 
EnduRenTM, did not lead to a fall in cell population on initial testing by haemocytometry or delayed testing by 
growth assay. 
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8.4.4 mTHPC, Long Incubation 
Incubation with mTHPC for 24 hrs, then subsequent incubation with EnduRenTM (see 
Figure 64), led to a fall in the cell population to 57.1 ± 3.11% of control (p < 0.001). 
This fall was more pronounced in the growth assay, where these ‘test’ cells were found 
to be 25.5 ± 5.79% of control (p < 0.0001). 
 
 
Figure 64 The effect of incubating U87-hRluc cells with mTHPC for 24 hrs followed by EnduRenTM, as 
demonstrated by haemocytometry and growth assay 
C = control, D = drug only, L = EnduRenTM only, D+L = cells exposed to drug and EnduRenTM. Asterisks 
indicate the degree of significance of the difference in cell number between each condition and control, where 
* p > 0.05, ** p ≤  0.05, *** p < 0.01, **** p < 0.001, ***** p < 0.0001. Incubation with mTHPC for 24 hrs, 
then EnduRenTM, led to a fall in the test cell population to 57.1 ±  3.11% (p < 0.001) and 25.5 ±  5.79% (p < 
0.0001) on initial haemocytometry and growth assay, respectively. 
Furthermore, in some experiments, incubation with mTHPC for 24 hrs, then subsequent 
exposure to EnduRenTM, would initially lead to a fall in the cell population. However, 
this fall was not sustained on growth assay. For example, in Figure 65, the test cell 
population initially fell to 60.9 ± 3.40% of control (p < 0.0001). However, on growth 
assay, the test cell population recovered and there was no difference between this and 
the control.  
 
In contrast, in other experiments, incubation with mTHPC for 24 hrs, then subsequent 
exposure to EnduRenTM, would not lead to an initial fall in the test cell population. 
However, a fall in the test cell population would become apparent on growth assay. For 
example, in Figure 66, although the test cell population fell to 76.5 ± 3.83% of control, 
which appeared to be significant (p ≤ 0.05), this was not significantly different to the 
‘drug only’ control, 77.9 ± 5.57%. However, on growth assay, the test cell population 
fell to 58.5 ± 3.03 of control (p < 0.0001). 
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Figure 65 The effect of incubating U87-hRluc cells with mTHPC for 24 hrs followed by EnduRenTM, as 
demonstrated by haemocytometry and growth assay: a second pattern for outcome 
C = control, D = drug only, L = EnduRenTM only, D+L = cells exposed to drug and EnduRenTM. Asterisks 
indicate the degree of significance of the difference in cell number between each condition and control, where 
* p > 0.05, ** p ≤  0.05, *** p < 0.01, **** p < 0.001, ***** p < 0.0001. Incubation with mTHPC for 24 hrs, 
then EnduRenTM, led to a fall in the test cell population to 60.9 ±  3.40 % (p < 0.0001), which was not sustained 
on growth assay where the test cell population was not significantly different to control.  
 
 
Figure 66 The effect of incubating U87-hRluc cells with mTHPC for 24 hrs followed by EnduRenTM, as 
demonstrated by haemocytometry and growth assay: a third pattern for outcome 
C = control, D = drug only, L = EnduRenTM only, D+L = cells exposed to drug and EnduRenTM. Asterisks 
indicate the degree of significance of the difference in cell number between each condition and control, where 
* p > 0.05, ** p ≤  0.05, *** p < 0.01, **** p < 0.001, ***** p < 0.0001. Incubation with mTHPC for 24 hrs, 
then EnduRenTM, led to a fall in the test cell population to 76.5 ±  3.83 % (p ≤  0.05), which was not 
significantly different to the ‘drug only’ control. However, on growth assay, the test cell population fell to 58.5 
±  3.03 of control (p < 0.0001). 
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The bioluminescence generated by the addition of EnduRenTM to U87-hRluc cells, did 
not seem to activate the photosensitisers, hypericin and mTHPC, to mediate a 
photodynamic effect leading to significant cell death, except in the condition where 
cells were incubated with mTHPC for 24 hrs. In this latter condition, cell death was 
either evident on initial haemocytometry and became more profound on growth assay 
or was not evident on initial haemocytometry, but became apparent on growth assay; or 
cell death was evident on initial haemocytometry, but cells had recovered on the 
growth assay such that there was no difference to control. Of note, although the U87-
hRluc cells grew well in culture and passaged well, once they were plated into 96 well 
plates, and particularly when they were transitioned to the 12 well plates for the growth 
assay, they did not grow well, such that the growth assay was performed 8 days after 
initial haemocytometry compared to the typical 5 days to allow control cells to reach 
subconfluence. In view of concerns for the robustness of this model, experiments were 
not repeated with ViviRenTM.  
8.5 Inhibiting the Effect  
To provide further proof that it is indeed bioluminescence activating photosensitiser to 
cause a photodynamic effect that is mediating cell kill, experiments were repeated but 
with the additional condition of lycopene. Lycopene is an antioxidant. As the 
photodynamic effect is mediated by the generation of singlet oxygen, the effect can be 
inhibited by an antioxidant. If the cell death in our model is truly secondary to bPDT, 
cell death should be inhibited by the presence of lycopene.  
 
Experiments were repeated as described in sections 8.1 and 8.2 using a U87-luc 
polyclonal cell line and d-luciferin as substrate; this model chosen for the robustness of 
results, but with the following variations. Control wells were divided into pure ‘control’ 
wells, which were exposed to neither photosensitiser, lycopene, acetone, nor d-
luciferin; ‘drug only’ wells, which were exposed only to photosensitiser; ‘lycopene 
only’ wells, which were exposed only to lycopene; ‘acetone only’ wells, which were 
exposed only to acetone; ‘light only’ wells, which were exposed only to d-lucferin; 
‘drug and acetone’ wells, which were exposed only to photosensitiser and acetone; 
‘drug and lycopene’ wells, which were exposed only to photosensitiser and lycopene; 
‘acetone and light’ wells, which were exposed only to acetone and d-luciferin; 
‘lycopene and light’ wells, which were exposed only to lycopene and d-luciferin. The 
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acetone controls were included to account for the acetone that lycopene was 
reconstituted in.  
 
After incubating with the photosensitisers, hypericin or mTHPC, for the appropriate 
times, all wells were washed twice with 0.1 ml of PBS and 0.1 ml of fresh complete 
media was replaced. 0.1 ml of d-luciferin was then added to ‘light only,’ ‘acetone and 
light,’ and ‘lycopene and light,’ ‘drug and light,’ and ‘drug, lycopene and light’ wells to 
give a final concentration of 2.5 mM of d-luciferin. Remaining wells had 0.1 ml of PBS 
added. At this time, 5 µM of lycopene (Sigma) was added to ‘lycopene only,’ ‘drug and 
lycopene,’ ‘lycopene and light,’ and ‘drug, light and lycopene’ wells. Additionally, at 
this time, acetone, equal to the volume used to reconstitute the lycopene, was added to 
‘acetone only,’ ‘drug and acetone,’ and ‘acetone and light’ wells. Cells were allowed to 
incubate for a further 20-24 hrs, following which cell viability was assessed by 
haemocytometry and growth assay. Each condition was tested in triplicate. 
Experiments repeated a minimum of three times. The most representative results are 
shown. 
8.5.1 Hypericin, Short Incubation 
Incubation with hypericin for 4 hrs, then subsequent incubation with d-luciferin (see 
Figure 67), led to a fall in the cell population to 38.0 ± 4.00% of control (p < 0.001) 
and this fall persisted in the growth assay where the test cell population was 38.0 ± 
1.78% of control (p < 0.0001). In contrast, when cells were incubated with 
photosensitiser, then exposed to d-luciferin and lycopene simultaneously, there was no 
significant fall in the cell population (87.8 ± 6.12% and 98.0 ± 5.57% with initial 
haemocytometry then growth assay, respectively): the lycopene was able to prevent the 
interaction between the photosensitiser and the bioluminescence generated by the 
addition of d-luciferin.  
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Figure 67 The effect of adding lycopene, an antioxidant, to U87-luc cells that have been incubating with 
hypericin for 4 hrs, then exposed to d-luciferin, as demonstrated by haemocytometry and growth assay  
C = control, D = drug only, A = acetone only, Ly = lycopene only, L = d-luciferin only, DA = cells exposed to 
drug and acetone, DLy = cells exposed to drug and lycopene, AL = cells exposed to acetone and d-luciferin, 
LyL = cells exposed to lycopene and d-luciferin, D+L = cells exposed to drug and d-luciferin, DLyL = cells 
exposed to drug, lycopene and d-luciferin. Asterisks indicate the degree of significance of the difference in cell 
number between each condition and control, where * p > 0.05, ** p ≤  0.05, *** p < 0.01, **** p < 0.001, ***** 
p < 0.0001. Incubation with hypericin for 4 hrs, then subsequent incubation with d-luciferin, led to a fall in 
the cell population to 38.0 ±  4.00% (p < 0.001) and 38.0 ±  1.78% (p < 0.0001) of control (p < 0.001) with initial 
haemocytometry then subsequent growth assay, respectively. When cells were incubated with photosensitiser, 
then exposed to d-luciferin and lycopene simultaneously, there was no significant fall in the cell population 
(87.8 ±  6.12% and 98.0 ±  5.57% with initial haemocytometry then growth assay, respectively). 
 
8.5.2 Hypericin, Long Incubation 
Incubation with hypericin for 24 hrs, then subsequent incubation with d-luciferin (see 
Figure 68), led to a fall in the cell population to 32.3 ± 4.82% of control (p < 0.0001). 
When cells were incubated with photosensitiser, then exposed to d-luciferin and 
lycopene simultaneously, although there was a significant fall in the cell population to 
57.1 ± 2.46% of control (p < 0.0001), this degree of cell death was significantly less 
profound than that of the test cell population (p ≤ 0.05), indicating partial inhibition of 
the bPDT effect. Furthermore, on growth assay, there was partial recovery of the cells 
exposed to photosensitier and d-lucifeirn to 61.7 ± 2.08% of control, which was still 
significantly less than control (p < 0.001), but there was complete recovery of the cell 
population exposed to drug, lycopene and light to 107 ± 4.16 % of control (p > 0.05), 
again indicating that lycopene was able to prevent the interaction between 
photosensitiser and the bioluminescence generated by the addition of d-luciferin.  
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Figure 68 The effect of adding lycopene, an antioxidant, to U87-luc cells that have been incubating with 
hypericin for 24 hrs, then exposed to d-luciferin, as demonstrated by haemocytometry and growth assay  
C = control, D = drug only, A = acetone only, Ly = lycopene only, L = d-luciferin only, DA = cells exposed to 
drug and acetone, DLy = cells exposed to drug and lycopene, AL = cells exposed to acetone and d-luciferin, 
LyL = cells exposed to lycopene and d-luciferin, D+L = cells exposed to drug and d-luciferin, DLyL = cells 
exposed to drug, lycopene and d-luciferin. Asterisks indicate the degree of significance of the difference in cell 
number between each condition and control, where * p > 0.05, ** p ≤  0.05, *** p < 0.01, **** p < 0.001, ***** 
p < 0.0001. Diamonds indicate the degree of significance in the difference in cell number between the D+L and 
DLyL conditions on initial haemocytometry, where ♦♦p ≤  0.05. Incubation with hypericin for 24 hrs, then 
subsequent incubation with d-luciferin, led to a fall in the cell population to 32.3 ±  4.82% of control (p < 
0.0001), with some recovery on growth assay to 61.7 ±  2.08% of control, which was still significantly less than 
control (p < 0.001). When cells were incubated with photosensitiser, then exposed to d-luciferin and lycopene 
simultaneously, although there was a significant fall in the cell population to 57.1 ±  2.46% of control (p < 
0.0001), this degree of cell death was significantly less profound than that of the test cell population (p ≤  0.05), 
and completely recovered to 107 ±  4.16 % of control (p > 0.05) on growth assay, indicating that lycopene was 
able to prevent the interaction between photosensitiser and the bioluminescence generated by the addition of 
d-luciferin.  
8.5.3 mTHPC, Short Incubation 
Incubation with mTHPC for 3 hrs, then subsequent incubation with d-luciferin (see 
Figure 69), led to a fall in the cell population to 22.3 ± 3.02% of control (p < 0.0001) 
and this fall persisted in the growth assay where the test cell population was 30.5 ± 
2.80% of control (p < 0.0001). In contrast, when cells were incubated with 
photosensitiser, then exposed to d-luciferin and lycopene simultaneously, there was no 
significant fall in the cell population (103 ± 6.81% and 105 ± 5.73% with initial 
haemocytometry then growth assay, respectively): the lycopene was able to prevent the 
interaction between the photosensitiser and the bioluminescence generated by the 
addition of d-luciferin.  
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Figure 69 The effect of adding lycopene, an antioxidant, to U87-luc cells that have been incubating with 
mTHPC for 3 hrs, then exposed to d-luciferin, as demonstrated by haemocytometry and growth assay  
C = control, D = drug only, A = acetone only, Ly = lycopene only, L = d-luciferin only, DA = cells exposed to 
drug and acetone, DLy = cells exposed to drug and lycopene, AL = cells exposed to acetone and d-luciferin, 
LyL = cells exposed to lycopene and d-luciferin, D+L = cells exposed to drug and d-luciferin, DLyL = cells 
exposed to drug, lycopene and d-luciferin. Asterisks indicate the degree of significance of the difference in cell 
number between each condition and control, where * p > 0.05, ** p ≤  0.05, *** p < 0.01, **** p < 0.001, ***** 
p < 0.0001. Incubation with mTHPC for 3 hrs, then subsequent incubation with d-luciferin, led to a fall in the 
cell population to 22.3 ±  3.02% (p < 0.0001) and 30.5 ±  2.80% of control (p < 0.0001) with initial 
haemocytometry then subsequent growth assay, respectively. When cells were incubated with photosensitiser, 
then exposed to d-luciferin and lycopene simultaneously, there was no significant fall in the cell population 
(103 ±  6.81% and 105 ±  5.73% with initial haemocytometry then growth assay, respectively). 
8.5.4 mTHPC, Long Incubation 
Incubation with mTHPC for 24 hrs, then subsequent incubation with d-luciferin (see 
Figure 70), led to a fall in the cell population to 28.2 ± 3.01% of control (p < 0.0001). 
When cells were incubated with photosensitiser, then exposed to d-luciferin and 
lycopene simultaneously, there was a only a mild fall in the cell population to 68.6 ± 
3.04% of control (p < 0.01); this cell population still being significantly greater than the 
cells that had been exposed to photosensitiser and d-luciferin only. The mild fall in the 
cell population exposed to photosensitiser, then d-luciferin and lycopene, was likely 
accounted for by a slight fall in cell population associated with the addition of d-
luciferin only (70.1 ± 3.95% of control, p ≤ 0.05), which was also seen in the ‘acetone 
and light’ (73.7 ± 3.43% of control, p ≤ 0.05), and ‘lycopene and light’ (73.7 ± 3.65% 
of control, p ≤ 0.05) controls. On growth assay, there was no lasting evidence of 
toxicity attributable to d-luciferin, and the cell population exposed to photosensitiser 
then d-luciferin remained significantly decreased at 42.2 ± 3.46% of control (p < 
0.0001). Moreover, there was no significant fall in the cell population that had been 
exposed to photosensitiser, then lycopene and d-luciferin (78.5 ± 5.61% of control). 
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Overall, results indicate that lycopene was able to prevent the interaction between 
photosensitiser and the bioluminescence generated by the addition of d-luciferin.  
 
 
Figure 70 The effect of adding lycopene, an antioxidant, to U87-luc cells that have been incubating with 
mTHPC for 24 hrs, then exposed to d-luciferin, as demonstrated by haemocytometry and growth assay  
C = control, D = drug only, A = acetone only, Ly = lycopene only, L = d-luciferin only, DA = cells exposed to 
drug and acetone, DLy = cells exposed to drug and lycopene, AL = cells exposed to acetone and d-luciferin, 
LyL = cells exposed to lycopene and d-luciferin, D+L = cells exposed to drug and d-luciferin, DLyL = cells 
exposed to drug, lycopene and d-luciferin. Asterisks indicate the degree of significance of the difference in cell 
number between each condition and control, where * p > 0.05, ** p ≤  0.05, *** p < 0.01, **** p < 0.001, ***** 
p < 0.0001. Incubation with mTHPC for 24 hrs, then subsequent incubation with d-luciferin, led to a fall in 
the cell population to 28.2 ±  3.01% of control (p < 0.0001). When cells were incubated with photosensitiser, 
then exposed to d-luciferin and lycopene simultaneously, there was a only a mild fall in the cell population to 
68.6 ±  3.04% of control (p < 0.01); this cell population still being significantly greater than the cells that had 
been exposed to photosensitiser and d-luciferin only. The mild fall in the cell population exposed to 
photosensitiser, then d-luciferin and lycopene, was likely accounted for by a slight fall in cell population 
associated with the addition of d-luciferin only (70.1 ±  3.95% of control, p ≤  0.05), which was also seen in the 
‘acetone and light’ (73.7 ±  3.43% of control, p ≤  0.05), and ‘lycopene and light’ (73.7 ±  3.65% of control, p ≤  
0.05) controls. On growth assay, there was no lasting evidence of toxicity attributable to d-luciferin, and the 
cell population exposed to photosensitiser then d-luciferin remained significantly decreased at 42.2 ±  3.46% of 
control (p < 0.0001). Moreover, there was no significant fall in the cell population that had been exposed to 
photosensitiser, then lycopene and d-luciferin (78.5 ±  5.61% of control).  
Lycopene was able to prevent the cell death that occurred when luciferase-producing 
cells were incubated with photosensitiser then d-luciferin. This further supports that it 
is the bioluminescence, generated by adding d-luciferin to luciferase-producing cells, 
that activates the photosensitiser to cause a photodynamic effect, which is an effect 
mediated by singlet oxygen, and subsequent cell death.  
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8.6 Establishing Subcellular Localisation 
To gain further understanding of bPDT, investigations were undertaken to establish the 
subcellular localisation of the luciferase substrate d-luciferin, compared to that of the 
photosensitisers, hypericin and mTHPC.  
 
U87-luc cells were harvested after trypsinisation, plated on 5.5 cm diameter plates, 
which had been coated with 0.42 ml of poly-l-lysine (Sigma-Aldrich), at a density of 
0.7x106 cells per plate, and returned to the incubator. After 24 hrs of incubation the 
plates were examined under the microscope to confirm that the cells had adhered 
adequately. Media was then aspirated from each plate, the cells washed twice with 2.5 
ml of PBS. The following conditions were tested: ‘control’ plates, which were not 
exposed to photosensitiser or d-luciferin; ‘hypericin only’ plates, which were exposed 
to hypericin alone for 24 hrs; ‘mTHPC only’ plates, which were exposed to mTHPC 
alone for 24 hrs; ‘light only’ plates, which were exposed to d-luciferin alone for 24 hrs; 
and ‘test plates,’ which were either exposed to hypericin for 4 or 24 hrs followed by d-
luciferin for 20-24 hrs or mTHPC for 3 or 24 hrs followed by d-luciferin for 20-24 hrs. 
 
‘Control’ plates had 5 ml of serum free media without phenol red replaced. 2.5 ml of 
photosensitiser, made up in serum free media without phenol red, was added to the 
appropriate plates to give final concentrations of either 12.5 µM or 10.0 µM of 
hypericin for 4 hrs and 24 hrs incubation respectively, or 12.5 µg/ml or 2.5 µg/ml of 
mTHPC for 3 hrs and 24 hrs incubation respectively. The ‘light only’ plate had 2.5 ml 
of serum free media without phenol red replaced, then 2.5 ml of d-luciferin added to 
give a final concentration of 2.5 mM.  
 
After 24 hrs, the ‘control,’ ‘hypericin only,’ ‘mTHPC only,’ and ‘light only’ plates 
were removed from the incubator. The media was aspirated, the plates were washed 
twice with 2.5 ml of PBS, and 5 ml of serum free media without phenol red was 
replaced. Cells were then examined using a Leica TCS microscope with a confocal SPE 
head and a x40 water immersion, quartz objective (NA 0.8). ‘Hypericin only’ and ‘light 
only’ plates were excited with 405, 488 and 532 nm of light, and ‘mTHPC only’ plates 
were excited with 488 and 532 nm of light, from the HeNe laser (45-50% total laser 
power). Data was analysed using LAS AF software. Lambda scans were generated for 
each control condition, detecting fluorescence up to 695-705 nm. From these, the 
excitation wavelengths that would allow the separate fluorescence signals to be 
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detected from exciting hypericin and d-luciferin simultaneously and from exciting 
mTHPC and d-luciferin simultaneously within specific emission parameters were 
determined. Once these parameters were determined, the ‘control’ plates were subject 
to each excitation wavelength as a negative control (see section 8.6.2.1). 
 
Regarding the test plates, after the appropriate time of incubation with the 
photosensitisers, media was aspirated and the plates washed twice with 2.5 ml of PBS. 
2.5 ml of serum free media without phenol red was replaced and 2.5 ml of d-luciferin 
was added to give a final concentration of 2.5 mM. The plates were incubated for a 
further 20-24 hrs, then examined under the confocal microscope. The plates were then 
subject to excitation with the appropriate wavelengths of light and the resulting 
fluorescence captured within the appropriate ranges, as determined by analysis of the 
control plates described above.  
8.6.1 Lambda scans 
Exciting cells that had been incubating with hypericin (see Figure 71) with light at a 
wavelength of 405 nm led to fluorescence characterised by moderate intensity peaks at 
595 and 645 nms. Exciting such cells with light at a wavelength of 488 nm led to 
fluorescence characterised by a high intensity peak at 600 nm and a moderate intensity 
peak at 660 nm. Exciting such cells with light at a wavelength of 532 nm led to 
fluorescence characterised by a high intensity peak at 600 nm and a moderate intensity 
peak at 650 nm. 
 
Exciting cells that had been incubating with mTHPC (see Figure 72) with light at a 
wavelength of 405 nm led to fluorescence characterised by a low intensity peak at 650 
nm. Exciting such cells with light at a wavelength at 532 nm led to fluorescence 
characterised by a high intensity peak at approximately 648 nm. 
 
Exciting cells that had been incubating with d-luciferin (see Figure 73) with light at a 
wavelength of 450 nm led to fluorescence characterised by moderate intensity peaks at 
502 and 554 nm. Exciting such cells with light at a wavelength of 488 nm led to 
fluorescence characterised by extremely low intensity and poorly defined peaks at 532 
and 660 nm. Similarly, exciting such cells with light at a wavelength of 532 nm led to 
an extremely low and poorly defined peak between 624 and 644 nm. 
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In examining the lambda scans, the excitation wavelengths that generated fluorescence 
signals in markedly different parts of the electromagnetic spectrum when comparing 
hypericin and d-luciferin, and mTHPC and d-luciferin, were identified, allowing co-
localisation (see Table 9). It was decided that cells that had been incubating with 
hypericin and d-luciferin be excited with 488 and 405 nm, capturing fluorescence from 
hypericin between 640-720 nm and that from d-luciferin between 410-530 nm. The 
smaller fluorescence peak from hypericin was chosen for detection, as the larger peak 
would have required capture between 580-620 nm, which would have also captured the 
second fluorescence peak generated by exciting d-luciferin with 405 nm (see Figure 71 
and Figure 73). Furthermore, it was decided that cells that had been incubating with 
mTHPC and d-luciferin be excited with 532 and 405 nm, capturing fluorescence from 
mTHPC between 620-690 nm and that from d-luciferin between 410-530 nm (see 
Figure 72 and Figure 73).  
 
To detect: Excitation Wavelength, nm Emission, nm, collected between: 
Hypericin 488 640-720 
mTHPC 532 620-690 
d-Luciferin 405 410-530 
 
Table 9 Excitation and Emission Parameters Used to Study the Subcellular Localisation of hypericin, 
mTHPC, and d-luciferin 
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Figure 71 Lambda scans obtained from cells incubated with hypericin then excited with light with 
wavelengths at a. 405 nm, b. 488 nm, and c. 532 nm 
Exciting cells incubated with hypericin with light at 405, 488, and 532 nm led to fluorescence with moderate 
intensity peaks at 595 and 645 nm; a high intensity peak at 600 nm and a moderate intensity peak at 660 nm; 
and a high intensity peak at 600 nm and a moderate intensity peak at 650 nm, respectively. 
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Figure 72 Lambda scans obtained from cells incubated with mTHPC then excited with light with wavelengths 
at a. 405 nm, and b. 532 nm 
Exciting cells incubated with mTHPC with light at 405, and 532 nm led to fluorescence with a low intensity 
peak at 650 nm and a high intensity peak at 648 nm, respectively.   
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Figure 73 Lambda scans obtained from cell incubated with d-luciferin then excited with light with 
wavelengths at a. 405 nm, b. 488 nm, and c. 532 nm 
Exciting cells that had been incubating with d-luciferin with light at wavelengths of 450, 488, and 532 nm led 
to fluorescence characterised by moderate intensity peaks at 502 and 554 nm; extremely low intensity and 
poorly defined peaks at 532 and 660 nm; and an extremely low and poorly defined peak between 624 and 644 
nm, respectively.  
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8.6.2 Subcellular Localisation of Photosensitiser and d-Luciferin 
8.6.2.1 Negative Control 
Having established the excitation wavelengths and the parameters for capturing 
emission (see Table 9), negative controls were first established. The ‘control’ plate was 
exposed to all three wavelengths, 405, 488, and 532 nm. For each excitation 
wavelength, fluorescence was captured within the pre-determined parameters. It was 
clear, as expected, that no fluorescence was detected (see Figure 74).   
 
 
Figure 74 Subcellular localisation of photosensitiers and d-luciferin: negative control 
When pure ‘control’ cells are excited with a. 405, b. 488, and c. 532 nm wavelengths, no fluorescence is 
detected within pre-determined parameters.  
8.6.2.2 Hypericin and d-Luciferin 
Cells that had been incubating with hypericin followed by d-luciferin, were excited 
with 405 nm, capturing fluorescence between 410-530 nm, and 488 nm, capturing 
fluorescence between 640-720 nm, revealing the cellular localisation of d-luciferin and 
hypericin, respectively (see Figure 75). d-Luciferin was evenly distributed throughout 
the cytoplasm of the cell. Hypericin was also localised throughout the cytoplasm of the 
cell after both 4 hr and 24 hr incubation, with some moderately prominent fluorescence 
in the perinuclear region, and in some cells, some brighter fluorescence within the 
cytoplasm to one side of the nucleus.  
 
These findings are consistent with the literature. d-Luciferin has been shown to have a 
diffuse cytosolic distribution140. The distribution of hypericin described above has also 
been reported165. Hypericin fluorescence is limited to the cytoplasm148 and has been 
observed in all subcellular organelles146, but particularly within lysosomes, consistent 
with the endocytic uptake of the drug, which has corresponded with the perinuclear 
enhancement observed166. There is suggestion that the brighter fluorescence to one side 
of the nucleus represents uptake in the endoplasmic reticulum165.  
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Figure 75 Subcellular localisation of a. d-luciferin b. hypericin after 4hr incubation and c. overlap of their 
fluorescence, as well as d. d-luciferin and e. hypericin after 24 hr incubation 
d-Luciferin was evenly distributed throughout the cytoplasm of the cell. Hypericin was also localised 
throughout the cytoplasm of the cell after both 4 hr and 24 hr incubation, with some moderately prominent 
fluorescence in the perinuclear region, and in some cells, some brighter fluorescence within the cytoplasm to 
one side of the nucleus.  
8.6.2.3 d-Luciferin and mTHPC  
Cells that had been incubating with mTHPC followed by d-luciferin, were excited with 
532 nm, capturing fluorescence between 620 -690 nm, then 405 nm, capturing 
fluorescence between 410-530 nm, revealing the cellular localisation of mTHPC and d-
luciferin and mTHPC, respectively (see Figure 76). When exciting with 405 nm 
followed by 532 nm, the 405 nm wavelength caused the fluorescence from mTHPC to 
bleach, hence excitation with 532 nm was undertaken first. d-Luciferin was evenly 
distributed throughout the cytoplasm of the cell, consistent with findings above (see 
section 9.6.2.2). mTHPC was also evenly distributed throughout the cytoplasm of the 
cell after 3 hr incubation. However, after 24 hr incubation, although mTHPC was still 
localised to the cytoplasm, the pattern was that of a more punctate fluorescence.  
 
This pattern of mTHPC fluorescence has been described, with a punctate, perinucelar, 
fluorescence characteristic of 24 hr incubation, representing the accumulation of 
aggregated species155. The primary sites of mTHPC localisation are the Golgi apparatus 
 173 
and endoplasmic reticulum. Extending incubation to 24 hrs results in leakage of 
mTHPC from the Golgi apparatus with an enhanced accumulation in the endoplasmic 
reticulum159.  
 
 
 
Figure 76 Subcellular localisation of a. mTHPC after 3 hr incubation b. d-luciferin and c. overlap of their 
fluorescence, as well as d. mTHPC after 24 hr incubation and e. d-luciferin  
Excitation with 532 nm was undertaken first, as excitation with 405 nm caused bleaching of the fluorescence 
from mTHPC. d-Luciferin and mTHPC after 3 hr incubation was evenly distributed throughout the 
cytoplasm of the cell. After 24 hr incubation, although mTHPC was still localised to the cytoplasm, the 
pattern was that of a more punctate fluorescence.  
Overall, d-luciferin co-localises with hypericin and mTHPC within the cytoplasm of 
cells. This study was challenging, as cells within the test plates containing both d-
luciferin and photosensitiser were undergoing cell death, as evident by the lytic 
changes particularly noticeable on the hypericin plates above (see Figure 75) and it was 
difficult to find patches of adherent cells to examine. With more time and resources, 
this study could have been repeated with fluorescent probes for various subcellular 
organelles, particularly as this has not been described in the literature for d-luciferin.  
 174 
8.7 Summary and Discussion 
Experiments have shown that bioluminescence, generated by the addition of d-luciferin 
to luciferase-producing cells, is able to activate a photosensitiser, and mediate a 
photodynamic effect resulting in significant cell death: bPDT. This has been most 
thoroughly studied in U87-luc cells (see Table 10). Incubation of these cells with the 
photosensitisers, hypericin or mTHPC, led to significant cell death with the addition of 
d-luciferin. When these experiments were repeated in non-luciferase producing U87 
cells, there was no change in cell survival, demonstrating that it is not the chemical 
interaction between photosensitiser and d-luciferin, but the interaction between 
photosensitiser and the bioluminescence generated by the addition of d-luciferin that 
leads to cell death. Moreover, lycopene was able to inhibit the cell death that occurred 
when luciferase-producing cells were incubated with photosensitiser followed by d-
luciferin. This further supports that cell death is occurring by a photodynamic effect, 
which is mediated by singlet oxygen, and hence, is inhibited by the presence of an anti-
oxidant such as lycopene.  
 
As there was good overlap between the emission profile of the bioluminescence 
generated by the oxidation of d-luciferin by firefly luciferase and the absorption spectra 
of hypericin and mTHPC, this result is not unexpected. Furthermore, our studies are 
consistent with current literature showing that d-luciferin and both photosensitisers co-
localise to the cytoplasm. Where U87-luc cells were incubated with hypericin, there 
was a suggestion, particularly from the MTT assay data, that longer incubation with the 
photosensitiser led to more profound cell death. It has been reported that higher doses 
of hypericin can lead to the formation of aggregates, which contribute negligible 
phototoxicity166. However, initial haemocytometry and growth assay data support a 
more comparable effect between short and long incubation with hypericin. This is more 
consistent with the confocal microscopy, which did not demonstrate aggregate 
formation. Moreover, there is little difference between the doses for short and long 
incubation, 12.5 vs 10.0 µM, respectively: the dose associated with aggregate 
formation was 50 µM. In contrast, when U87-luc cells were incubated with mTHPC, 
the short incubation time more consistently led to more profound cell death compared 
with the longer incubation time, evident on initial haemocytometry and on growth 
assay. This is consistent with reports of aggregate formation, again associated with a 
reduction in extinction coefficient and less phototoxicity than the monomeric form, 
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with longer incubation times155. This is further supported by confocal images that are 
suggestive of aggregate formation with the longer incubation with mTHPC.  
 
When repeating the experiments in U87-CBG68luc cells, the bioluminescence 
generated by the oxidation of d-luciferin by click beetle luciferase was able to activate 
hypericin to mediate a photodynamic effect that led to significant cell death. Although 
an emission profile of the bioluminescence in this model was not generated, from the 
literature and knowing that the peak bioluminescence is expected to be at 537 nm, this 
is an expected result. However, this bioluminescence was not able to activate mTHPC. 
This was surprising as there should be enough overlap of the emission profile of this 
bioluminescence with the absorption spectra of mTHPC. An emission profile of this 
bioluminescence was not generated, the experiment was only conducted in one 
polyclonal line, and conditions were not optimised in this cell line due to time 
constraints: this would be a further avenue to explore.  
 
The bioluminescence generated by the oxidation of EnduRenTM by Renilla luciferase in 
U87-hRluc cells did not activate hypericin to cause cell death. This was not unexpected 
as the emission profile of this bioluminescence was shown to have poor overlap with 
the absorption spectra of hypericin. Interestingly, this bioluminescence was able to 
activate mTHPC to cause a photodynamic effect and cell death, but only when the cells 
had been incubated with mTHPC for 24 hrs and not 3 hrs. There is some overlap of the 
emission profile of bioluminescence generated by Renilla luciferase with the absorption 
spectrum of mTHPC, although there is no overlap of peak emission with peak 
absorption. A bPDT effect was not necessarily expected with these conditions either. 
However, it is unexpected that an effect should occur with 24 hr incubation of mTHPC 
but not 3 hr incubation. As mentioned above, the longer incubation leads to the 
formation of aggregates, which are less phototoxic, hence a bPDT effect, if any, would 
be expected with the shorter incubation. This experiment was only performed in one 
monoclonal cell line, and there were concerns with the health of this cell line as 
mentioned above. Further study would be warranted.  
 
These studies have also served to demonstrate the value of the growth assay. bPDT 
seems to be most effective when there is an initial fall in cell survival as seen by 
haemocytometry, and this fall continues and is evident on growth assay, representing 
an ongoing effect despite the removal of substrates, such as is seen most commonly in 
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U87-luc cells that have been incubated with mTHPC for 3 hrs then exposed to d-
luciferin. However, the following circumstances are also seen: where a fall in cell 
survival is seen on initial haemocytometry and persists on the growth assay, showing 
definitive cell kill by bPDT without recovery; a fall in cell survival is seen on initial 
haemocytometry with partial recovery on growth assay, indicating that cells, although 
damaged, can recover; and rarely, there is no evidence of cell kill on initial 
haemocytometry, but cell kill becomes apparent on growth assay, again demonstrating 
a delayed effect.  
 
Overall, there is good evidence to support that bPDT can cause cell death. It was most 
effectively demonstrated with U87-luc cells that had been incubated with mTHPC for 3 
hrs then exposed to d-luciferin. Animal studies therefore proceeded, with the plan of 
generating an animal model of glioma using U87-luc cell, then exposing the animal to 
mTHPC followed by d-luciferin.  
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U87-luc Hypericin 4 hr Incubation Hypericin 24 hr Incubation 
 Cell Survival, % Control ± SEM Cell Survival, % Control ± SEM 
Cell Line MTT IH GA MTT IH GA 
Monoclonal D1 48.8 ± 
7.42***** 
61.5 ± 
4.68*** 
55.3 ± 
4.16***** 
26.1 ± 
2.29***** 
31.4 ± 
3.34***** 
34.6 ± 
3.64***** 
Monoclonal A1 45.2 ± 
2.76***** 
  32.1 ± 
5.22***** 
  
Monoclonal B1 40.5 ± 
1.33***** 
  26.1 ± 
2.49***** 
  
Polyclonal 40.5 ± 
2.44***** 
34.3 ± 
2.48***** 
13.0 ± 
2.48***** 
27.3 ± 
0.46**** 
34.0 ± 
3.72***** 
17.8 ± 
3.32***** 
Polyclonal  38.0 ± 
4.00**** 
38.0 ± 
1.78***** 
 32.3 ± 
4.82***** 
61.7 ± 
2.08**** 
 
U87-luc mTHPC 3 hr Incubation mTHPC 24 hr Incubation 
 Cell Survival, % Control ± SEM Cell Survival, % Control ± SEM 
Cell Line IH GA IH GA 
Monoclonal D1 
 
22.1 ± 3.32***** 49.8 ± 3.03***** 43.8 ± 4.41***** 59.7 ± 7.48*** 
Monoclonal D1, 
HIS 
47.2 ± 8.17*** 21.8 ± 4.00*****   
Polyclonal 
 
25.8 ± 4.00***** 4.26 ± 1.57*****   
Polyclonal,  
HIS 
9.55 ± 2.26***** 5.59 ± 1.62***** 31.9 ± 3.65***** 31.1 ± 6.56***** 
Polyclonal 
 
22.3 ± 3.02***** 30.5 ± 2.80***** 28.2 ± 3.01***** 42.2 ± 3.46***** 
 
Table 10 Summary of the results of investigating bPDT in U87-luc cells 
Cell survival of the ‘test’ plates are tabulated as % of control ±  SEM, where IH = initial haemocytometry, GA 
= growth assay. Asterisks indicate the degree of significance of the difference in OD or cell number between 
each test and control, where * p > 0.05, ** p ≤  0.05, *** p < 0.01, **** p < 0.001, ***** p < 0.0001. Regarding 
cell lines, HIS = heat inactivated serum. 
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Chapter 9 Using Bioluminescence to Mediate Photodynamic 
Therapy in vivo 
Before being able to study the concept of bPDT in vivo, an animal model bearing a 
luciferase-expressing tumour had to be created. The generation of a subcutaneous 
model was embarked upon first. Then, as this treatment was originally envisioned for 
astrocytoma, attempts to develop an intracranial model were also made. As the 
luciferase-expressing cell line, U87-luc, originated from a human tumour, to limit the 
potential for rejection, an athymic mouse breed, which has previously been used to 
propagate human glioma subcutaneously and intracranially172-176, was used as the host. 
Although athymic rats177 have been successfully used to propagate human glioma, 
producing larger tumours more easily localised with imaging modalities, mice were 
chosen for logistical reasons. Tumour development was followed with bioluminescence 
imaging (BLI), which has been validated as a reliable measure of tumour progression 
both in subcutaneous132 and intracranial175 tumour models. If a successful animal model 
was achieved, bPDT could then be tested.  
9.1 Developing an animal model 
9.1.1 Methodology 
9.1.1.1 Animals 
4-6 week old CD1 nu/nu mice (athymic) were purchased from Charles River 
Laboratories (France). The animals were maintained under pathogen-free conditions, 
using sterilised plastic cages, covered with polyester bacterial filter tops, and were fed 
sterilised fat enriched food and sterilised water. All animal work was conducted at the 
Queen Mary University of London Cancer Institute in accordance with institutional 
guidelines. The animals were experimented on when they were 6-8 weeks old.  
9.1.1.2 Source of Cells Injected 
9.1.1.2.1 Cell Lines 
Both the U87-luc polyclonal and monoclonal cell lines that were shown to produce the 
strongest bioluminescence with the addition of d-luciferin were used to provide cells to 
develop the animal models. All cells were maintained using standard cell culture 
techniques and in complete media containing 1 mg/ml neomycin, which will continue 
to be referred to as ‘media’ for ease of discussion. For injection into animals, cells were 
harvested using standard techniques, resuspended in complete media, counted, then 
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resuspended in PBS, and kept on ice for injection. Variations in the standard techniques 
are mentioned within context below.  
9.1.1.2.2 Subcutaneous tumour 
In order to improve the survival of the xenografts and also to shorten the time taken for 
the tumours to reach their exponential growth phase, the subcutaneous tumours were 
passaged subcutaneously from one animal into another172. Here, an animal with a 
subcutaneous tumour, originating from the cells described above, identified to have 
reached its exponential growth phase with BLI (see below), was culled, and the tumour 
dissected out. The tumour was carefully minced with a one-sided razor blade and 
resuspended in PBS. The tumour suspension was aspirated into a syringe and reinjected 
into the dorsal flank of another animal. 
9.1.1.2.3 Intracranial tumour 
In order to optimise tumour survival and shorten the time taken to reach the exponential 
growth phase, the effect of repeat xenografting an intracranial U87-luc tumour was 
tested. Here, an animal with an intracranial tumour, originating from the cells described 
above, identified to have reached its exponential growth phase on BLI (see below), was 
culled and the tumour dissected out. The tumour was carefully minced with a one-sided 
razor blade. 1 ml of trpysin was added and the tumour, incubated for 4 mins, after 
which the tumour was transferred to a 15 ml tube and resuspended in 5 ml of complete 
media. The tumour suspension was centrifuged at 1000 rpm for 5 mins and the 
supernatant aspirated. The pellet was resuspended in 12 ml of complete media and the 
cells replated in all 6 wells of a 6 well plate. These cells were then expanded, passaged 
and maintained using standard cell culture techniques. This cell line was denoted 
U87bp-luc and were used for intracranial injection to produce a ‘repeat-xenograft 
tumour’ in certain experiments.  
 
Additionally, to select out the cells with putatively improved tumour initiating ability, 
cells from the U87bp-luc line were cultured to form neurospheres178, which were then 
injected intracranially. U87bp-luc cells were harvested and resuspended in the pro-
mitogenic Dulbecco’s modified Eagle’s medium/Ham F12 medium (DMEM/Ham F12, 
Sigma) supplemented with 1x1 B27 (Gibco), 1.000 U/ml Penicillin/Streptomycin (P/S, 
Lonza), 20 ηg/ml recombinant murine EGF (Peprotech), and 20 ηg/ml recombinant 
human bFGF (Peprotech). The cells were plated out and left in the incubator for five 
days before replacing the medium. Following this, media changes were performed 
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every two to three days. The cells grew as free-floating aggregates (neurospheres). 
Once the spheres were deemed big enough, they were harvested for intracranial 
injection. The neurospheres in their media were transferred to a 50 ml tube and 
centrifuged at 700 rpm for 3 mins. The supernatant was aspirated and 2.5 ml of trypsin 
added. After incubation for 2 mins, the cells were dissociated by gentle resuspension 
using a glass pipette, following which 5 ml of pro-mitogenic media was added to 
inactivate the trypsin, and the cells were counted. After counting, the cells were 
centrifuged again at 700 rpm and resuspended in an appropriate volume of PBS for 
intracranial injection, and placed on ice.  
9.1.1.3 Anaesthesia 
For subcutaneous tumour implantation, the inhalational anaesthetic, isofluorane, was 
used. For intracranial tumour implantation, the animals were anaesthetised with a 2:1:3 
volume ratio of ketamine (100 mg/ml), xylazine (20 mg/ml), and 0.9% saline, given 
intraperitoneally (ip). At the beginning of experimentation, the mice weighed 20-22g 
on average and required 80-100 µl of anaesthesia.  
9.1.1.4 Tumour Implantation: Subcutaneous Model 
Having ensured that the animals were adequately anaesthetised, the harvested cells 
were injected subcutaneously into the dorsal flank.  
9.1.1.5 Tumour Implantation: Intracranial Model 
The stereotaxic method for injecting tumour cells intracranially was used179,180. Having 
ensured that the animals were adequately anaesthetised, the head was secured in a 
stereotaxic frame (see Figure 77). A linear incision was made in the midline from the 
level of the orbits to the occiput and the bregma identified. A Hamilton needle was 
loaded with 10 µl of cell suspension and the co-ordinates were set to allow an injection 
0.5 mm posterior and 2.5 mm lateral to the bregma, to a depth of 3.5 mm into the brain 
parenchyma. The cells were injected slowly over 5 minutes before the needle was 
pulled out.  
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Figure 77 Stereotaxic intracranial injection 
For intracranial injections, animals were anaesthetised and their head secured in a stereotaxic frame. A linear 
incision was made in the midline from the level of the eyes to the occiput and the bregma identified. A 
Hamilton needle was loaded with 10 µ l of cell suspension and the co-ordinates were set to allow an injection 
0.5 mm posterior and 2.5 mm lateral to the bregma, to a depth of 3.5 mm into the brain parenchyma. The 
cells were injected slowly over 5 minutes before the needle was pulled out.  
9.1.1.6 Bioluminescence Imaging (BLI) 
The day after tumour implantation, then weekly thereafter, mice were imaged with the 
Xenogen IVIS system (Xenogen Corporation, Alameda, CA) to record the 
bioluminescent signal emitted from the engrafted tumours. The animals were 
anaesthetised with isofluorane, given an ip injection of 1.5 mg/g of d-luciferin (Caliper 
Life Sciences), and placed in the imaging chamber, which was set at a temperature of 
270C and allowed maintenance of inhalational anaesthesia. The IVIS 100 cooled CCD 
camera system was used for emitted light acquisition and Living Image software 
(Xenogen Corp.) was used for data analysis. Imaging started approximately 2-3 mins 
after injection. Acquisitions were then obtained at 30 secs, 1 min, then every minute 
thereafter for a total of 5 mins to ensure that peak photon emission was captured. 
Exposure times of 0.5 secs-5 mins were used, depending on the strength of the signal. 
Photon emission was recorded as total flux (photons/sec) and average radiance 
(photons/sec/cm2/sr). From the displayed images, regions of interest (ROI) were 
designated around the tumour sites.  Data was analysed based on the average radiance, 
which is normalised for exposure time and size of ROI, over the ROI. 
9.1.1.7 Computed Tomography Imaging 
In an attempt to validate the use of BLI as an accurate assessment of change in 
intracranial tumour volume, a second imaging modality was employed, computed 
tomography (CT): magnetic resonance imaging (MRI) was not available. Imaging was 
performed with 1000 msec exposure and 180 projections were taken. 125 µl of contrast 
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(Binitio eXIA160XL 160 mg/ml) was then injected into the tail vein, and a repeat CT 
was taken at 0 and 20 mins following contrast injection.  
9.1.2 The Subcutaneous Model 
In the first trial, 5x106 cells from the U87-luc polyclonal cell line were injected 
subcutaneously in a volume of 200 µl into 5 mice. Figure 78 is an image of the 
bioluminescent signal captured by the Xenogen IVIS 100 cooled CCD camera system 
(Xenogen Corp.) after the animals were injected with 1.5 mg/g of d-luciferin ip. The 
animals were positioned in the imaging chamber with their heads set in a nasal piece 
that delivered inhalational anaesthesia. 1 week after cell transplantation, the cells 
seemed to be growing well. From Figure 78a, it seemed that the cells injected into 
mouse 5 were not producing bioluminescence. However, this was likely due to 
misinjection of d-luciferin, as repeat injection generated a signal, as illustrated in 
Figure 78b. By week 7, it became clear qualitatively (Figure 78c) and quantitatively 
(Figure 78d) that there was a 60% success rate in establishing tumour implantation with 
3 out of the 5 tumours beginning their exponential growth phase at week 7.  
 
In order to improve the survival of the xenografts and establish a tumour line that 
would consistently reach its exponential growth phase within 1-2 weeks of tumour 
implantation, subcutaneous passaging of tumour was attempted. The animal displaying 
the strongest bioluminescent signal from the trial above, Mouse 5, was culled, the 
subcutaneous tumour isolated, prepared, and injected into two other mice: 
subcutaneous passage 1 (see Figure 79). From observation, it was clear that these 
tumours started their exponential growth phase at week 3 following tumour 
implantation and this was confirmed with BLI and expressed quantitatively in Figure 
79a. Again, the animal displaying the strongest bioluminescent signal at week 3, Mouse 
2, was culled, the subcutaneous tumour isolated, prepared, and injected into two other 
mice: subcutaneous passage 2. There was a marked difference between the degree of 
bioluminescence generated by these animals, hence the results are plotted on two 
different graphs (see Figure 79b and c). Despite this, the onset of the exponential 
growth phase was unclear. Again, the animal displaying the strongest bioluminescent 
signal at week 5, Mouse 2, was culled, the subcutaneous tumour isolated, prepared, and 
injected into three other mice: subcutaneous passage 3. Here (see Figure 79d), the 
implanted tumours reached their exponential growth phase by week 2 and the 
bioluminescent signal being generated between the tumours was uniform. Based on 
this, the fourth subcutaneous passage of tumour was planned for a treatment group. Of 
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note, from the first subcutaneous passage, the rate of successful tumour establishment 
was 100%.  
 
 
                                 
Figure 78 Qualitative and quantitative assessment of injecting U87-luc polyclonal cells subcutaneously 
‘a’ and ‘b’ are qualitative illustrations of the effect of injecting U87-luc cell subcutaneously at 1 week post 
tumour implantation. The signal is the bioluminescence captured by the Xenogen IVIS 100 cooled CCD 
camera system after the animals were injected with 1.5 mg/g of d-luciferin ip. Due to misinjection of d-
luciferin, the cells injected into Mouse 5 did not seem to produce bioluminescence (a), but with reinjection, a 
bioluminescent signal was detected (b). At 7 weeks post injection, the bioluminescent signals detected are 
illustrated qualitatively (c) and quantitatively (d). In ‘d,’ the bioluminescent signal within a designated ROI is 
expressed as average radiance.  There was a 60% success rate in establishing tumour implantation with 3 out 
of the 5 tumours beginning their exponential growth phase at week 7.   
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Figure 79 Subcutaneous passaging of tumour 
In developing a robust subcutaneous model, the tumour from Mouse 5 in the first trial above was harvested, 
prepared and reinjected into 3 mice (subcutaneous passage 1, ‘a’). This U87-luc polyclonal derived tumour 
was passaged 2 further times (subcutaneous passages 2, ‘b’ ‘c’ and 3, ‘d’) in this way. The bioluminescence 
from the tumour was captured by the Xenogen IVIS 100 cooled CCD camera system after the animals were 
injected with 1.5 mg/g of d-luciferin ip. The bioluminescent signal within a designated ROI was expressed as 
average radiance and expressed quantitatively. With each passage, the start of the exponential growth phase 
became earlier, thus, by the third subcutaneous passage, the exponential growth phase started within 2 weeks 
of tumour implantation. Furthermore, by this third passage, the tumours were generating a more uniform 
bioluminescence.  
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9.1.3 The Intracranial Model 
8 attempts were made to produce a robust intracranial model, and each will be 
described as follows.  
9.1.3.1 Intracranial Model: Trial 1 
In the first trial, 1x105 cells from the U87-luc polyclonal cell line were injected 
intracranially in a volume of 10 µl, as per standard protocol, into 6 mice (as 
exemplified in Figure 77). Mouse 3 died from anaesthetic complications. Figure 80a-e 
are images of the bioluminescent signal captured by the Xenogen IVIS 100 cooled 
CCD camera system (Xenogen Corp.) after the animals were injected with 1.5 mg/g of 
d-luciferin ip. The animals were positioned in the imaging chamber with their heads set 
in a nasal piece that delivered inhalational anaesthesia. 1 day after injection, BLI 
confirmed that cells had been successfully delivered intracranially (see Figure 80a): 
although the fourth mouse from the left, Mouse 5, did not seem to emit a 
bioluminescent signal initially, reinjection and a longer exposure time revealed a 
bioluminescent signal, albeit weak (see Figure 80b).  
 
One week after injection, BLI revealed that there had been a drop in the bioluminescent 
signal in all mice (see Figure 80c and d): mouse 1 was imaged separately with a longer 
exposure time to detect the relatively weaker bioluminescent signal (see Figure 80c), 
and note Mouse 5, in position 4 in Figure 80d, had no qualitatively detectable signal, 
which may have been due to poor health and the mouse was culled after imaging.  
Furthermore, at this time point, CT imaging was undertaken in an attempt to provide 
validation for BLI. The CT was performed without and with contrast; the ‘with’ 
contrast images being taken immediately after contrast was delivered and also 20 min 
later. The mouse with the highest BLI signal was selected for CT imaging (see Figure 
80f). CT was not able to detect the tumour. Moreover, an artifact in the left lower 
quadrant of the image, corresponding with the intracranial injection site, produced a 
distortion of the image that compromised the resolution. In view of logistics and 
resources, further CT imaging was not pursued.  
 
The remaining mice were followed with weekly BLI and the progression of 
bioluminescent signal over time is represented quantitatively in Figure 80g and h. The 
results for Mouse 2 and 4 were plotted separately in order to ascertain more clearly the 
change over time (see Figure 80h). The exponential growth phase for Mouse 2 started 
at week 8. However, by week 10, the mouse developed exophthalmos and displayed 
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signs of neurological deficit. BLI revealed not only increasing intracranial 
bioluminescent signal reflecting tumour growth, but also the development of a spinal 
metastasis (see Figure 80e): the mouse was culled at this time. In Mouse 4, the tumour 
seemed to start its exponential growth phase at week 5. However, after a peak in 
bioluminescent signal at week 10, there was a dramatic fall in signal that did not 
recover, and hence the mouse was culled at week 24. The tumour implanted into Mouse 
6 began its exponential growth phase at week 14: the mouse was electively culled at 
week 17, the tumour dissected out, and regrown in culture, thereby generating the 
U87bp-luc cell line, which was subsequently used for further intracranial injections. 
The tumour implanted in the remaining mouse, Mouse 1, started its exponential growth 
phase at week 20, and developed neurological deficit by week 29, which coincided 
with a dramatic increase in bioluminescent signal: the mouse was culled at this time. 
Overall, of the 6 mice that were injected, two mice were lost for reasons unrelated to 
tumour implantation. Of the remaining 4 mice, there was a 75% success rate in the 
implanted tumour establishing growth. However, the time taken for the tumours to 
reach exponential growth was long, 8, 14 and 20 weeks, which is not optimal for a 
tumour model in which to test treatment.  
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Figure 80 Quantitative and qualitative assessment of injecting U87-luc polyclonal cells intracranially 
‘a-e’ are qualitative illustrations of the bioluminescent signal generated after injecting U87-luc cells 
intracranially. The bioluminescent signal generated by the implanted cells was captured by the Xenogen IVIS 
100 cooled CCD camera system after the animals were injected with 1.5 mg/g of d-luciferin ip. BLI on day 1 
following intracranial injection (a) indicated that the cells had been delivered successfully: one mouse 
required reinjection and a longer exposure time to demonstrate successful implantation of cells (b). BLI 1 
week following injection (c, d) revealed a dramatic fall in bioluminescent signal, one mouse requiring a longer 
exposure time to demonstrate ongoing survival of the cells (c). CT of the mouse generating the highest 
bioluminescent signal at this time failed to reveal the tumour and was complicated by artifact in the lower left 
quadrant in the region of tumour injection (f), and was therefore abandoned as an imaging modality. BLI was 
used to follow tumour development weekly thereafter and ‘g’ and ‘h’ quantitatively illustrate the change in 
bioluminescent signal over time: the bioluminescent signal within a designated ROI was expressed as average 
radiance and expressed quantitatively. Overall, of the 6 mice that were injected, two mice were lost to reasons 
unrelated to tumour implantation. Of the remaining 4 mice, there was a 75% success rate in the implanted 
tumour establishing growth. However, the time taken for the tumours to reach exponential growth was long, 
8, 14 and 20 weeks, which is not optimal for a tumour model in which to test treatment. ‘e’ is a BLI image that 
illustrates the development of a spinal metastasis in one of the mice (Mouse 2) at week 10. 
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9.1.3.2 Intracranial Model: Trial 2 
With the aim of improving the survival of the xenografts and to establish a tumour line 
that would consistently reach its exponential growth phase within weeks of injection, 
the effect of increasing the inoculate was investigated. Using U87-luc polyclonal cells, 
1.25 x105 cells (n=1), 2.5 x 105 cells (n=2), and 5 x 105 (n=2) cells were injected in 10 
µl into the brain parenchyma of 5 mice. Figure 81a demonstrates that over 14 weeks, 
none of the implanted tumours in the animals had reached their exponential growth 
phase, hence the experiment was terminated.  
9.1.3.3 Intracranial Model: Trial 3 
Another strategy employed was to inject a monoclonal line instead of the polyclonal 
line. Using U87-luc monoclonal cells, 5x105 cells were injected into the brain 
parenchyma of 3 mice in 10 µl. Figure 81b indicates that the tumour in Mouse 2 
entered exponential growth at week 4. However, when the mouse was culled, this 
tumour was found to be extra-axial. None of the tumours implanted intraparenchymally 
reached their exponential growth phase within a reasonable time, and hence the animals 
were culled.  
 
 
Figure 81 Effect of increasing the concentration of U87-luc polyclonal cells injected and the effect of injecting 
U87-luc monoclonal cells intracranially on tumour establishment and growth 
Using U87-luc polyclonal cells, 1.25 x105 cells (M1), 2.5 x 105 cells (M2 and 3), and 5 x 105 (M4 and 5) cells 
were injected in 10 µ l into the brain parenchyma of 5 mice (a). Using U87-luc monoclonal cells, 5x105 cells 
were injected into the brain parenchyma of 3 mice in 10 µ l (b). The bioluminescent signal generated by the 
implanted cells was captured by the Xenogen IVIS 100 cooled CCD camera system after the animals were 
injected with 1.5 mg/g of d-luciferin ip. The bioluminescent signal within a designated ROI was expressed as 
average radiance and expressed quantitatively. Neither increasing the concentration of U87-luc polyclonal 
cells or injecting U87-luc monoclonal cells led to tumours that reached an exponential growth phase within an 
acceptable time: although results from Mouse 1 of the group injected with U87-luc monoclonal cells seemed 
promising, autopsy revealed that the tumour was extra-axial.  
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9.1.3.4 Intracranial Model: Trial 4 
In an ongoing effort to establish a more robust intracranial tumour model, the effect of 
repeat xenografting was attempted. The tumour implanted into Mouse 6 from the first 
trial of intracranial injections (see Figure 80g) started its exponential growth phase at 
week 14 post injection. At week 17, the mouse was electively culled, the tumour 
harvested, and the cells regrown in culture, thereby establishing the U87bp-luc cell 
line. These cells grew well in culture (see Figure 82a). After two passages, 1x105 cells 
in 10 µl were injected into the brain parenchyma of 3 mice. It was clear after 2 weeks 
that the implanted tumour had not reached an exponential growth phase, indicating that 
the exponential growth phase of the original tumour was not maintained, and the 
experiment was terminated (see Figure 82b).  
9.1.3.5 Intracranial Model: Trial 5 
The effect of increasing the concentration of the cells injected for serial xenografting 
was also investigated. Using U87bp-luc cells, 5 x 105 cells were injected in 10 µl into 
the brain parenchyma of 5 mice. The tumour in one animal, Mouse 3, displayed a 
bioluminescent signal consistently superior to the others and entered into its 
exponential growth phase at week 6 (see Figure 82c). However, on autopsy, this 
tumour was found to be extra-axial. Of the remaining tumours, this method achieved 
tumours with a more uniform bioluminescent signal (see Figure 82d). However, after 5 
weeks, the tumours had not entered into their exponential growth phase, and for the 
same reason as above, the animals were culled and the experiment terminated.  
9.1.3.6 Intracranial Model: Trial 6 
In all the above xenograft experiments, cells had been resuspended in PBS for 
injection. Hypothesizing that the cell survival may be improved by resuspending cells 
in serum free media for injection, using U87bp-luc cells, 1x105 cells in 10 µl of serum 
free media were injected into the brain parenchyma of 2 mice. Figure 82e demonstrates 
that although the bioluminescent signal immediately following injection was an order 
of magnitude greater than when cells were resuspended in PBS (see Figure 82b), this 
did not translate into improved establishment of tumour growth, hence, after 7 weeks, 
the animals were culled electively and the experiment aborted.  
9.1.3.7 Intracranial Model: Trial 7 
Lastly, the effect of resuspending cells in serum free media as well as increasing the 
concentration was investigated.  Using U87bp-luc cells, 1x105 cells (M0) and 2x105 
(M1 and M2) were injected in 10 µl of serum free media into the brain parenchyma of 
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3 mice. The tumour implanted into Mouse 1 was seen to enter its exponential growth 
phase at week 1 (see Figure 82f). By week 4, the mouse became unwell, which 
coincided with a dramatic increase in bioluminescent signal consistent with marked 
tumour growth, and hence the mouse was culled. At autopsy the tumour was found to 
be extra-axial. Of the remaining mice, although resuspending cells in serum free media 
increased the bioluminescent signal immediately following injection, this did not 
translate into faster establishment of tumour growth and there was no advantage to 
injecting an increased concentration of cells (see Figure 82g). These mice were culled 
electively after 5 weeks. 
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Figure 82 The effect of repeat xenografting cells derived from U87-luc polyclonal cells grown intracranially  
The cells from a successfully implanted intracranial tumour derived from U87-luc polyclonal cells were 
harvested and regrown in culture, developing the U87bp-luc cell line. These cells grew well in culture (a). 
1x105 (b) and 5x105 cells (c and d) in 10 µ l of PBS were injected intracranially. 1x105 (e) and 1x105  (Mouse 0) 
and 2x105 cells (Mouse 1 and 2) (f and g) in 10 µ l of serum free media were also injected. The animals 
underwent BLI weekly. The bioluminescent signal generated by the implanted cells was captured by the 
Xenogen IVIS 100 cooled CCD camera system after the animals were injected with 1.5 mg/g of d-luciferin ip. 
The bioluminescent signal within a designated ROI was expressed as average radiance and expressed 
quantitatively. Injection of serial xenograft did not increase the time to reach exponential growth phase. 
Increasing cell concentration was not advantageous. Although resuspending the tumour cells in serum free 
media led to a higher bioluminescent signal the day after injection, this did not translate into a faster time to 
exponential growth. The tumours that did begin exponential growth within weeks of injection (c, Mouse 3; f, 
Mouse 1) were extra-axial.  
9.1.3.8 Intracranial Model: Trial 8 
In a separate set of experiments to achieve a robust intracranial tumour model, U87bp-
luc cells were cultured in pro-mitogenic media to form neurospheres178, in an attempt to 
select out the cells with tumour initiating capacity. Neurospheres were successfully 
grown (see Figure 83a and b) and once deemed of sufficient size were harvested and 
1x105 cells were injected in 10 µl of serum free media into the brain parenchyma of 2 
mice. The bioluminescent signal of the implanted cells the day after implantation were 
on average an order of magnitude greater than that of the cells previously injected 
intracranially, as described above (see Figure 83c). Furthermore, exponential growth 
seemed to be established 1 week after injection.   
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Figure 83 The effect of injecting neurospheres derived from U87bp-luc cells intracranially 
Neurospheres were successfully generated by culturing U87bp-luc cells in pro-mitogenic media (a and b). 
Once large enough the neurospheres were harvested and 1x105 cells were injected in 10 µ l of serum free 
media into the brain parenchyma of 2 mice. The animals underwent BLI weekly. The bioluminescent signal 
generated by the implanted cells was captured by the Xenogen IVIS 100 cooled CCD camera system after the 
animals were injected with 1.5 mg/g of d-luciferin ip. The bioluminescent signal within a designated ROI was 
expressed as average radiance and expressed quantitatively. The bioluminescent signal of the implanted cells 
the day after implantation were on average an order of magnitude greater than that of any of the cell lines 
previously injected intracranially and exponential growth seemed to be established 1 week after injection.   
9.1.4 Summary and Discussion 
Using an athymic mouse as the host for a human-derived glioma transplanted 
subcutaneously172-174,181 and intracranially175,176,181,182 has been well described. Regarding 
the subcutaneous model, it has been demonstrated here that by passaging the tumours 
subcutaneously, a higher success rate of tumour establishment and a shorter time for 
the tumour to reach its exponential growth phase is achieved, and indeed, this is 
supported by the literature172,181. In fact, not all human-derived glioma lines will survive 
upon initial injection181. Although the athymic mouse is immunocompromised in that it 
does not produce T cells, it still has natural killer cells and is able to mount an antibody 
response. As human neoplastic tissue retains a human karyotype and human enzymatic 
phenotypes even after serial passage in athymic mice183-185, a host immune response is 
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likely to underlie this observed phenomenon. As the tumour is serially passaged 
subcutaneously, it most likely gains a degree of immune compatibility and/or the host 
develops a degree of immunologic tolerance, and hence improved tumour 
establishment and growth. 
 
Despite there being reports of luciferase-expressing U87 cells having been successfully 
transplanted and grown intracranially in nude mice175, attempts at establishing an 
intracranial tumour in this study proved more challenging. 8 trials, summarised in 
Table 11, were required before finding a suitable model. The variables included the cell 
line injected, the cell number injected, and the solute in which the cells were injected. 
Overall, the complication rate of the actual procedure was low, with only 2 deaths out 
of the 8 trials, which were associated with anaesthetic complications. Regarding 
technique, there were only 3 extra-axial tumours out of a total of 29 subjects.  
 
 Intracranial Trials 
 1 2 3 4 5 6 7 8 
Cell Line U87-luc 
polyclon
al 
U87-luc 
polyclon
al 
U87-luc 
monoclon
al 
U87bp-
luc 
U87bp-
luc 
U87bp-
luc 
U87bp-
luc 
U87bp-
luc NS 
Cell Number 1x105 1.25x105 
2.5x105 
5x105 
5x105 1x105 5x105 1x105 1x105 
2x105 
1x105 
 
Solute 
 
PBS PBS PBS PBS PBS SFM SFM SFM 
Subject 
number 
6 5 3 3 5 2 3 2 
T, weeks 
 
8-20 >14 >8 >2 >5 >7 >5 1 
Complication 2 deaths   1 extra-
axial 
 1 extra-
axial 
 1 extra-
axial 
 
 
Table 11 Summary of the 8 trials conducted to develop an intracranial model of high-grade astrocytoma 
The variables in each trial were the cell line, the number of cells injected, and the solute in which the cells 
were suspended. A model was deemed successful once the exponential rate of tumour growth reached within 
1-2 weeks of xenografting. Overall, the complication rate was low, with only 2 deaths related to anaesthesia, 
and the generation of only 3 extracranial tumours, which reflects the competence of technique. SFM = serum 
free media, t = time to exponential growth of tumour.  
Several contributing factors may be attributable to our challenge of generating a robust 
intracranial model. One may be the athymic mouse mounting an immune response to 
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the transplanted human-derived tumour line. Certainly, patients with a high-grade 
astrocytoma have been shown to mount a humoral response to the tumour186,187, albeit 
the clinical significance remains questionable. However, as the tumours that had been 
inadvertently xenografted extra-axially tended to establish growth with more success, 
the local environment within the brain itself may have also been inhibitory. In order to 
overcome either local or systemic humoral responses, an intraparenchymal tumour that 
had successfully established growth was harvested and the cells regrown in culture 
U87bp-luc) before reinjection. However, all attempts with this cell line did not show 
improved growth rates. This may have partly been due to the cells being exposed to 
trypsin upon reculturing: it has been observed that exposing cells to trypsin prior to 
reinjection has been inhibitory to cell growth172, leading to the attempts at establishing 
an intracranial tumour by direct implantation of a subcutaneous tumour188. 
 
Aside from host immune responses, it has also been demonstrated that not all brain 
tumour cells have the ability to form a new tumour189,190. There is increasing evidence 
to support that the tumour-initiating ability resides in a specific subpopulation of cells, 
termed ‘brain tumour stem cells,’ with characteristics similar to normal neural stem 
cells190,191 i.e. the ability for self-renewal, multipotential properties, and the ability to 
initiate tumour growth. Neurosphere assays that utilise a selective serum-free culture 
system that allows neural stem cells and brain tumour stem cells to proliferate and 
generate multipotent floating cell clusters are used to identify these unique stem cell 
populations178,192-194. In our final attempt to generate an intracranial tumour model, trial 
8, neurospheres were cultured from the intraparenchymal tumour that had successfully 
grown from the implanted U87-luc polyclonal cells. Using this method, an intracranial 
model with improved implant survival and established growth was achieved.  
 
In summary, subcutaneous and intracranial animal models with established and 
growing tumours derived from a human high-grade glioma cell line with the ability to 
bioluminesce were generated. The subcutaneous model was achieved by subcutaneous 
passaging. The most robust intracranial model was achieved by implanting 
neurospheres derived from an intraparenchymal tumour that had successfully grown 
from implanted U87-luc polyclonal cells. In preparation for testing bPDT, the character 
of the bioluminescence that could be generated from these tumours was investigated 
further.  
 195 
9.2 Characterising Bioluminescence Generated in vivo 
Using the successfully established subcutaneous and intracranial models developed 
above, a more detailed investigation into the bioluminescence that could be generated 
was performed. First, the change in bioluminescence over time following an ip bolus of 
d-luciferin was assessed. Then a method of generating a more sustained 
bioluminescence was tested.  
9.2.1 Change in bioluminescence over time 
The first group of mice xenografted with U87-luc polyclonal cells intracranially were 
given an ip injection of 1.5 mg/g of d-luciferin 1 week later. The bioluminescent signal 
was recorded immediately following injection, then at 1, 2, 3, 4, and 5 mins, then every 
5 mins thereafter for a total of 60 mins. 
 
The bioluminescent signal quickly peaked within 2-3 mins, before gradually declining 
over 60 mins to near negligible levels at 55-60 mins (see Figure 84). 
 
                               
Figure 84 Change in bioluminescence over time following a bolus of d-luciferin 
1 week after intracranial injection of U87-luc polyclonal cells, the bioluminescent signal generated by the 
tumours implanted into the first trial group of mice following an ip bolus of 1.5 mg/g of d-luciferin was 
followed over 60 mins with BLI.  The bioluminescent signal generated by the implanted cells was captured by 
the Xenogen IVIS 100 cooled CCD camera system. The bioluminescent signal within a designated ROI was 
expressed as average radiance and expressed quantitatively. The bioluminescent signal quickly peaked within 
2-3 mins, before gradually declining over 60 mins to near negligible levels at 55-60 mins. 
It seemed unlikely that such a short exposure to bioluminescence would be able to 
activate a photosensitiser, and therefore a method of generating a more sustained 
bioluminescence over time was needed.  
9.2.2 Generating Sustained Bioluminescence: Use of an Osmotic Pump 
With the aim of generating a more sustained bioluminescence over time, the use of a 
subcutaneous osmotic pump (model 2001, ALZET, Durect Corporation, Cupertino, 
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USA) was tested. The model selected was the largest that could be tolerated by the size 
of animal being used (3.0 x 0.7 cm, 1.1g wt). Under sterile conditions, the osmotic 
pump was filled to its maximum volume of 200 µl with 50 mg/ml of d-luciferin. One 
mouse with a xenografted subcutaneous tumour and one with a xenografted intracranial 
tumour derived from U87-luc polyconal and U87bp-luc cells cultured to derive 
neurospheres, respectively, were anaesthesised with inhalational anaesthesia and an 
incision made in their dorsal cervical skin. A subcutaneous pocket was bluntly created 
and the pump implanted. The skin was closed with interrupted, 3’0 prolene, vertical 
mattress sutures. This pump delivered drug at a rate of 1.0 µl/hr for 1 week. Using BLI, 
the mice were imaged after pump implantation, thereby providing a measurement of 
the bioluminescent signal generated by the pump alone. The mice were then given a 1.5 
mg/g ip bolus of d-luciferin and reimaged, thereby providing the comparison signal 
achieved with a standard bolus of d-luciferin. The bioluminescent signal generated by 
the d-luciferin delivered by the pump was also followed with BLI over the course of 1 
week in the subcutaneous model with images being taken at days 1, 4, and 7 after the 
pump was inserted.  
 
Figure 85a and Figure 85b show the subcutaneously placed osmotic pump and the 
bioluminescent signal generated by the d-luciferin that it was delivering in a 
subcutaneous and intracranial model. It is clear that the bioluminescent signal 
generated by the d-luciferin being delivered via the pump was orders of magnitude 
lower than the signal generated by giving d-luciferin as an ip bolus (see Figure 85c and 
d), which is consistent with the dose of d-luciferin being given at any one time (0.05 
mg/hr via the pump vs a 1.5 mg/g bolus). However, the pump was able to produce a 
more sustained bioluminescent signal over the course of one week (see Figure 85e). 
 197 
 
                        
 
         
                            
                                               
Figure 85 Delivering d-luciferin via an osmotic pump.  
One mouse with a transplanted subcutaneous tumour and one with a transplanted intracranial tumour were 
implanted with a subcutaneous osmotic pump containing 200 µ l of 50 mg/ml d-luciferin, which delivered d-
luciferin at 1.0 µ l/hr for 1 week. The mice were imaged with BLI after pump implantation (a, b), then were 
given a 1.5 mg/g ip bolus of d-luciferin and reimaged. The mouse with the subcutaneous tumour was also 
imaged over 1 week with BLI without a d-luciferin bolus. The bioluminescent signal generated by the 
implanted cells was captured by the Xenogen IVIS 100 cooled CCD camera system. The bioluminescent signal 
within a designated ROI was expressed as average radiance and expressed quantitatively. The bioluminescent 
signal generated by d-luciferin delivered by the pump alone was orders of magnitude less than that generated 
by the standard bolus dose of d-luciferin (c, d), although it was sustained over the course of 1 week (e). 
9.2.3 Summary and Discussion 
The literature demonstrates that with a single-dose ip injection of d-luciferin, there is a 
slow rise in bioluminescent signal, reaching a peak at approximately 15 mins, followed 
by a more gradual drop195. The change in bioluminescence over time in this study was 
more akin to that achieved with an intravenous injection195. Nevertheless, as the 
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photosensitiser selected for testing bPDT, mTHPC, remains at a significant 
concentration in tumour tissue over days (see below), a method of delivering d-
luciferin in a sustained manner, thereby maximising the time over which mTHPC 
would be exposed to bioluminescence, might be more efficacious. The subcutaneous 
osmotic pump was shown to be able to do this, enabling the generation of a stable 
amount of bioluminescence over a week, albeit sacrificing the peak-value of 
bioluminescence.  
9.3 Bioluminescence-Mediated Photodynamic Therapy: a Pilot Study 
By transplanting U87bp-luc cells that had been cultured to form neurospheres (see 
Figure 83), a reliable intracranial tumour model with established exponential growth 
within a week of implantation had been achieved. As the model was being followed, 
then used to test the subcutaneous osmotic pump (see Figure 85), the opportunity to 
carry out a small pilot study was taken.  
 
7 weeks following cell implantation, both mice in this group had osmotic pumps filled 
with d-luciferin implanted subcutaneously, as described in section 9.2.2. The mice 
underwent BLI to confirm d-luciferin delivery. The following day, Mouse 2, was 
injected with 0.3 mg/kg ip of mTHPC (see section 9.4.1.3). 1 week later, both mice 
underwent BLI. 
 
After implantation of the osmotic pump, BLI revealed that the pump was effectively 
delivering d-luciferin (see Figure 86a). BLI 1 week after the start of treatment, 8 weeks 
after cell implantation, Mouse 1, the mouse that only had an osmotic pump inserted but 
no exposure to mTHPC, was found unwell, thin, and with an ataxic gait, which was 
consistent with the dramatic increase in bioluminescent signal from the intracerebral 
tumour, signifying significant tumour growth (see Figure 86b). In contrast, the tumour 
of the mouse that had been exposed to both d-luciferin and mTHPC, Mouse 2, showed 
markedly less growth, indicating relative inhibition in growth compared to the tumour 
in Mouse 1. Both mice were culled at this point.  
 
From Figure 83c, the tumours of both Mouse 1 and Mouse 2 were following a similar 
growth curve before institution of treatment. These results suggest that the treatment at 
least suppressed the natural growth of the tumour in the treated mouse. For 
demonstration of true cell kill, Mouse 2 would have had to have been followed for 
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longer, particularly as in vitro studies have shown that bPDT can have a delayed effect. 
Although a limited study, based on these results, further investigation was warranted.  
 
 
Figure 86 Using bioluminescence to mediate photodynamic therapy: a pilot study in an intracranial model 
7 weeks after intracranial injection of neurospheres derived fromU87bp-luc cells into two mice, the mice were 
implanted with a subcutaneous osmotic pump loaded with d-luciferin. The day after implantation, mouse 2 
was injected with 0.03 mg/kg mTHPC. The bioluminescent signal generated by the implanted cells was 
captured by the Xenogen IVIS 100 cooled CCD camera system after the animals were injected with 1.5 mg/g 
of d-luciferin ip. The bioluminescent signal within a designated ROI was expressed as average radiance and 
expressed quantitatively. BLI, without a bolus of d-luciferin, after the implantation of the osmotic pumps 
confirmed that they were delivering d-luciferin effectively (a). 1 week after treatment, the tumour in Mouse 1, 
exposed to d-luciferin only, had a dramatic increase in bioluminescent signal, indicating marked tumour 
growth, consistent with the development of neurological signs. However, the tumour in Mouse 2, exposed to 
sustained d-luciferin and mTHPC, did not seem to follow the same growth curve as Mouse 1 as indicated by 
BLI, and seemed to have undergone suppression of growth. 
9.4 Testing Bioluminescence Mediated Photodynamic Therapy 
As results from the pilot study were encouraging, a more extensive test of bPDT 
seemed justified. A summary of the animal models used, the derivation of the tumours, 
and the outcomes measured is given in Table 12. 3 subcutaneous models and 1 
intracranial model were used. Outcomes measured included survival, tumour volume, 
and bioluminescent signal. Once all animals were culled, all tumours were subjected to 
histolopathological and immunohistochemical analysis.  
 
The bPDT treatment required two elements, the delivery of photosensitiser and the 
generation of bioluminescence. mTHPC was delivered ip at a dose of 0.3 mg/kg, which 
is a standard in vivo dose114,196. In rodents, mTHPC reaches its maximum concentration 
within the tumour between 36 and 48 hrs after administration, then gradually decreases, 
with just under half of its maximum concentration remaining between 6 and 7 days 
after administration114,115. Bioluminescence was generated by supplying the implanted 
U87-luc cells with a constant dose of d-luciferin over 7 days via a subcutaneous 
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osmotic pump. Use of the osmotic pump allowed the prolonged exposure of the 
photosensitiser to bioluminescence, thereby maximising upon the duration that the 
photosensitiser remains in significant levels within the tumour.  
 
 bPDT Trial 
 1 2 3 4 
Outcomes Subcutaneous, 
Passage 4 
Subcutaneous, 
U87-luc cells 
Subcutaneous, 
Passage 3 
Intracranial, 
Neurospheres 
Survival " " - - 
Tumour Volume " - " - 
Bioluminescent Signal " " " " 
Histopathology and 
Immunohistochemistry 
" " " " 
 
Table 12 Summary of the animal models used and the outcomes measured in each trial 
bPDT was tested in 4 trials: 3 subcutaneous models and 1 intracranial model. This table summarises the 
origin of the tumours in each of the trials and the outcomes measured.  
9.4.1 Detailed Methodology  
9.4.1.1 The Animal Models 
Using the methods described in section 9.1 animal models were generated for testing 
bPDT: bPDT trials 1-3 were conducted in subcutaneous models and bPDT trial 4 was 
conducted in an intracranial model (see Table 12).  
 
In bPDT trial 1, the subcutaneous tumours were derived from 4 subcutaneous passages 
of a tumour that had originated from U87-luc polyclonal cells. The tumours for bPDT 
trial 3 were derived in a similar manner, but resulted from 3 subcutaneous passages of 
tumour. In bPDT trial 2, the subcutaneous tumours were derived from injection of U87-
luc polyclonal cells into the dorsal flank of the animals.  In bPDT trial 4, the cells 
injected intracranially were the neurospheres that had been derived from U87bp-luc 
cells. The details of each model are described within the context of each experiment 
discussed below. 
9.4.1.2 The Substrate: d-Luciferin 
d-Luciferin was delivered via an osmotic pump (model 2001, ALZET, Durect 
Corporation, Cupertino, USA). The pump was filled to its maximum volume of 200 µl 
with 50 mg/ml of d-luciferin and implanted subcutaneously under inhalational 
anaesthesia, as described above (section 9.2.2).  
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9.4.1.3 The Photosensitiser, mTHPC 
A stock solution of mTHPC (4mg/ml) was diluted in 3 mls PEG 400, 2 mls ethanol, 
and 5 mls distilled water to achieve a final concentration of 0.03 mg/ml. The drug was 
sterile filtered and injected ip into the animals at a dose of 0.3 mg/kg. Once the 
photosensitiser had been injected into the mice, they were kept in the dark, with black 
plastic used to shield their cages and their daily care was undertaken with the room 
lights switched off to minimise inadvertent photoactivation of the photosensitiser by 
ambient light.  
9.4.1.4 The Treatment 
At a designated time point following tumour implantation, which is detailed within the 
context of each experiment below, the mice were divided into ‘control’ only, ‘drug 
only,’ ‘light only,’ and ‘treatment’ (i.e. drug + light) groups following either random 
allocation or randomisation according to bioluminescent signal. The mice in the ‘light 
only’ and ‘treatment’ groups were implanted with the d-luciferin filled osmotic pumps. 
Then the mice in the ‘drug only’ and ‘treatment’ groups were injected with 0.3 mg/kg 
of mTHPC ip. After 1 week, the osmotic pumps were removed. BLI was not 
undertaken during the first week of treatment to avoid the confounding effect of the d-
luciferin bolus necessary for BLI.  
9.4.1.5 Outcome Measures 
9.4.1.5.1 Survival  
Animals were culled at the designated end point of the experiment, or if they became 
unwell and displayed any signs of distress. Animals with subcutaneous tumours were 
also culled if the tumours reached > 12 mm in any direction, as per institutional 
protocol. Survival was recorded in bPDT trials 1 and 2.  
9.4.1.5.2 Tumour Volume 
The subcutaneous tumours generated in bPDT trials 1 and 3 became large enough for 
caliper measurements to be made. From these measurements, tumour volume was 
estimated: the depth of the tumour was difficult to determine and was assumed to equal 
the width, and thus, assuming the tumour to be a rectangle, the volume was estimated 
as ‘width2 x length.’ In bPDT trial 1, tumour volumes were trended throughout the 
course of the experiment. 
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9.4.1.5.3 Bioluminescent Signal 
After the end of treatment, in all bPDT trials, bioluminescent signal was trended 
throughout the course of the experiment. BLI was conducted as detailed in section 
9.1.1.6.  
9.4.1.5.4 Validation of BLI  
In bPDT trials 1 and 3, where both tumour volume and bioluminescent signal were 
measured at a specific time point, an attempt at validating BLI as a measure of tumour 
progression was made.  
9.4.1.6 Histopathology and Immunohistochemistry 
2 hrs before culling, the mice were injected with 5 mg/ml ip of 5-bromo-2’-
deoxyuridine (BrdU) to allow identification of cells that were actively replicating their 
DNA at the time of injection via anti-BrdU antibody detection. The mice were culled 
with CO2 then cervical fracture, in accordance with institutional guidelines. In the 
subcutaneous model, the tumours were dissected out and placed in formalin. In the 
intracranial model, the brains were dissected out and placed in formalin. The tissues 
were then sectioned. Slides were stained with haematoxylin and eosin (H and E) and 
labelled with antibody to BrdU. A piece of small intestine was also harvested to act as 
the positive control for the immunohistochemistry.  
 
A representative section of each tumour was selected. The H and E stained slides were 
examined, the characteristics of the tumours noted, and a subjective assessment of the 
degree of necrosis made. Regarding immunohistochemistry, the BrdU positive and 
negative cells were counted in 4 randomly picked locations at x 40 magnification using 
Image-Pro Plus 50 software. The number of BrdU positive cells was expressed as the 
percentage of the total count and averaged for each group.   
9.4.1.7 Statistical Analysis 
Statistical analysis was conduced using GraphPad Prism software. For survival 
analysis, Kaplan-Meier curves were generated for each of the experimental groups and 
log-rank analysis using a Bonferroni correction threshold for multiple comparisons was 
used to determine if there was a significant difference between the groups.  
 
For tumour volume, bioluminescent signal, and proportion of BrdU positive cells, 
results were averaged for each experimental group and expressed as the average ±SEM. 
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1-way ANOVA analysis was then conducted to determine if a significant difference 
existed between each group.  
 
In validating BLI as a measure of tumour progression, linear regression was undertaken 
to examine the relationship between tumour volume and bioluminescent signal at a 
particular time point. An r2 value was calculated to assess the goodness-of-fit of this 
relationship. 
9.4.2 bPDT Trial 1: Subcutaneous Model – subcutaneous passage of tumour, passage 4 
The mice implanted with tumours that had undergone 3 passages of subcutaneous 
transfer (see Figure 79d) were culled and the tumours harvested, prepared, and 100 µl 
of cell suspension was injected subcutaneously into the dorsal flank of 15 mice; 
subcutaneous passage 4. 4 days after injection, the mice underwent BLI. Based on their 
bioluminescent signal, the mice were randomised into ‘control’ only (n=3), ‘drug only’ 
(n=3), ‘light only’ (n=4), and ‘treatment’ (n=5) groups, such that each group generated 
similar amounts of bioluminescence. The following day, 5 days after tumour 
implantation, treatment began. After its completion, the animals underwent BLI every 
other day. Once the tumours were large enough, caliper measurements of the implanted 
tumours were also made in conjunction with BLI, and tumour volumes estimated. 
9.4.2.1 Randomisation 
Randomisation 4 days after tumour implantation allowed the animals to be divided into 
4 groups whose collective bioluminescent signal within each group following a bolus 
of d-luciferin was not significantly different between each group (see Figure 87). 
Groups A, B, C, and D became the ‘control’ (n=3), ‘drug only’ (n=3), ‘light only’ 
(n=4), and ‘treatment’ (n=5) groups, respectively. 
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Figure 87 Randomisation of animals according to bioluminescent signal 4 days after tumour implantation 
A, B, C, and D denote the 4 groups that the animals were randomised into. Asterisks indicate the degree of 
significance of the difference in bioluminescent signal generated between each group and group A, where *p > 
0.05. The bioluminescent signal generated by the implanted cells was captured by the Xenogen IVIS 100 
cooled CCD camera system after the animals were injected with 1.5 mg/g of d-luciferin ip. The bioluminescent 
signal within a designated ROI was expressed as average radiance and expressed quantitatively. 
Randomisation allowed the animals to be divided into 4 groups whose collective bioluminescent signal within 
each group was not significantly different between groups.  
9.4.2.2 Validation of BLI 
Caliper measurements of the subcutaneous tumours began the day after the end of 
treatment, 13 days following tumour implantation. The bioluminescent signal from 
each tumour was plotted against its estimated volume and linear regression analysis 
undertaken. Figure 88 shows that overall the greater the tumour volume, the greater the 
bioluminescent signal. However, this relationship becomes stronger over time: 
although the r2 value 13 days after tumour implantation is close to and not significantly 
different from 0 (0.093, p > 0.05), indicating that bioluminescent signal is not 
predictable from tumour volume, this value increases to close to 0.5 (0.48, p < 0.01) 
over the next 4 days. Only 2 mice survived beyond day 17 and on days 19 and 21 this 
relationship continued. However, on day 24, there was a reversal in the correlation, 
with a lower bioluminescent signal being associated with the greater tumour volume. 
This likely reflected the point where the tumour outgrew its blood supply and necrosis 
became predominant. Overall, the bioluminescent signal detected by BLI can be used 
as a surrogate measure for tumour volume. However, care should be taken in 
interpreting the findings both early and late in tumour progression.  
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Figure 88 Validation of BLI: correlating bioluminescent signal with tumour volume 
The bioluminescent signal from each tumour was plotted against its estimated volume and linear regression 
analysis undertaken. The bioluminescent signal generated by the implanted cells was captured by the 
Xenogen IVIS 100 cooled CCD camera system after the animals were injected with 1.5 mg/g of d-luciferin ip. 
The bioluminescent signal within a designated ROI was expressed as average radiance and expressed 
quantitatively. Asterisks indicate the degree of significance of the difference in the slope generated from linear 
regression analysis and 0 where *p > 0.05, **p ≤  0.05, ***p < 0.01. Tumours became large enough for caliper 
measurements on day 13 post tumour implantation. The greater the tumour volume, the greater the 
bioluminescent signal, and as the tumours became larger from days 13 to 17, this relationship became 
stronger, as reflected by the r2 value. In the 2 mice surviving beyond day 17, this relationship continued until 
day 24, when there was a reversal in the correlation, likely reflecting the point where the tumour outgrew its 
blood supply and necrosis became predominant. Overall, the bioluminescent signal detected by BLI can be 
used as a surrogate measure for tumour volume. However, care should be taken in interpreting the findings 
both early and late in tumour progression.  
9.4.2.3 Outcome: Survival 
14 days after tumour implantation, one control mouse, Mouse 2, was culled due to 
ulceration of the subcutaneous tumour. One mouse from the treatment group, Mouse 0, 
was chosen at random and culled at the same time point to enable histopathological 
comparison (see Figure 93a and b): this mouse was censored from the survival analysis. 
17 days after tumour implantation, all remaining mice, except for two treatment mice, 
Mouse 3 and Mouse 4, fulfilled the criteria for culling. Mouse 3 and Mouse 4 from the 
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treatment group finally succumbed 24 and 26 days following tumour implantation, 
respectively.  
 
A Kaplan-Meier curve was generated for each of the groups (see Figure 89). Although 
the median survival of the ‘treatment’ group was greater than that of the ‘control,’ 
‘drug only,’ and ‘light only’ groups, 20.5 vs 17 days respectively, log-rank analysis 
using a Bonferroni correction threshold for multiple comparisons did not find any 
significant difference between the curves: the p value of 0.0926 resulted from 
comparing the survival curves of the ‘control’ and ‘treatment’ groups as an example.  
 
There seems to be a trend towards improved survival in the ‘treatment’ group. 
However, the data is limited by the size of the population tested.  
 
 
Figure 89 Kaplan-Meier curves demonstrating survival: bPDT Trial 1 
A Kaplan-Meier curve was generated for each of the groups in the study, where C = control, D = drug only, L 
= d-lucifeirn only, and D+L = animals exposed to drug and d-luciferin. The x axis represents the number of 
days following tumour implantations. Although the median survival of the ‘treatment’ group was greater 
than that of the ‘control,’ ‘drug only,’ and ‘light only’ groups, 20.5 vs 17 days respectively, log-rank analysis 
using a Bonferroni correction threshold for multiple comparisons did not find any significant difference 
between the curves: the p value of 0.0926 resulted from comparing the survival curves of the ‘control’ and 
‘treatment’ groups as an example.  
9.4.2.4 Outcome: Tumour Volume 
Caliper measurements of the subcutaneous tumours began 13 days following tumour 
implantation, allowing an estimation of tumour volume. From this point, the change in 
tumour volume over time was trended. The data for the individual animals (see Figure 
90a) and the average tumour volumes in each group (see Figure 90b) are presented. 
 
The data for the individual animals revealed an aberrant measurement for Mouse 5 in 
the ‘treatment’ group on day 15: this data point was excluded from the average 
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calculations. There was no significant difference between the groups at any time point. 
However, from the grouped data, the ‘treatment’ group did seem to have lower tumour 
volumes. Furthermore, there seemed to be a delay in the onset of the exponential 
growth phase of the tumours in the ‘treatment’ group: tumours in the animals in the 
control groups had reached their exponential growth by day 13, whereas this started at 
day 19 in the ‘treatment’ group. Moreover, there seemed to be a halt in tumour growth 
in the ‘treatment’ group from day 13-17, with a fall in tumour volume from day 17-19, 
before the onset of exponential growth. From the individual data, this trend in the 
‘treatment’ group was mainly due to the effect of treatment on two mice, Mouse 3 and 
Mouse 4, and was reflected by their increased survival.  
 
Overall, there is a suggestion that the treatment had at least some effect in suppressing 
tumour growth. However, the data is limited by the size of the population tested.  
 
Figure 90 Bioluminescence-mediated photodynamic therapy: the effect on tumour volume – bPDT Trial 1 
C = control, D = drug only, L = d-luciferin only, DL/D+L = animals exposed to drug and d-luciferin, M = 
mouse. The x axis represents the number of days following tumour implantation. Caliper measurements of 
the subcutaneous tumours began 13 days after tumour implantation. The data for individual animals (a) and 
the average tumour volumes in each group (b) are presented: what seemed to be an aberrant measurement 
from mouse 5 in the ‘treatment’ group on day 15 was excluded from the ‘averaged’ data. Although there was 
no significant difference in tumour volume between the groups at any time point, the ‘treatment’ group 
seemed to have a lower average tumour volume and a delay in the tumour starting exponential growth, This 
trend was mainly due to the effect of treatment on two mice in the treatment group, Mouse 3 and Mouse 4, 
and was also reflected in their increased survival.  
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9.4.2.5 Outcome: Bioluminescent Signal 
The day after the end of treatment, 13 days after tumour implantation, the animals 
underwent BLI, and every other day thereafter. The data for the individual animals (see 
Figure 91a) and the average bioluminescent signal in each group (see Figure 91b) are 
presented. 
 
There was no significant difference in the bioluminescent signal between the groups at 
any time point. From the ‘grouped’ data, the exponential growth phase of the tumours 
in the control groups seemed to start 13 days following tumour implantation. In the 
‘treatment’ group, the start of exponential growth was less clear, with a subtle fall in 
bioluminescent signal from days 15-19, before a brief increase from days 19-21, then 
another gradual fall in signal from days 21-26.  
 
The trends in tumour progression are less clear when measuring bioluminescent signal 
compared to tumour volume. The balance between ongoing tumour growth and the 
degree of necrosis that occurs as the tumour outgrows its blood supply likely confounds 
the bioluminescent signal, as discussed above. This was demonstrated by Mouse 2 in 
the ‘light only’ group and Mouse 4 in the ‘treatment’ group, where a rapid increase in 
bioluminescent signal was followed by a steep decline, even though progressively 
increasing tumour volumes were seen (see Figure 90). A trend towards a treatment 
effect was less clear when analysing bioluminescent signal, which is consistent with the 
limitations of BLI revealed by the validation study.    
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Figure 91 Bioluminescence-mediated photodynamic therapy: the effect on bioluminescent signal – bPDT Trial 
1 
C = control, D = drug only, L = d-luciferin only, DL/D+L = animals exposed to drug and d-luciferin, M = 
mouse. The x axis represents the number of days following tumour implantation. The bioluminescent signal 
generated by the implanted cells was captured by the Xenogen IVIS 100 cooled CCD camera system after the 
animals were injected with 1.5 mg/g of d-luciferin ip. The bioluminescent signal within a designated ROI was 
expressed as average radiance and expressed quantitatively. The data for the individual animals (a) and the 
average bioluminescent signal in each group (b) are presented. There was no significant difference in the 
bioluminescent signal between the groups at any time point. From the ‘grouped’ data there seemed to be a 
delay in the exponential growth phase in the ‘treatment’ group compared with the control groups. Overall, 
the trends in tumour progression were less clear when following bioluminescent signal compared to tumour 
volume.  
9.4.2.6 Outcome: Histopathology and Immunohistochemistry 
As the mice were culled, their tumours were harvested, fixed in formalin, embedded in 
paraffin, and sectioned. H and E stain revealed the tumours to be hypercellular and 
consist of a monomorphic population of cells on a fibrillary background, consistent 
with astrocytoma. Areas of necrosis were evident, as were several mitoses, (see Figure 
92), consistent with a grade 4, tumour. 
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Figure 92 H and E stained section of an implanted subcutaneous tumour derived from U87-luc polyclonal 
cells 
This is an H and E stained section from the tumour of a mouse in the ‘control’ group seen at low (x4) and 
high (x20) magnifications, and is representative of the tumours derived from U87-luc polyclonal cells 
subjected to 4 passages of subcutaneous transfer. The tumour is seen to be hypercellular and to consist of a 
monomorphic population of cells on a fibrillary background, consistent with astrocytoma. There is evidence 
of both multiple mitoses (M) and necrosis (N), consistent with a grade 4 astrocytoma tumour.   
Furthermore, subjectively, there was more necrosis seen in the ‘treatment’ group 
compared with the control groups. This was first evident when comparing the tumour 
of the control mouse that was culled 13 days following tumour implantation due to 
tumour ulceration and the tumour of the ‘treatment’ group mouse that was electively 
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culled at the same time for comparison (see Figure 93a and b). This observation was 
also made during the final analysis (see Figure 93c, d, and e). 
 
 
 
 
 
Figure 93 Comparing H and E stained sections of subcutaneous tumours derived from U87-luc polyclonal 
cells from the different study groups.  
Subjectively, more necrosis was seen in the ‘treatment’ group compared with the control groups. This was 
first evident when comparing the tumours from the ‘control’ (a) and ‘treatment’ group (b) mice that were 
culled on day 13. This observation was also made during the final analysis: representative sections of tumour 
from the ‘control’ (c), ‘drug only’ (d), ‘light only’ (e), ‘treatment’ groups (f) are presented.  
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2 hours prior to being culled, the mice were injected with BrdU. Sections were 
subsequently labelled with antibody to BrdU, which labelled cells that were actively 
replicating their DNA at the time of injection. A typical section labelled with antibody 
to BrdU is seen (see Figure 94a) along with its positive control, a piece of small 
intestine (see Figure 94b) with the constantly dividing stem cells in the crypts being 
labelled: the BrdU positive cells are coloured brown, compared to the blue of the BrdU 
negative cells. For each tumour, the BrdU positive and negative cells were counted in 4 
randomly picked locations at x 40 magnification. The number of BrdU positive cells 
was expressed as the percentage of the total count and averaged for each group (see 
Figure 94c). 3 tumours were excluded from analysis due to poor immunolabelling: 
Mouse 1 from the ‘drug only’ group, Mouse 2 from the ‘light only’ group, and Mouse 4 
from the ‘treatment’ group. There were significantly less BrdU positive cells in the 
‘treatment’ group compared to the ‘control,’ ‘drug only,’ and ‘light only’ groups (16.0 
± 0.546 vs 29.4 ± 0.996, 29.2 ± 0.738, 29.8 ± 1.02, respectively, p < 0.0001). This 
suggests that the treatment caused partial inhibition of DNA replication. 
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Figure 94 BrdU immunolabelling of subcutaneous tumours derived from U87-luc polyclonal cells 
2 hours prior to being culled, the mice were injected with BrdU. Sections were subsequently labelled with 
antibody to BrdU. A typical section labelled with antibody to BrdU is seen (a) along with a positive control, a 
piece of small intestine (b): the BrdU positive cells are coloured brown, compared to the blue of the BrdU 
negative cells. For each tumour, the BrdU positive and negative cells were counted in 4 randomly picked 
locations at x 40 magnification. The number of BrdU positive cells was expressed as the percentage of the 
total count and averaged for each group, where C = control, D = drug only, L = d-luciferin only, D+L = 
animals exposed to drug and d-luciferin. There were significantly less BrdU positive cells in the ‘treatment’ 
group compared to the control groups (c), indicating that the treatment, at the very least, caused some 
inhibition of DNA replication. 
9.4.2.7 Summary: bPDT Trial Group 1, Subcutaneous Model 
There was a trend to prolonged survival in the ‘treatment’ group. This is consistent 
with the suggestion of a delay in onset of exponential growth in the ‘treatment’ group, 
as revealed by trending tumour volumes, and certainly correlates with significantly 
reduced DNA replication in the ‘treatment’ group.  
 
The change in tumour progression was not so clearly reflected by following 
bioluminescent signal as with tumour volume. As shown by the validation study, 
interpretation of the trend in bioluminescent signal requires some caution.  
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9.4.3 bPDT Trial 2: Subcutaneous Model – U87-luc polyclonal cells 
40 mice were injected with 5 x106 U87-luc polyclonal cells in 200 µl of PBS.  The 
following day, the mice were randomly designated into ‘control’ only (n=22), ‘drug 
only’ (n=6), ‘light only’ (n=6), and ‘treatment’ (n=6) groups and treatment was started. 
At the end of treatment, the animals underwent BLI, and weekly thereafter. 
9.4.3.1 Survival  
2 mice, one from the ‘light only’ group and one from the ‘treatment’ group were culled 
during the first week after tumour implantation as the site of the osmotic pumps 
appeared inflammed and infected. These mice were censored from ongoing analysis. 1 
mouse from the ‘control’ group was culled 6 weeks following tumour implantation as 
the mouse had developed a large tumour affecting the movement of its leg. This tumour 
was harvested for subcutaneous passaging (see Trial 3). 5 mice from the control group 
were removed from the study at 7 weeks, as no subcutaneous tumours were developing, 
as indicated by persistent negligible bioluminescent signal: these mice were censored 
from ongoing analysis and were used as hosts for subcutaneous passaging (see Trial 3). 
2 mice, one from the ‘control’ group and one from the ‘drug only’ group were culled 8 
weeks following tumour implantation, as the tumour was affecting movement of the leg 
and the mouse was losing weight, respectively. Overall, there was no significant 
difference in survival between the groups (see Figure 95): the p value of 0.361 resulted 
from comparing the survival curves of the ‘control’ and ‘treatment’ groups as an 
example.  
 
Figure 95 Kaplan-Meier curves demonstrating survival: bPDT Trial 2 
A Kaplan-Meier curve was generated for each of the groups in the study, where C = control, D = drug only, L 
= d-lucifeirn only, and D+L = animals exposed to drug and d-luciferin. The x axis represents the number of 
weeks following tumour implantations. The plot for D+L follows that of L. There was no significant difference 
in survival between the groups: the p value of 0.361 resulted from comparing the survival curves of the 
‘control’ and ‘treatment’ groups as an example.  
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9.4.3.2 Outcome: Bioluminescent Signal 
Animals underwent BLI at the end of treatment, then weekly thereafter. The average 
bioluminescent signal in each group (see Figure 96) is presented. There was no 
significant difference in the bioluminescent signal between the groups at any time 
point. Consistent with findings from development of the model (see Figure 78d), the 
tumours started their exponential growth phase 7 weeks after tumour implantation.  
 
 
Figure 96 Bioluminescence-mediated photodynamic therapy: the effect on bioluminescent signal – bPDT Trial 
2 
C = control, D = drug only, L = d-luciferin only, DL/D+L = animals exposed to drug and d-luciferin. The x 
axis represents the number of weeks following tumour implantation. The bioluminescent signal generated by 
the implanted cells was captured by the Xenogen IVIS 100 cooled CCD camera system after the animals were 
injected with 1.5 mg/g of d-luciferin ip. The bioluminescent signal within a designated ROI was expressed as 
average radiance and expressed quantitatively. The average bioluminescent signal in each group is presented. 
There was no significant difference in the bioluminescent signal between the groups at any time point.  
9.4.3.2 Outcome: Histopathology and Immunohistochemistry 
When the mice were culled, their tumours were harvested, fixed in formalin, embedded 
in paraffin, and sectioned. H and E stain revealed little difference between these 
tumours obtained from U87-luc polyclonal cells harvested from culture then directly 
implanted compared with the tumours that had undergone several subcutaneous 
passages. Again, the tumours were hypercellular and consisted of a monomorphic 
population of cells on a fibrillary background, consistent with astrocytoma, with areas 
of necrosis and several mitoses, consistent with a grade 4 tumour (see Figure 97a and 
b).  
 
Mice were again injected with BrdU ip 2 hours prior to culling. There was no clear 
difference between the proportions of BrdU positive cells, expressed as a percentage of 
the total cell count, between the study groups (see Figure 97c): there was only slight 
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toxicity demonstrated in the ‘light only’ group compared to ‘control’ (33.6 vs 25.3%, p 
≤ 0.05, 95% CI 0.675 to 15.9). 
 
 
 
 
Figure 97 Histopathology and Immunohistochemistry: bPDT Trial 2 
H and E stain revealed little difference between these tumours obtained from U87-luc polyclonal cells 
harvested from culture then directly implanted compared with the tumours that had undergone several 
subcutaneous passages: again, the tumours were hypercellular and consisted of a monomorphic population of 
cells (a) with areas of necrosis and several mitoses (b), consistent with a grade 4 astroyctoma. Mice were 
injected with BrdU ip 2 hours prior to culling. There was no clear difference between the proportions of BrdU 
positive cells between the study groups (c), where C = control, D = drug only, L = d-luciferin only, D+L = 
animals exposed to drug and d-luciferin: only slight toxicity was demonstrated in the ‘light only’ group 
compared to ‘control’ (33.6 vs 25.3%, p ≤  0.05, 95% CI 0.675 to 15.9). 
9.4.3.3 Summary: bPDT Trial Group 2, Subcutaneous Model 
From tumour model development, it was known that this model has a 60% success rate 
in generating subcutaneous tumours, and hence a large number of mice were injected to 
account for this. Furthermore, it was known that the rate of tumour growth was slow, 
with tumours predicted to start their exponential growth 7 weeks after tumour 
implantation. Upon final analysis, there was no evidence of a treatment effect, or even 
a trend towards an effect. Results from Trial 1 suggest that any treatment effect would 
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have been a short-lived suppression in tumour growth. It would be consistent that if 
there had been such an effect, it would have likely been lost over the long follow up of 
9 weeks.   
9.4.4 bPDT Trial 3: Subcutaneous Model – subcutaneous passage of tumour, passage 3 
The subcutaneous tumour from the mouse of the ‘control’ group of Trial 2 culled at 
week 6 was harvested, prepared, and 100 µl of cell suspension injected into the dorsal 
flank of 6 mice, passage 1. After 10 days of growth, these 6 tumours were harvested, 
pooled, prepared, and 100 µl of cell suspension injected into the dorsal flank of the 5 
‘control’ group mice from Trial 2 removed from the study at week 7, on the 
contralateral side to the first cell implantation, passage 2. After another 10 days, these 
tumours were harvested, pooled, prepared, and 100 µl of cell suspension injected into 
the dorsal flank of the 12 mice, passage 3.  
 
2 days after tumour implantation, the mice underwent BLI. Based on their 
bioluminescent signal, the mice were randomised into ‘control’ only (n=3), ‘drug only’ 
(n=3), ‘light only’ (n=3), and ‘treatment’ (n=3) groups, such that each group generated 
similar amounts of bioluminescence. The following day, 3 days after tumour 
implantation, treatment began. After 1 week of treatment, 10 days after tumour 
implantation, caliper measurements were made of all the implanted tumours and 
tumour volumes estimated. The animals also underwent BLI allowing tumour volumes 
to be correlated with bioluminescent signal. The animals were then culled due to time 
constraints.  
9.4.4.1 Randomisation 
Randomisation 2 days after tumour implantation allowed the animals to be divided into 
4 groups whose collective bioluminescent signal within each group following a bolus 
of d-luciferin was not significantly different between the groups (see Figure 98). 
Groups A, B, C, and D became the ‘control’ (n=3), ‘drug only’ (n=3),  ‘light only’ 
(n=3), and ‘treatment’ (n=3) groups, respectively.  
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Figure 98 Randomisation of animals according to bioluminescent signal 4 days after tumour implantation 
A, B, C, and D denote the 4 groups that the animals were randomised into. Asterisks indicate the degree of 
significance of the difference in bioluminescent signal generated between each group and group A, where *p > 
0.05. The bioluminescent signal generated by the implanted cells was captured by the Xenogen IVIS 100 
cooled CCD camera system after the animals were injected with 1.5 mg/g of d-luciferin ip. The bioluminescent 
signal within a designated ROI was expressed as average radiance and expressed quantitatively. 
Randomisation allowed the animals to be divided into 4 groups whose collective bioluminescent signal within 
each group was not significantly different between groups.  
9.4.4.2 Validation of BLI 
Before the mice were culled at the end of treatment, 10 days after tumour implantation, 
caliper measurements of the subcutaneous tumours were made before BLI.  It was 
noted that determining tumour volume at this early time point was challenging, as the 
tumours were not yet well formed with distinct margins. Nevertheless, an attempt at 
correlating the estimated tumour volume with bioluminescent signal was made. At this 
time point, there was a weak correlation between bioluminescent signal and tumour 
volume (see Figure 99): no significant difference was found between the slope 
generated by linear regression analysis and 0. Supported by findings from Trial 1, this 
confirms that using bioluminescent signal as a measure of early tumour growth must be 
interpreted with caution. 
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Figure 99 Validation of BLI: correlating bioluminescent signal with tumour volume 
At the end of treatment, 10 days after tumour implantation, the bioluminescent signal from each tumour was 
plotted against its estimated volume and linear regression analysis undertaken. The bioluminescent signal 
generated by the implanted cells was captured by the Xenogen IVIS 100 cooled CCD camera system after the 
animals were injected with 1.5 mg/g of d-luciferin ip. The bioluminescent signal within a designated ROI was 
expressed as average radiance and expressed quantitatively.  Asterisks indicate the degree of significance of 
the difference in the slope generated from linear regression analysis and 0 where *p > 0.05. At this time point, 
there was a poor correlation between volume and bioluminescent signal, where there was no significant 
difference found between the slope generated by linear regression analysis and 0. 
9.4.4.3 Outcome: Tumour Volume 
Caliper measurements of the subcutaneous tumours 10 days following tumour 
implantation were made to attempt an estimation of tumour volume. As mentioned 
above, at this early time point, determining tumour volume was challenging as the 
tumours were not yet well formed with distinct margins. No significant difference was 
found in tumour volume between the study groups (see Figure 100). 
  
 
Figure 100 Bioluminescence-mediated photodynamic therapy: the effect on tumour volume – bPDT Trial 3 
C = control, D = drug only, L = d-luciferin only, D+L = animals exposed to drug and d-luciferin. Asterisks 
indicate the degree of significance of the difference in the average tumour volume of each group compared to 
control, where *p > 0.05. Tumour volumes were estimated at the end of treatment. There was no significant 
difference in tumour volume between groups. 
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9.4.4.4 Outcome: Bioluminescent Signal 
Animals underwent BLI the day before and the day after the end of treatment. The 
average bioluminescent signal in each group (see Figure 101) is presented. There was 
no significant difference in the bioluminescent signal between the groups at any time 
point.  
 
Figure 101 Bioluminescence-mediated photodynamic therapy: the effect on bioluminescent signal – bPDT 
Trial 3 
C = control, D = drug only, L = d-luciferin only, D+L = animals exposed to drug and d-luciferin. The x axis 
represents the number of days following tumour implantation. The bioluminescent signal generated by the 
implanted cells was captured by the Xenogen IVIS 100 cooled CCD camera system after the animals were 
injected with 1.5 mg/g of d-luciferin ip. The bioluminescent signal within a designated ROI was expressed as 
average radiance and expressed quantitatively. There was no significant difference in the bioluminescent 
signal between the groups at any time point.  
9.4.4.5 Outcome: Histopathology and Immunohistochemistry 
When the mice were culled, their tumours were harvested, fixed in formalin, embedded 
in paraffin, and sectioned. It was noted that these tumours were not as well defined as 
the tumours in the previous studies, likely associated with the early end point, and the 
tumours were commonly harvested in several pieces. Furthermore, upon harvesting, 
tumours of 2 mice in the ‘treatment’ group were noted to be haemorrhagic and necrotic, 
unlike the tumours harvested from the other animals. Microscopically, although 
tumours in all study groups had some degree of necrosis, that of the ‘treatment’group 
seemed more profound (see Figure 102a, b, c, and d).  
 
Mice were injected with BrdU ip 2 hours prior to culling. The number of BrdU positive 
cells were expressed as the percentage of the total count and averaged for each group 
(see Figure 102e). There were significantly less BrdU positive cells in the ‘treatment’ 
group compared to the ‘control,’ ‘drug only,’ and ‘light only’ groups (23.4 ± 0.850 vs 
34.6 ± 1.01, 33.9 ± 0.757, 36.8 ± 1.77, respectively, p < 0.0001). This suggests that the 
treatment caused partial inhibition of DNA replication. 
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Figure 102 Histopathology and Immunohistochemistry: bPDT Trial 3 
Representative H and E stained sections from the ‘control’ (a), ‘drug only’ (b), ‘light only’ (c), and 
‘treatment’ (d) groups are presented. Examination of the sections suggested that although there was some 
degree of necrosis in all the tumours in each study group, that of the ‘treatment’ group was most profound. 
Mice were injected with BrdU ip 2 hours prior to culling. The difference in proportion of BrdU positive cells 
as a percentage of the total cell count is presented (e), where C = control, D = drug only, L = d-luciferin only, 
D+L = animals exposed to drug and d-luciferin. Asterisks indicate the degree of significance of the difference 
in the proportion of BrdU positive cells in each group compared to control, where *p > 0.05, ** p ≤  0.05, ***p 
< 0.01, ****p < 0.001, *****p < 0.0001. There were significantly less BrdU positive cells in the ‘treatment’ 
group. 
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9.4.4.6 Summary: bPDT Trial 3, Subcutaneous Model 
This experiment was markedly limited by time. Despite using a robust tumour model 
derived from U87-luc polyclonal cells that had undergone 3 subcutaneous passages, the 
tumours were not well defined either at the beginning or by the end of the treatment.  
For this reason, estimated tumour volumes were challenging to obtain. Nevertheless, 
results from attempting to validate BLI as measure of tumour progression supported 
findings from Trial 1, where there was poor correlation between BLI and tumour 
volume at such an early time point. Neither tumour volumes nor bioluminescent signal 
revealed a treatment effect. However, both macroscopically and microscopically, the 
tumours from the ‘treatment’ group seemed to be more necrotic, which was consistent 
with significantly less BrdU positive cells in the ‘treatment’ group, suggesting that 
treatment had a suppressive effect on tumour progression. If time had allowed the 
tumour to establish growth before the onset of treatment and the animals to have been 
followed for longer, trending tumour volumes and bioluminescent signal might have 
revealed a significant treatment effect. 
9.4.5 bPDT Trial 4: Intracranial Model – U87bp-luc cells grown as neurospheres 
Following the appropriate anaesthesia, 1x105 cells of U87bp-luc cells that had been 
grown to form neurospheres were injected in 10 µl of PBS into 18 mice. The mice were 
randomly designated into ‘control’ (n=4), ‘drug only’ (n=4), ‘light only’ (n=4), and 
‘treatment’groups (n=6). The day after tumour implantation treatment started. At the 
end of treatment, the animals underwent BLI, and weekly thereafter for 8 weeks.  
9.4.5.1 Outcome: Bioluminescent Signal 
Animals underwent BLI 1 week after tumour implantation, at the end of treatment, and 
weekly thereafter for 8 weeks. The data for the individual animals (see Figure 103a) 
and the average bioluminescent signal in each group (see Figure 103b) are presented.  
 
There was no significant difference in the bioluminescent signal between the groups at 
any time point. The tumour from Mouse 0 from the ‘treatment’ group seemed to 
generate an aberrantly high bioluminescent signal compared to the other tumours in its 
group and this was consistent with the tumour having a significant extraparenchymal 
component (see Figure 104), discovered upon autopsy. Even when this mouse was 
excluded from analysis, there was no significant difference between the ‘treatment’ 
group and the controls (see Figure 103c). Lastly, closer analysis of tumour progression 
in the first 4 weeks following tumour implantation (see Figure 103d) revealed that only 
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the tumours in 3 mice entered into their exponential growth phase during this time: 
Mouse 2 and Mouse 3 from the ‘control’ group and Mouse 0 from the ‘treatment’ 
group. This was consistent with the finding that not only did the tumour from Mouse 0 
of the ‘treatment’ group have a significant extraparenchymal component, so did Mouse 
2 and Mouse 3 from the ‘control’ group (see Figure 104). 
 
 
Figure 103 Bioluminescence-mediated photodynamic therapy: the effect on bioluminescent signal – bPDT 
Trial 4 
C = control, D = drug only, L = d-luciferin only, DL/D+L = animals exposed to drug and d-luciferin, M = 
mouse. The x axis represents the number of weeks following tumour implantation. The bioluminescent signal 
generated by the implanted cells was captured by the Xenogen IVIS 100 cooled CCD camera system after the 
animals were injected with 1.5 mg/g of d-luciferin ip. The bioluminescent signal within a designated ROI was 
expressed as average radiance and expressed quantitatively. The data for the individual animals (a) and the 
average bioluminescent signal in each group (b) are presented. The tumour from Mouse 0 from the 
‘treatment’ group generated a bioluminescent signal aberrantly high compared to others in its group. The 
average bioluminescent signal was represented having excluded this mouse from analysis (c). Overall, there 
was no significant difference in the bioluminescent signal between the groups at any time point. Further 
analysis of the first 4 weeks of tumour progression indicated that only tumours in 3 mice (Mouse 2 and Mouse 
3 in the ‘control’ group and Mouse 0 in the ‘treatment’ group) entered into their exponential growth during 
this time, which was subsequently found to be consistent with a significant extraparenchymal component. 
9.4.5.2 Outcome: Histopathology and Immunohistochemistry 
When the mice were culled, their brains were harvested, fixed in formalin, embedded in 
paraffin, and sectioned. H and E stain revealed the tumours to be hypercellular and to 
consist of a monomorphic population of cells on a fibrillary background, consistent 
with astrocytoma. Several mitoses, as well as areas of necrosis and vascular endothelial 
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proliferation were evident, all of which are characteristic of a grade 4 tumour (see 
Figure 104).  
 
Mice were injected with BrdU ip 2 hours prior to culling. The number of BrdU positive 
cells were expressed as the percentage of the total count and averaged for each group 
(see Figure 104f). There were significantly less BrdU positive cells in the ‘treatment’ 
group compared to the ‘control,’ ‘drug only,’ and ‘light only’ groups (8.38 ± 1.15 vs 
21.1 ± 1.44, 24.5 ± 4.23, 25.9 ± 3.17, respectively, p < 0.01). This suggests that the 
treatment caused partial inhibition of DNA replication. 
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Figure 104 Histopathology and Immunohistochemistry: bPDT Trial 4 
Representative H and E stained sections of the intracranial tumours from the control group of Trial 4 are 
shown.  Most tumours were intra-axial (a). The area within the square in (a) is shown at higher magnification 
in (b) and (c): several mitoses (M) and necrosis (N) were seen (b), and also vascular endothelial proliferation 
(V) (c).  Some extra-axial tumours (d and e) resulted from cell injection. Mice were injected with BrdU ip 2 
hours prior to culling. The difference in proportion of BrdU positive cells as a percentage of the total cell 
count is presented (f), where C = control, D = drug only, L = d-luciferin only, D+L = animals exposed to drug 
and d-luciferin. Asterisks indicate the degree of significance of the difference in the proportion of BrdU 
positive cells in each group compared to control, where *p > 0.05, ** p ≤  0.05, ***p < 0.01, ****p < 0.001, 
*****p < 0.0001. There were significantly less BrdU positive cells in the ‘treatment’ group.  
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9.4.5.3 Summary: bPDT Trial 4, Intracranial Model 
Consistent tumour growth was not achieved despite injecting neurospheres that had 
been derived from U87bp-luc cells (compare to Figure 83c). Due to time constraints, 
treatment had to start the day after injection, rather than after giving the tumours time 
to become well established as in the pilot (see section 9.3). Furthermore, some cell 
injections led to extraparenchymal tumours, indicating that our technique required 
refining. However, the tumours that did develop displayed characteristics consistent 
with grade 4 astrocytoma.  
 
BLI data did not reveal a treatment effect. This was not unexpected as validation 
studies in the subcutaneous tumour models advise that these results should be 
interpreted with caution. Validating BLI as a reliable measure of tumour progression 
was not possible in the intracranial model as CT was found not to be sensitive enough 
to detect the tumours and MRI was not available. 2D or even 3D capture of 
bioluminescence might have been more accurate.  
 
Immunohistochemistry demonstrated significantly fewer BrdU positive cells in the 
‘treatment’ group compared with the control groups.  As in the other trials, this 
represents a treatment effect where treatment has been shown to suppress tumour 
growth. 
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9.5 Summary and Discussion 
A summary of the results from the 4 trials of bPDT is given in Table 13.  
 
 bPDT Trial 
 1 2 3 4 
Model Subcutaneous, 
Passage 4 
Subcutaneous Subcutaneous, 
Passage 3 
Intracranial 
Cell line of origin U87-luc 
polyclonal cells 
U87-luc 
polyclonal cells 
U87-luc 
polyclonal cells 
Neurospheres 
from U87bp-
luc cells  
Duration of study 
 
26 days 9 weeks 10 days 8 weeks 
Outcomes 
 
 
Survival Trend towards 
improved 
survival  
No difference 
in survival 
- - 
Tumour Volume Trend towards a 
decrease in 
tumour volume 
- No difference in 
tumour volume 
- 
Bioluminescent Signal Trend towards a 
reduction in 
bioluminescence 
signal 
No difference 
in 
bioluminescenc
e signal 
No difference in 
bioluminescence 
signal 
No difference 
in 
bioluminescenc
e signal 
Histopathology Increased 
necrosis 
- Increased 
necrosis 
- 
Immunohistochemistry Reduced 
proportion of 
BrdU positive 
cells, p < 0.0001 
No difference 
in proportion of 
BrdU positive 
cells 
Reduced 
proportion of 
BrdU positive 
cells, p < 0.0001 
Reduced 
proportion of 
BrdU positive 
cells, p < 
0.0001 
 
Table 13 Summary of findings from the 4 trials of bPDT 
The results for the treatment group are described for each outcome compared to the control groups.  
bPDT Trial 1 was the most comprehensive study. It revealed a trend towards reduced 
tumour growth and delay in the start of the exponential growth phase with treatment, 
particularly evident when following tumour volumes. This was consistent with the 
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trend towards improved survival and the significantly reduced proportion of BrdU 
positive cells in the ‘treatment’ group.  
 
A trend towards a treatment effect when measuring survival, tumour volume, or 
bioluminescent signal was not seen in the other trials. However, bPDT Trials 3 and 4 
did reveal a significantly reduced proportion of BrdU positive cells in their ‘treatment’ 
groups. Endpoints for bPDT Trial 3 were taken at the cessation of treatment and 
provide the most accurate insight into the immediate effects of bPDT. Interestingly, 
after a long follow up of 8 weeks in bPDT Trial 4, a treatment effect still persisted, 
with a significantly reduced proportion of BrdU positive cells.  
 
In contrast, in bPDT Trial 2, which had a long follow up of 9 weeks, there was no 
significant difference in the proportion of BrdU positive cells in the ‘treatment’ group 
compared to the control groups. This was most likely secondary to the length of follow 
up (9 weeks) and any initial treatment effect, as indicated by bPDT Trial 3, would 
likely have been masked.  
 
Overall, in 3 out of 4 trials, 2 in subcutaneous models and 1 in an intracranial model, a 
treatment effect was demonstrated by there being significantly fewer BrdU positive 
cells in the ‘treatment’ group compared to controls, indicating suppression of tumour 
cell replication and growth. Although numbers are small, these results are 
encouraging, and further investigation is certainly warranted. 
 
In order to develop this study further, a number of adjustments should be made. Firstly, 
the development of a more reliable and robust intracranial model is required. A reliable 
subcutaneous model has been achieved by serial subcutaneous passaging. Consistent 
with the literature, the morphology of the subcutaneous tumours displayed the 
characteristics of a high-grade astrocytoma and there was little change from one 
passage to the next172. Although successful xenografting of luciferase-expressing U87 
cells into mouse brain has been described175, development of a model for this study was 
challenging. The transplantation of neurospheres was associated with the best survival 
rate, and those tumours displayed features consistent with a grade 4 astrocytoma. 
However, bPDT Trial 4 demonstrates that the neurospheres should be given time to 
establish growth before treatment is commenced. Furthermore, mirroring the serial 
passaging technique of the subcutaneous model, perhaps the neurospheres should be 
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passaged several more times by harvesting established intracranial tumours and 
growing neurospheres in culture, then re-injecting them intracranially, to develop a 
more reliable subculture. Failing these methods, a different host, such as a Swiss 
Webster nude mouse, which was used in the study cited above, could be tried.  
 
Although BLI has been validated and used as a method of following tumour 
progression in subcutaneous132 and intracranial175,176,197 models used for testing various 
treatments, results of this study indicate that BLI may not be wholly reliable, 
particularly when tumours are either small or large. Ideally, for proof-of-principle 
studies, BLI would have to be validated within the studies. For the subcutaneous 
tumours, growth can also be followed by caliper measurements, as performed here. 
Following growth of intracranial tumours would be more challenging: CT is not 
sensitive enough to detect these small tumours and MRI is time consuming, and the 
length of anaesthetic required demanding on the wellbeing of the mouse. Part of the 
intracranial study may need to involve mice being culled at specified time points, the 
tumours dissected out and sectioned, and a volume measured. This would then be 
correlated with a BLI signal obtained just before the mouse was culled.  
 
Lastly, in order to provide proof-of-principle, some variations within the treatment 
protocol could be made. One option would be to increase the concentration of d-
luciferin loaded into the osmotic pumps thereby increasing the amount of sustained 
bioluminescence that could be generated. A study to find the optimal concentration of 
d-luciferin would need to be undertaken, such that there would be no toxicity to the 
host or the tumour and such that the enzyme, luciferase, would not be saturated. 
Another option would be to supplement the d-luciferin delivered by the pump with ip 
boluses of d-luciferin. The boluses could be given 3 times a day either over the 7 days 
of treatment or only over 2 days to cover the 36-48 hrs of peak tissue mTHPC 
concentration.  
 
Although limited by time and resources, results from this study are definitely 
encouraging with 3 of the 4 trials consistently showing a suppressive effect on DNA 
replication. A more robust intracranial model, more reliable methods of following real-
time tumour progression, and changes to treatment protocol may all provide definitive 
proof-of-principle.   
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Part 3 Conclusion and The Future 
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Chapter 10 Future Directions 
10.1 Summary of Results 
Experiments in cell culture have shown that bioluminescence, generated by the 
addition of d-luciferin to luciferase-producing cells, is able to activate a 
photosensitiser, and mediate a photodynamic effect resulting in significant cell death: 
bPDT. This has been most thoroughly studied in U87-luc cells: a cell line derived from 
a human grade 4 astrocytoma cloned to express luciferase. Incubation of these cells 
with the photosensitisers, hypericin or mTHPC, led to significant cell death with the 
addition of d-luciferin. When these experiments were repeated in non-luciferase 
producing U87 cells, there was no change in cell survival, demonstrating that it is not 
the chemical interaction between photosensitiser and d-luciferin, but the interaction 
between photosensitiser and the bioluminescence generated by the addition of d-
luciferin that leads to cell death. Moreover, lycopene was able to inhibit the cell death 
that occurred when the luciferase-producing cells were incubated with photosensitiser 
followed by d-luciferin. This further supports that cell death is occurring by a 
photodynamic effect, which is mediated by singlet oxygen, and hence, is inhibited by 
the presence of an anti-oxidant such as lycopene.  
 
In animals xenografted with luciferase-expressing U87 cells subcutaneously or 
intracranially, then treated with a systemic photosensitiser and continuous d-luciferin, 
DNA replication within the tumour is consistently suppressed. This was demonstrated 
by finding significantly fewer BrdU positive cells in harvested tumours of the 
‘treatment’ group compared to controls. In the most comprehensive study where 
tumours were xenografted subcutaneously, treatment was also associated with a trend 
towards suppression of tumour growth, as shown by trending tumour volumes, and 
improved survival. Although limited, these early in vivo studies suggest a bPDT effect. 
 
As discussed above, in the first instance efforts should be made to provide definitive 
proof-of-principle in animals transplanted with luciferase-expressing U87 cells. This 
will involve developing a more robust and reliable intracranial animal model and 
optimising the treatment protocol, mainly by improving light dosimetry. If bPDT 
mediated cell kill can be demonstrated effectively, then the ability of bPDT to kill the 
infiltrating cells of high-grade astrocytomas that underlie the poor prognosis of disease 
can be tested. For these experiments, an animal model that can replicate the true 
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invasive nature of high-grade astrocytoma will be needed, and methods of targeting the 
tumour to confer an ability to bioluminescence will need to be developed.  
10.2 Transgenic Animal Models  
Xenograft models, as used in this study, lack the stepwise genetic changes that are 
thought to underlie tumour development. Furthermore, implanted cells have often 
undergone several passages leading to alterations in genetic profile due to different 
selective pressures198. As a result, xenograft tumours rarely recapitulate the phenotype 
of the desired tumour: intracranial injection of human high-grade glioma cells into mice 
tend to form well circumscribed, compact tumours with little infiltration into the 
surrounding brain parenchyma199,200. In contrast, by replicating mutations in genes 
characteristic of a particular human malignancy, strains of mice have been genetically 
engineered to spontaneously and predictably develop tumours with similar 
characteristics to the human malignancy: the phenotype of the desired tumour is 
therefore more accurately represented. In the case of grade 4 astrocytoma, a transgenic 
model should replicate the true invasive nature of the disease. 
 
Inactivation of several tumour suppressor genes has been implicated in the 
development of gliomas, such as Nf1, PTEN, and Rb. However, global knockout of 
these genes, which are widely expressed, would likely result in early lethality201. More 
recently, the Cre/lox system has been used to limit gene modifications or deletions to 
specific cells of interest. This strategy requires two stages. The first stage is to generate 
transgenic mice that express the Cre enzyme under the control of a cell-specific 
promoter. The second stage requires the breeding of the Cre transgenics with mice 
carrying an allele containing the critical region flanked by loxP sites. This results in 
excision of the floxed sequence specifically in the cells expressing the Cre transgene202-
204. With respect to astrocytomas, a transgenic mouse line expressing Cre under the 
control of the promoter of glial fibrillary acidic protein (GFAP), a protein relatively 
specific to astrocytes, has been developed205. Recombination of floxed Rb, p53, and 
PTEN alleles in various combinations by tamoxifen-inducible GFAP-cre activation in 
parenchymal astrocytes and subventricular zone progenitor cells has yielded high-grade 
astrocytomas206-208. Furthermore, recombination of floxed p53 and PTEN in 
combination by an hGFAP-Cre transgene has been shown to generate a tumour with 
striking clinical, pathological and molecular resemblance to grade 4 astrocytoma in 
humans209. 
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An additional advantage of such transgenic models compared to tumour xenografts is 
that they can remain immunocompetent. As the cell kill caused by PDT is partly 
mediated by stimulation of the host immune system, the use of a transgenic model of 
grade 4 astrocytoma will allow a more true reflection of the cell kill that can be 
achieved with bPDT.  
10.3 Targeting Astrocytomas in situ  
With a transgenic animal model that will spontaneously develop an intracranial tumour 
with clinical, histopathological, and molecular characteristics similar to that of a grade 
4 astrocytoma, in order to test bPDT, a method of conferring the ability to bioluminesce 
to the tumour cells has to be found. Firstly, the cells of the astrocytoma have to be 
targeted. Then, once targeted, either the luciferase enzyme or the gene encoding for the 
enzyme, luc, can be delivered to the cell.  
10.3.1 Potential Targets 
The recognition that epigenetic silencing of the MGMT (O6-methylguanine-DNA 
methyltransferase) gene by promoter methylation is associated with a survival 
advantage and an increased responsiveness to temozolomide chemotherapy in those 
with grade 4 astrocytoma24 spurred the interest in the molecular characterisation of 
gliomas. Extensive genetic analyses across a range of diffuse gliomas have been carried 
out210,211 and amongst many genetic alterations, mutations in two particular genes have 
been associated with grade 4 astrocytoma; epidermal growth factor receptor (EGFR) 
and isocitrate dehydrogenase 1 (IDH1). 
 
Clinically, two types of grade 4 astrocytoma have been identified; primary and 
secondary. Primary tumours are those that develop de novo. They are typically 
associated with an older age of presentation and a relatively rapid clinical progression. 
Secondary tumours arise from lower grade tumours and typically arise in younger 
patients. Although primary and secondary tumours have similar histopathological 
features, they differ markedly on a molecular level.  
 
Primary grade 4 astrocytomas are classically characterized by the amplification and 
mutation of EGFR. Amplification of EGFR leads to overexpression of the EGFR 
protein, and is the most common genetic alteration, occurring at frequencies of 34-
63%212-218. Of these cases, 63-75% also carry mutations of the gene, resulting in 
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tumours carrying both the wild type (wt) and mutated receptor213,219-222. The most 
common mutation is an inframe deletion of exons 2-7, leading to translation of the 
mutated protein termed EGFRvIII, which is found at a frequency of 25-64%. Epidermal 
growth factor receptor is a transmembrane, tyrosine kinase, cell surface receptor. 
Activation of the receptor by its growth factor ligands leads to a transition from an 
inactive monomeric form to an active homodimer, and this dimerisation stimulates its 
intrinsic intracellular protein-tyrosine kinase activity, ultimately resulting in DNA 
synthesis and proliferation. EGFRvIII, the mutated receptor, is tumour specific and 
devoid in normal tissues. It is not able to bind any known ligands. Despite this, 
EGFRvIII displays constitutive signalling that is augmented by reduced internalization 
and downregulation. It has been found to be the driving force in tumour progression, 
being clinically correlated with increased glioma cell growth, proliferation, invasion, 
and angiogenesis222-224. Some studies suggest that EGFRvIII is associated with poor 
prognosis216,225. One study has shown that EGFRvIII expression in combination with 
EGFR gene amplification is an independent and significant negative prognostic factor 
for survival216. Although, not all studies have been able to link EGFRvIII with patient 
outcome226,227, EGFR and EGFRvIII are potential targets for primary grade 4 
astrocytomas.  
 
In contrast to EGFR, mutations in IDH1 have been shown to be expressed at high 
frequency in approximately 75% of all glioma subtypes except for primary grade 4 
astrocytoma. As mutations in IDH1 are homogenously expressed in all tumour cells, 
even single infiltrating cells, it has been hypothesised that mutations in IDH1 represent 
some of the earliest genetic events that drive the malignant transformation of lower 
grade tumours. In fact, mutations in IDH1 are so fundamental to gliomas that two large 
studies of glioma genetics211,228 base their classification of gliomas on the presence or 
absence of the mutation in combination with the presence of other key alterations e.g. 
1p 19q co-deletion. IDH1 is an enzyme located in the cytoplasm and in peroxisomes 
where it participates in lipid metabolism and glucose detection. It catalyses the 
oxidative decarboxylation of isocitrate to 2-alpha ketoglutarate (αKG). The most 
widely cited tumour-specific mutation of IDH1 consists of a missense mutation at 
amino acid 132 that replaces an active site arginine residue with histidine. The mutant 
enzyme consists of a dimer between the wild-type and mutant proteins. Among many 
proposals of how mutant IDH1 leads to tumourogensis, one suggests that whereas 
normal IDH1 converts isocitrate to αKG, mutant IDH1 converts αKG to 2-
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hydroxyglutarate (2HG)229. It has been suggested that 2HG inhibits a variety of 
dioxygenases, including prolyl hydroxylase, TET2, and histone demethylases230, which 
could trigger aberrant angiogenesis and aberrant gene expression. Interestingly, the 
presence of the IDH1 mutation has been shown to be a prognostic indicator, but not 
predictive of response to therapy231-236: patients with the mutation have a better 
prognosis that those without. Due to its high frequency in gliomas except for primary 
grade 4 astrocytomas, the IDH1 mutant enzyme could potentially be a good target for 
secondary grade 4 astrocytomas. 
 
Notably, as well as providing information on potential targets, the molecular 
classification of gliomas has been found to capture the biologic features of glioma 
variants better than histopathological evaluation. Indeed, it is beginning to redefine the 
range of gliomas and their treatment.  
10.3.2 Method of Delivery: Conjugation to a Monoclonal Antibody 
Monoclonal antibodies to EGFR have been developed and have been trialed as anti-
tumour agents in themselves. Cetuximab is a recombinant human-murine chimeric 
monoclonal antibody specifically targeting EGFR. It is has been approved for use in the 
treatment of metastatic colorectal cancer, metastatic non-small cell lung cancer, and 
squamous cell carcinoma of the head and neck. in vitro and in vivo studies of grade 4 
astrocytoma have shown that cetuximab is able to bind to both EGFR237,238 and 
EGFRvIII239,240 with high specificity and affinity, and has effective anti-tumour activity. 
Phase 1 studies with nonhumanised anti-EGFR monoclonal antibody demonstrated the 
presence of the monoclonal antibody within resected glioma tissue241,242. Unfortunately, 
phase II studies have been disappointing in not revealing a robust effect of cetuximab 
against grade 4 astrocytoma243.  
 
Nevertheless, the targeting capabilities of monoclonal antibodies raised against EGFR 
and EGFRvIII, like cetuximab, have been exploited. These antibodies have been 
successfully used to selectively deliver boron for neutron capture therapy244 and 
chemotherapeutic agents such as methotrexate245 in vivo, as well as radiolabelled iodine 
in humans246,247, to treat grade 4 astrocytomas by direct conjugation. A systemically 
administered cetuximab-fluorescent probe conjugate was sensitive and specific enough 
to human grade 4 astrocytoma cells transplanted subcutaneously and intracranially in 
mice to allow optimisation of resection by fluorescence guidance248.  
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Furthermore, a monoclonal antibody has been raised against the protein resulting from 
the most common IDH1 mutation249. Although there has been some recent interest in 
developing vaccinations against IDH1 and its mutant proteins250,251, overall there is little 
in the literature regarding their targeting.  
 
With monoclonal antibodies being raised against two potential targets for grade 4 
astrocytoma, EGFR and IDH1, and their mutants, and evidence that chemicals with 
therapeutic potential can be conjugated to these antibodies, suggests that perhaps the 
enzyme luciferase can also be conjugated to these monoclonal antibodies. Certainly, 
luciferase has been successfully conjugated to a monoclonal antibody. An anti-
carcinoembryonic antigen (CEA) antibody fragment, anti-CEA diabody, has been fused 
to luciferase from Renilla reniformis to generate a novel optical imaging probe that 
when injected intravenously successfully localizes to subcutaneously transplanted CEA 
expressing cells and causes those cells to bioluminesce252 with the addition of 
coelenterazine as the substrate.  
10.3.3 Method of Delivery: Nanoparticles 
Nanoparticles are objects generally less than 100 nm in dimension. There are several 
general advantages to using nanoparticles as a drug delivery platform. Firstly, the 
loading and releasing of active agents can be controlled: the loaded amount is 
controlled by changing the size of the nanoparticle or the number of linkers inside and 
on the surface of the nanoparticles, and release can be controlled by the type of 
nanoparticle polymer matrix. Secondly, specific molecular targeting factors can be 
attached for localized binding to and/or uptake by the tumour cells. Thirdly, a 
hydrophilic coating can be given to the nanoparticle to reduce uptake by the reticular 
endothelial system, thereby increasing drug delivery to the tumour and reducing 
systemic side effects. Fourthly, the nanoparticle matrix provides protection for the drug 
from enzymatic or environmental degradation. Lastly, the nanoparticle can overcome 
multidrug resistance by masking the drugs trapped inside it.  
 
Specific to brain cancer, the biggest challenge in delivering drugs is overcoming the 
BBB, and some nanoparticles have been found to successfully cross the BBB. They are 
often nanoparticles covalently linked to peptides or coated with surfactant (for example 
polysorbate). The exact mechanism of nanoparticle transport into the brain is not fully 
understood, but most likely relies on receptor-mediated endocytosis, phagocytosis, 
and/or passive leakage of nanoparticles across defects in the BBB253,254.  For example, 
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nanoparticles conjugated with synthetic peptides similar in structure to opioid peptides 
can be successfully transported across the BBB, presumably via the mechanism used 
by endogenous opioid peptides255; the opioid peptides binding to specific receptors on 
the capillary walls, which help carry them into the brain256. Additionally, polysorbate 
coated nanoparticles are thought to mimic low-density lipoproteins (LDLs), allowing 
them to be transported into the brain by the same endocytotic process LDLs undergo at 
the BBB257,258. Polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles have 
enabled an improved distribution of doxorubicin into the brain. Rats xenografted 
intracranially with grade 4 astrocytoma were given different intravenous formulations 
of doxorubicin, including one formulation where doxorubicin was bound to 
polysorbate-coated nanoparticles. High intracerebral doxorubicin concentrations were 
achieved with this formulation, whereas all control preparations did not achieve any 
detectable levels in the brain259. Furthermore, animals treated with this formulation had 
significantly longer survival times compared with all other groups with over 20% of the 
animals showing long term remission. Histology also confirmed smaller tumour sizes 
and lower values for proliferation and apoptosis in the group260.  
10.3.3.1 Targeting Nanoparticles  
Not only can nanoparticles cross the BBB, but they can also be designed to target brain 
tumours. Two different monoclonal antibodies, an anti-mouse transferrin receptor 
antibody and a mouse autoimmune anti-nucleosome antibody 2C5, have been 
simultaneously covalently conjugated onto a poly(beta-L-malic acid) drug delivery 
nanoplatform. The active anti-tumour drug, antisense oligonucleotides to vascular 
protein laminin-8, were attached to the same carrier molecule. The resulting drug was 
administered intravenously into mice bearing xenografted intracranial gliomas. The 
anti-mouse transferrin receptor antibody targeted the mouse endothelial system, 
allowing uptake of the drug across the BBB, and the anti-nucleosome antibody 2C5 
targeted the tumour cell surface. The targeting efficacy with two antibodies was found 
to be greater than with one antibody alone261.  
 
Human grade 4 astrocytomas have been found to selectively express receptors for 
IL13262 and when liposomes are conjugated with IL13, they will deliver 
chemotherapeutics to subcutaneously xenografted gliomas in mice more effectively 
than unconjugated liposomes. Furthermore, when mice bearing intracranial U87 
xenografts were given ip doxorubicin encapsulated by IL13-conjugated liposomes, they 
had a 5-fold reduction in intracranial tumour volume over 6 weeks and 4 of the 7 
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animals survived beyond 200 days after tumour implantation. In contrast, the animals 
that received doxorubicin encapsulated by unconjugated liposomes displayed no 
evidence of reduction in tumour size and did not survive beyond 35 days.  
 
Another glioma targeting molecule that has been conjugated with nanoparticles is 
Chlorotoxin (Cltx). Unlike other targeting ligands that are specific to only certain types 
of glioma cells e.g. the EGFR receptor, Cltx targets the vast majority of glial-derived 
tumours263. It is a small 36 amino acid peptide purified from the venom of the giant 
Israeli scorpion and binds with high affinity to the membrane-bound matrix 
metalloproteinase-2 (MMP-2) endopeptidase, which is preferentially upregulated in 
gliomas264-266. A nanoprobe synthesized by coating iron oxide nanoparticles with 
covalently bound bifunctional polyethylene glycol polymer and functionalized with 
Cltx and a near infrared fluoresceing molecule is preferentially taken up by glioma 
cells in vitro, as demonstrated by MRI and fluorescence microscopy267. Conjugating 
small peptides such as Cltx on nanoparticles is attractive, as they overcome the 
restrictions of the widely used antibodies, which are bulky, exhibit a short half-life in 
blood268, have limited tissue penetration269 and retention268, and have reduced cellular 
uptake269.  
10.3.3.2 Nanoparticles and PDT 
Nanoparticles have been engineered to deliver photosensitisers for PDT to brain 
tumours. F3 is a vascular homing peptide specific to the angiogenic endothelial cells 
within tumour vasculature. An F3 targeted polymeric nanoparticle was engineered to 
encapsulate iron oxide and the photosensitiser, Photofrin®270. The nanoparticle was 
delivered intravenously to rats bearing 9L gliomas xenografted intracranially. The 
animals underwent PDT with the light source being introduced via the same burr hole 
used for xenografting the tumours. Tumour uptake of the nanoparticle was confirmed 
with MRI, which could detect the iron oxide. Increased survival was associated with 
use of the F3 targeted Photofrin® encapsulated nanoparticle, compared to use of a non-
targeted Photofrin® encapsulated nanoparticle or Photofrin® alone.   
10.3.3.3. Nanoparticles and Bioluminescence 
Nanoparticles that confer bioluminescence have also been designed. Renilla luciferase 
has been successfully conjugated to gold nanoparticles, which were then used for 
protease detection271. Moreover, a gold nanoparticle (AuNP)-capped mesoporous silica 
nanoparticle (Au-MSN) platform has been used to co-deliver luciferase and luciferin to 
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cells. Luciferin is released from the interior pores of MSN upon AuNP uncapping in 
response to disulfide-reducing antioxidants. Simultaneously, luciferase is co-delivered 
from the PEGylated exterior surface of Au-MSN. When such nanoparticles are 
incubated with HeLa cells, the cells are subsequently seen to bioluminesce272. There are 
several advantage to such a co-delivery system. Mesoporous silica nanoparticles are 
excellent candidates for co-delivery as they have an interior pore and exterior particle 
surface for loading various guest molecules. Additionally, luciferin has a short half-life 
and encapsulation by a nanoparticle allows a greater concentration of luciferin to be 
delivered directly to the cell, thereby potentially increasing the degree of 
bioluminescence that can be generated.  
 
Not only are nanoparticles able to deliver luciferin and luciferase, but they can also 
deliver the gene that encodes luciferase (luc). Gelatin nanoparticles loaded with 
plasmids containing luciferase DNA (pCMV-luc) have been used to successfully 
transfect B16 and F10 cells in culture with luc, conferring to them an ability to 
bioluminesce with the addition of luciferin273. A deferoxamine-coated 
superparamagnetic iron oxide nanoparticles containing circular plasmid DNA of 
Renilla luciferase has been shown to be internalised by U87 cells274.  
 
Luciferase gene delivery via nanoparticles has also been successful in vivo. 
Compacting luc into discrete nanoparticles using polyethylene glycol-substituted poly-
l-lysine, the formulation was then delivered into mice via intratracheal and intranasal 
instillation275. Luciferase activity was then measured in lung tissue post mortem. Mice 
that were given the compacted luc plasmid were not only found to display luciferase 
activity in their lungs, as measured by the degree of bioluminescence generated with 
the addition of substrate, but this activity was 200 fold more than that seen in animals 
treated with naked DNA.  
10.3.4 Method of Delivery: Viral Vectors 
A more classic method of gene delivery is via viral vectors. Indeed, the luciferase gene 
has already been incorporated into several different viral vectors, mainly to act as a 
reporter gene.  
 
One of the most favoured vectors is that of the adenovirus. Adenoviruses have evolved 
into being highly efficient at delivering, transcribing, and translating their genome in 
eukaryotic cells. They are known to infect a wide variety of human cells. The two 
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particular serotypes that are most extensively used in clinical applications, Ad5 and 
Ad2, are associated with self-limiting and usually mild human diseases, most 
commonly respiratory tract infections, gastroenteritis, and conjunctivitis. Adenoviruses 
have long been engineered to function as vectors for delivering therapeutic genes by 
replacing part of their genome with a therapeutic anticancer gene276. The region that is 
typically replaced is the part that would prepare the host cell for viral DNA replication 
by driving the host cell into S phase and suppressing the host cell’s apoptotic 
machinery, otherwise known as the E1 region. By replacing another region, termed the 
E3 region, which modifies the host’s immunological environment, larger inserts can be 
introduced. As these regions are of vital importance in viral replication, removing them 
typically renders the adenovirus replication deficient and converts it from being a lytic 
pathogen to a vector for gene delivery. Specific to brain tumours, adenoviruses have 
been used to deliver the herpes simplex-thymidine kinase (HSV-TK) gene, the 
interferon-β gene, the interferon-α gene, and the p53 gene. These have been tested in 
phase 1 clinical trials.  
 
With regards to the luciferase gene, an adenovirus recombinant containing the firefly 
luciferase gene (Ad5-Luc 3) has been shown to infect HeLa cells in vitro with relative 
efficiency277. When inoculated into mice via ip injection, luciferase activity was 
subsequently detected in the liver, spleen, kidney, and lung. Although a single ip 
inoculation was sufficient to raise anti-luciferase antibodies, luciferase activity could 
still be detected in these organs following a second inoculation. Adenoviral vectors 
have also been engineered where the luciferase gene replaces either the E1 or E3 region 
whilst maintaining their oncolytic and replication properties. In this way, the luciferase 
gene acted as reporter enabling BLI to assess the effect of the virus on a panel of 
glioma cells in culture, and also on a subcutaneously xenografted U87 tumour in a 
mouse model when injected intratumourally. The effectiveness of BLI was independent 
of the position of luciferase gene insertion278.  
 
An alternative to an adenovirus vector is a lentivirus vector, which enables stable 
integration of a transgene into the host genome irrespective of their state of 
division279,280. A bimodal viral vector has been engineered by fusing a lentivirus vector 
with the dual bioluminescent and fluorescent markers, Renilla luciferase-DsRed2 and 
GFP-Renilla luciferase281. Human neural stem cells were transfected with these vectors 
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in vitro, then implanted intracranially into mice. The migration of the stem cells could 
then be followed by BLI. 
 
The luciferase gene has also been successfully incorporated into herpes simplex virus 
vectors. For example, the luciferase gene has been integrated into a herpes virus vector 
under the control of a tetracycline-responsive promoter system allowing BLI to reveal 
the effect of using tetracycline to control inducible gene expression in vitro in cultures 
of hippocampal neurons and in vivo when directly injected intracerebrally into 
Ammon’s horn of the hippocampus282.  
 
Lastly, the luciferase gene has been integrated into the vaccina virus, which is attractive 
as a vector because due to its large size there are many non-essential genes that can be 
exchanged for therapeutic genes. A gene encoding a bioluminescent-fluorescent fusion 
protein (Renilla-luciferase-Aequorea green fluorescent protein) has been inserted into a 
vaccina virus vector283 and when given intravenously to human breast tumour bearing 
nude mice, BLI clearly demonstrated localisation of the vector to the tumour and 
allowed the response of the tumour to the oncolytic properties of the vector to be 
followed over time284.  
10.4 Concluding Remarks 
The concept of bioluminescence-mediated PDT was conceived to overcome the diffuse 
infiltrative nature of grade 4 astrocytoma. The in vitro studies carried out here have 
provided proof-of-principle that bPDT can lead to tumour cell kill in human grade 4 
astrocytoma derived cell lines. Results from the in vivo studies carried out in 
subcutaneous and intracranial mouse models with xenografted tumours derived from 
human grade 4 astrocytoma derived cell lines provide encouraging results. However, to 
provide definitive proof-of-principle in an in vivo model, a more robust and reliable 
intracranial animal model is needed and the treatment protocol requires optimisation. 
With such improvements, we contend that proof-of-principle in vivo is hopeful.  
 
Once achieved, to advance the field, bPDT will need to be proven in a transgenic 
animal model, where the diffuse and infiltrative nature of grade 4 astrocytoma is 
recapitulated. With the Cre/loxP system, there are several options. However, before 
doing this, a means of targeting the tumour cells to confer to them the ability to 
bioluminesce must be found. Understanding the molecular biology of grade 4 
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astrocytoma has provided several targeting options, and several delivery platforms have 
been explored. Of these, nanoparticles do seem the most versatile. With nanoparticles, 
either the luciferase protein or the gene encoding luciferase can be delivered to the 
tumour cell, with or without luciferin, and targeting options can include a more 
traditional antibody or a smaller peptide. 
 
Such an endeavour draws from so many scientific disciplines that include photobiology 
and photochemistry, molecular biology, and nanotechnology; and the specific interest 
in grade 4 astryoctoma requires expertise in neurobiology, neuroscience and 
neuropathology. It is vital that time be spent in developing an infrastructure that can 
support success in this intriguing field of study.  
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Appendix 
1 Conventional Photodynamic Therapy, ‘Light Only’ Wells 
The effect of exposing U87, U251, MCF-7 and NIH 3T3 cells to varying light 
intensities compared to a ‘control’ not exposed any light, as part of the conventional 
PDT experiments described in Chapter 6.2, is presented here. Where more than one 
graph is used to illustrate the effect of varying light intensities on a particular cell line, 
this represents separate experiments where those particular light intensities were tested 
at separate times. 
1.1 Short Incubation Experiments 
See Figure 105. For U87 cells, there is no significant difference in survival between 
‘control’ and the cells exposed to light, regardless of light intensity. For U251 cells, 
strict p-value interpretation would indicate the exposure to 1 sec of light caused 
significant toxicity. However, the OD of cells exposed to this intensity of light was 
82.8% of control and the 95% CI (0.0191 – 0.187) extremely close to 0, hence, the 
result was not considered significantly different from control. Exposure to 180 secs of 
light caused significant cell growth in MCF-7 cells. Similarly, exposure to 10 and 180 
secs of light caused significant cell growth in NIH 3T3 cells. 
 244 
 
 
 
 
Figure 105 The Effect of Exposing Cell Lines to Varying Intensities of Light in ‘Short Incubation’ 
Experiments 
For U87 and U251 cells, exposure to varying intensities of light has no significant effect on cell growth. 
Although p-value interpretation would indicate exposure of U251 cells to 1 sec of light is toxic, the actual OD 
of these cells is 82.8% of control and the 95% CI (0.0191-0.187) close to 0, hence, this intensity of light was not 
considered toxic. For MCF-7 cells, exposure to 180 secs of light stimulated growth, as did exposure of NIH 
3T3 cells to 10 and 180 secs of light.   
1.2 Long Incubation Experiments  
See Figure 106. For U87 cells, exposure to 3 secs of light caused significant cell 
growth. Likewise, exposure of U251 cells to 5 and 500 secs of light caused significant 
cell growth. For MCF-7 and NIH 3T3 cells, exposure of cells of light to various light 
intensities caused no significant change in cell growth compared to control.  
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Figure 106 The Effect of Exposing Cell Lines to Varying Intensities of Light in ‘Long Incubation’ 
Experiments.  
Exposure of U87 cells to 3 secs of light caused significant cell growth. Likewise, exposure of U251 cells to 5 
and 500 secs of light caused significant cell growth. Exposure of MCF-7 and NIH 3T3 cells to light to various 
intensities caused no significant change in cell growth compared to control.  
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Exposure to light alone has been show to be non-toxic to cells, and this is well-
established in the literature153. Moreover, in some circumstances, light has been shown 
to cause cell proliferation: MCF-7 cells with a light fluence of 1260 mJcm-2 (equivalent 
to180 secs of illumination) and NIH 3T3 cells with light fluences of 70 and 1260 
mJcm-2 (equivalent to 10 and 180 secs of illumination) in the short incubation 
experiments, and U87 cells with a light fluence of 21mJcm-2 (equivalent to 3 secs of 
illumination) and U251 cells with light fluences of 35 and 3500 mJcm-2 (equivalent to 5 
and 500 secs of illumination) in the long incubation experiments. This phenomenon of 
low light fluences stimulating cell growth has been described in the literature in both 
non-tumour285 and tumour cell lines152. Suggested underlying mechanisms include an 
increase in the transmembrane electrochemical proton-gradient in mitochondria 
stimulating calcium release into the cytoplasm thereby triggering mitosis286, and also 
the stimulation of growth factors285.  
2 Vector circle maps of pcDNA3.1(+), pGL3[luc], pCBG68, and pGL4.70 
[hRluc] 
See Figure 107. The pcDNA3.1(+) map is reproduced from Invitrogen, and the 
pGL3[luc], pCBG68, and pGL4.70 [hRluc] maps are reproduced from Promega. Note 
the origin of replication for E.Coli, a CMV promoter, and sequences for ampicillin and 
neomycin resistance in the pcDNA3.1(+) vector, and the HindIII and XbaI cleavage 
sequences in the multiple cloning region of the pcDNA3.1(+) vector, and either side of 
the luciferase gene in the pGL3[luc] and pCBG68 vectors. The HindIII cleavage site is 
shown on the 5’ end of the hRluc gene. Although not clear, Xba I is on the other end 
and is evident in the actual map.  
 247 
	
 
Figure 107 Vector circle maps of pcDNA3.1(+), pGL3[luc], pCBG68, and pGL4.70 [hRluc] 
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